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Abstract 
Introduction: Oxygen-glucose deprivation (OGD)±reperfusion and hyperglycaemia 
exacerbate the ischaemic cerebral injuries during or after a stroke. The key biochemical 
events associated with these pathologies include excessive cytoskeletal remodelling, 
modulation of tight junction proteins and the induction of oxidative stress. Recently, the 
overactivities of protein kinase C (PKC), RhoA/Rho-kinase, and pro-oxidant NADPH 
oxidase have been shown to account for the development of these events and the consequent 
disruption of human blood-brain barrier (BBB) integrity. 
Objectives: This thesis focused on the putative roles of RhoA/Rho-kinase signalling in OGD 
and OGD+reperfusion-evoked modulation of cytoskeletal remodelling, tight junction proteins 
and oxidative stress in human brain microvascular endothelial cells (HBMEC). The effects of 
hyperglycaemia-mediated PKC overactivities in modulating the RhoA/Rho-kinase pathway 
with reference to the aforementioned parameters i.e. cytoskeletal remodelling and tight 
junction protein expression and localisation have also been the focus of this thesis.  
Methods: For the OGD studies, the HBMEC were exposed to normoxia (controls), OGD (4, 
20 hours) alone and followed by reperfusion (20 hours). The HBMEC-human astrocyte (HA) 
cocultures were established to mimic human BBB before exposing them to the experimental 
conditions. The integrity and function of HBMEC-HA cocultures were measured by 
transendothelial electrical resistance (TEER) and flux of permeability markers sodium 
fluorescein (NaF) and EvanÕs blue-labelled albumin (EBA), respectively. For the 
hyperglycaemia studies, the HBMEC monolayers and the cocultures were exposed to 
normoglycaemia (5.5 mM D-glucose), hyperglycaemia (25 mM D-glucose), and 
hyperglycaemia with inhibitors of Rho-kinase, PKC, PKC-α, PKC-β, PKC-βII, PKC-δ; and 
the BBB integrity and function were measured by the TEER and flux studies, respectively. 
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Fold differences in the protein expression or activity of RhoA, Rho-kinase-2, mono- and di-
phosphorylated myosin light chain-2 (MLC2), total MLC2, gp91-phox (a pivotal NADPH 
oxidase subunit), catalase, occludin, claudin-5, zonula occludens-1 (ZO-1), β-catenin, and 
vinculin were either measured by in-cell or ordinary Western analyses.  
Results from the OGD studies: OGD compromised the barrier integrity as observed by 
decreases in TEER values and concomitant increases in flux of EBA and NaF across the 
cocultures. Transfection of HBMEC with constitutively active RhoA also decreased the 
TEER and increased the NaF paracellular permeability, whereas inactivation of RhoA by 
anti-RhoA-IgG electroporation exerted barrier protective effects. Moreover, OGD alone and 
after constitutively active RhoA transfection introduced stress fibres in HBMEC, which were 
abrogated by inactivation of RhoA and the specific inhibition of its main effector Rho-kinase 
by Y-27632. In addition, dramatic increases in the protein expressions of RhoA-GTP, Rho-
kinase-2, gp91-phox, and antioxidant catalase were observed in HBMEC exposed to 
OGD+reperfusion conditions. These along with increases in the NADPH oxidase activity and 
total superoxide anion levels confirmed the oxidative stress in HBMEC under these 
experimental conditions. A marked rise in the protein expressions of claudin-5 and β-catenin 
observed after OGD (20 hours) alone and followed by reperfusion may represent the effects 
of oxidative stress on tight and adherens junction proteins stability, respectively. These 
results also concurred with marked decreases in TEER and concomitant increases in the flux 
of EBA across the in vitro models of human BBB exposed to OGD±reperfusion conditions 
when compared with the controls. Cotreatment with Y-27632 under OGD±reperfusion 
normalised the protein expressions of RhoA, Rho-kinase-2, gp91-phox, claudin-5, catalase; 
activities of RhoA and NADPH oxidase; and total superoxide anions levels, alongside 
improving the expression of occludin and the coculture integrity under the OGD±reperfusion 
conditions. 
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Results from the hyperglycaemia studies: Hyperglycaemia also increased RhoA-GTP, 
Rho-kinase-2, mono- and di-phosphorylated MLC2 protein levels and total PKC activity. 
These changes were consistent with the actin stress fibre formations, ZO-1 and occludin 
redistribution from HBMEC periphery. Hyperglycaemia-mediated endothelial-barrier 
dysfunction was further characterised by reduction in TEER and elevation in flux of EBA. 
Glucose normalisation, RhoA neutralisation by anti-RhoA-IgG electroporation and Rho-
kinase-2 inhibition by Y-27632 normalised all abovementioned protein expressions, restored 
actin and tight junction protein localisations and barrier integrity. Cotreatment of HBMEC 
with hyperglycaemia and a general PKC inhibitor namely, bisindolylmaleimide-I normalised 
the Rho-kinase-2, mono- and di-phosphorylated MLC2 levels. Moreover, specific inhibitors 
of PKC-α (Ro-32-0432), PKC-β (LY333531), PKC-βII (CGP53353) attenuated the PKC 
overactivity, normalised all protein expressions, restored actin localisation and improved 
barrier integrity. In addition, the PKC-α and PKC-β siRNA transfections mimicked the 
effects of the specific inhibitors and attenuated the hyperglycaemia-evoked RhoA-GTP, 
mono- and di-phosphorylated MLC2 protein levels and stress fibre formations.  
Conclusions: The RhoA/Rho-kinase overactivities compromise the endothelial-barrier 
integrity, in part, by modulating the cytoskeletal remodelling and inducing the NADPH 
oxidase-evoked oxidative stress under OGD±reperfusion pathology. Moreover, 
hyperglycaemia-mediated increases in PKC-α and PKC-β activities exacerbate the 
endothelial-barrier dysfunction by modulating RhoA/Rho-kinase signalling pathway. 
Summary: These findings support the hypothesis that OGD±reperfusion and hyperglycaemia 
perturb BBB integrity through regulation of RhoA/Rho-kinase activity and modulation of 
cytoskeletal reorganisation, oxidative stress and tight junction protein expressions or 
localisations. 
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      The blood-brain barrier (BBB) serves as a selectively permeability barrier 
between systemic circulation and the central nervous system (CNS) whereby it plays a 
crucial role in maintaining the integrity and normal function of CNS. Several 
conditions associated with vascular abnormalities including hypertension, 
hyperglycaemia, ischaemia and hypercholesterolaemia exacerbate brain endothelial-
barrier dysfunction and cause paracellular flow of circulating molecules into the brain 
parenchyma, leading to vasogenic oedema and possibly death after a stroke (Sydow, 
2003, Hayashi et al., 2004). A plethora of deleterious molecular events are responsible 
for the endothelial-barrier dysfunction, which prominently include enhanced oxidative 
stress and inflammatory mediators (Petty and Wettstein, 2001, Brouns and De Deyn, 
2009). Recently, the roles of small GTP-binding protein RhoA and its effector Rho-
kinase have been highlighted in several cerebrovascular pathologies associated with 
increased vascular tone and endothelial remodelling (Chrissobolis and Sobey, 2006).  
This thesis focuses on the specific roles of RhoA/Rho-kinase pathway in cellular 
contractility, induction of the oxidative stress, modulation of tight junction and 
adherens junction proteins under physiological and pathological conditions, namely 
oxygen-glucose deprivation alone and followed by reperfusion (OGD±R) and 
hyperglycaemia. 
1. BBB structure and function 
     It is important to maintain the fragile extracellular microenvironment of the 
neuronal parenchyma for the normal functioning of the brain. The BBB is responsible 
for this protection and maintenance against noxious chemicals, variations in blood 
compositions and breakdown of concentration gradient and therefore regarded as the 
physical and the metabolic barrier between the CNS and the systemic circulation 
(Huber et al., 2001, Petty and Lo, 2002). 
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     The normal BBB phenotype consists of cerebral endothelial cells and their 
basement membrane together with perivascular cells including pericytes embedded 
within the basement membrane, perivascular monocytes, astrocytes and microglia. 
The cerebral microvasculature is ensheathed by astrocytic endfeet, which play an 
essential role in maintaining the BBB phenotype. It has been shown that astrocytes 
confer a protective role on the BBB against the hypoxia and aglycemia (Huber et al., 
2001, Ballabh et al., 2004). The BBB accounts for two main functions which are to 
protect the brain from the blood-borne substances that may damage its fragile 
extracellular environment and to ensure the supply of nutrients through specific 
transport systems, namely transcellular pathway (passage through the endothelial 
cells) and paracellular pathway (passage between the endothelial cells) (Zhang and 
Pardridge, 2001). The endothelial cells at the BBB are specially adapted to prevent 
the flow of molecules either between or across cells because these cells have a low 
rate of transcytosis and limited transcellular solutes trafficking (Vorbrodt and 
Dobrogowska, 2003). Moreover, the presence of the continuous strands of tight 
junction proteins completely seal the paracellular cleft between the lateral endothelial 
cells (Gloor et al., 2001). 
     The tight junction and the adherens junctions together form the junctional complex 
between the adjacent endothelial cells at the BBB (Petty and Lo, 2002). The number 
of tight junction strands and their frequency is variable. The tight junction is 
composed of three integral membrane proteins; claudins, occludins and the junction 
adhesion molecules (JAM) (Figure 1). The adherens junctions consist of a cadherin–
catenin complex and its associated protein. The third set of proteins includes the 
cytoplasmic accessory proteins such as zonula occludens (ZO-1, ZO-2, ZO-3) and 
cingulin. These proteins link the membrane proteins to actin, which is the main 
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cytoskeleton protein maintaining the structure and functionality of endothelium 
(Ballabh et al., 2004).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. A schematic representation of tightly sealed human brain microvascular 
endothelial cells forming a typical BBB. ZO: Zonula occludens; AF6, 7H6: accessory 
proteins. 
 
2. Proteins which mediate BBB integrity  
2.1. Tight junction proteins 
     The three integral proteins of the tight junction are occludin, claudins and JAMs. 
The former two constitute the backbone of tight junction strands while JAMs play an 
important role in routine trafficking of T-lymphocytes, neutrophils and dentritic cells 
from lymphoid and vascular compartments of tissue (Furuse et al., 1993, González-
Mariscal et al., 2003).  
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2.1.1. Claudins  
 
     Claudins are small phosphoproteins of about 20-22 kDa in size and have four 
transmembrane domains. They have two extracellular loops where the first one is 
significantly longer than the second one, and a short carboxy-intracellular tail. The 
last few amino acid of this tail are highly conserved within the family. The primary 
seal of tight junction is formed by the claudin dimers which bind homotypically to 
claudins on adjacent endothelial cells (Huber et al., 2001). Mammalian endothelial 
cells express solely claudin-1 and claudin-5 of which claudin-5 is expressed primarily 
in endothelial cells of blood vessels (Petty and Lo, 2002). 
2.1.2. Occludins  
 
     Occludins are phosphoproteins of 60-65 kDa in size. They are significantly larger 
than claudins and show no similarities to the claudins at amino acid sequence level 
(Wolburg and Lippoldt, 2002). Occludins have four transmembrane domains with 
amino and carboxy-terminals located intracellularly. They have two similar size 
extracellular loops and three cytoplasmic domains. Their extracellular loops have 45 
amino acids mainly tyrosine and glycine and are involved in cell-cell adhesion (Petty 
and Lo, 2002). Moreover, these extracellular loops of claudins and occludins 
originating from neighbouring endothelial cells form the paracellular barrier of tight 
junction at the BBB. The cytoplasmic domain of occludin is directly associated with 
the ZO proteins. The expression of occludin is much higher in brain endothelial cells 
as compared to nonneural tissues and they together with claudins contribute to the 
electrical resistance across the BBB (Sonoda et al., 1999, Gloor et al., 2001). 
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2.1.3. Junctional adhesion molecules 
 
     The JAM make up the third type of transmembrane tight junction proteins (Martìn-
Padura et al., 1998). The JAM belong to immunoglobulin super family and are about 
40 kDa in size. They have a single transmembrane domain and their extracellular 
portion (215 residues) contains two domains with intra-chain disulfide bonds typical 
of immunoglobulin like loops of the V-type (Citi and Cordenonsi, 1998). Three JAM 
related proteins have been identified while JAM-1 is expressed in endothelial and 
epithelial cells; JAM-2 and JAM-3 are expressed in most vascular endothelial cells 
(Ando-Akatsuka et al., 1996, Palmeri et al., 2000, Wolburg and Lippoldt, 2002).  
JAM are involved in cell-cell adhesion and contribute to monocyte extravasation.  
2.2. Adherens junction proteins 
     The adherens junction proteins also play a significant role in sealing the adjacent 
endothelial cells and  participate in preserving the endothelial-barrier integrity by 
stabilising the tight junction proteins. Like tight junction proteins, the adherens 
junction proteins also have transmembrane components like Ca2+-dependent 
cadherins, and the cytoplasmic components which include β-catenin, γ-catenin, 
vinculin, α-actinin, and p120-catenin. The cytoplasmic proteins link cadherins with 
actin cytoskeleton via α-catenin (Ballabh et al., 2004, Dejana et al., 2008).   
2.3. Cytoplasmic Accessory proteins 
 
     The cytoplasmic accessory proteins are involved in linking the membrane proteins 
to the cytoskeleton (Citi and Cordenonsi, 1998). They include ZO-1, ZO-2 and ZO-3, 
cingulin, 7H6 and several others. The ZO proteins belong to the membrane–
associated guanylate kinase proteins family which is involved in the coupling of the 
transmembrane proteins to cytoskeleton (Gloor et al., 2001). The ZO-1 (220 kDa), 
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ZO-2 (160 kDa) and ZO-3 (130 kDa) contains three PDZ domains (PDZ-1, PDZ-2 
and PDZ-3), one SH3 domain and one guanyl kinase like domain and bind to the actin 
filaments providing structural support to the endothelial cells (Gloor et al., 2001, Petty 
and Lo, 2002, Wolburg and Lippoldt, 2002). The other cytoplasmic accessory 
proteins include AF6 (180 kDa), 7H6 (155 kDa) and cingulin (140-160kDa). These 
are phosphoproteins which are found to localise on the cytoplasmic surface of the 
tight junctions and are pivotal in maintaining the tight junction complex stability and 
function. (Denker and Nigam, 1998). 
3. Physiology of RhoA/Rho-kinase pathway 
3.1. Rho GTPases  
     The low-molecular-weight (20-30 kDa) or small GTP-binding protein superfamily 
consists of more than 100 structurally similar proteins which act as molecular “on-
off” switches and control multiple intracellular signalling pathways. They are broadly 
divided into 5 families i.e. Ras, Rho, Arf, Rab, and Ran (Heo and Meyer, 2003). 
Among them, the Rho GTPase family has received much of the attention in recent 
years mainly because of their role in actin-cytoskeleton remodelling, cell adhesion, 
motility, migration and contraction  (Takai et al., 1995, Narumiya et al., 1997). 
Moreover, their activation also alters signalling pathways that regulate cell 
proliferation, gene expression, smooth muscle contraction, ion channel activity, 
endothelial permeability, reactive oxygen species (ROS) production and 
phospholipids metabolism  (Burridge and Wennerberg, 2004, Schwartz, 2004). The 
Rho family members differ from other small GTPases by the presence of a Rho-
specific insert domain and are approximately 25% identical to the members of Ras 
family (Ridley, 2001a, Boureux et al., 2007). So far, 20 members of Rho family have 
been identified in mammals, which are divided into 8 different subfamilies including 
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a Rho subfamily consisting of 3 members: RhoA, RhoB and RhoC (Miyagi et al., 
2000, Miao et al., 2001, Miao et al., 2002, Chrissobolis et al., 2004). The best studied 
members of Rho-GTPase family are RhoA, Rac1 and Cdc42 for their contribution to 
cell migration, cell division and contraction. Past studies have shown that RhoA 
regulates the actin stress fibre assembly, whereas Rac and Cdc42 regulate actin 
polymerization and cellular protrusions respectively (Ridley and Hall, 1992, Ridley et 
al., 1992). This precise regulation is reflected in a diverse set of cellular events, such 
as leukocyte infiltration, smooth muscle contraction, axon growth, cytokinesis and 
angiogenesis (Schlessinger, 1993, Ridley, 2001b, Etienne-Manneville and Hall, 2002, 
De Smet et al., 2009). Moreover, recent studies have shown cumulative roles of 
RhoA, Rac1 and Cdc42 in regulation and maintenance of endothelial barrier integrity, 
during various vascular pathologies (Wojciak-Stothard and Ridley, 2002, 
Vandenbroucke et al., 2008). In addition, it has been shown that RhoA plays a pivotal 
role in Ca2+ sensitization in both cerebral and noncerebral vascular tissues (Akopov et 
al., 1998).  
     The effects of active Rho GTPase on the actin cytoskeleton and cell morphology 
are mediated via stimulation of downstream effector kinases. These include citron 
kinase, p140 mammalian diaphanous (mDia), protein kinase N (PKN), p21-activated 
protein kinase (PAK), rhophillin, and rhotekin. However, the best known downstream 
effectors of RhoA are Rho-kinase and mDia (Leung et al., 1995, Ishizaki et al., 1996, 
Matsui et al., 1996, Riento and Ridley, 2003).      
3.2. Activation and regulation of RhoA  
     As mentioned earlier, RhoA is involved in regulation of various cellular activities 
like motility, proliferation, adhesion, remodelling, apoptosis, and gene expression 
(Burridge and Wennerberg, 2004). It regulates these activities by functioning as a 
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molecular “on-off” switch, cycling between an active GTP-bound state and an 
inactive GDP-bound state. 3 classes of enzymes regulate the cycle between active and 
inactive form of RhoA (Figure 2): (a) guanine-nucleotide exchange factors (GEF) that 
catalyses the exchange of GDP for GTP in the switch regions of RhoA and rendering 
RhoA activation; (b) GTPase-activating proteins (GAP) which inactivates active 
RhoA by accelerating intrinsic GTPase activity and dephosphorylating GTP to GDP 
and (c) guanine dissociation inhibitors (GDI) which keep RhoA in its inactive state by 
inhibiting the dissociation of bound GDP thereby preventing the membrane 
translocation of RhoA from the cytoplasm (Aspenström, 1999, Beckers et al., 2010).     
 
    
 
 
 
 
 
 
Figure 2. Activation and inactivation of RhoA regulated by small peptides 
     There are various agonists that regulate the activity of RhoA through 
heterotrimeric G protein coupled receptors (GPCR). It has been observed in non-
muscle cells that following stimulation by agonists like thrombin and thromboxane 
A2, the activated subunit of GPCR, Gα13 binds to p115Rho GEF and stimulates its 
activity to catalyze the GDP exchange for GTP on RhoA (Hart et al., 1998, Seasholtz 
et al., 1999). However, it has been reported that protein kinase C-α (PKC-α) and focal 
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adhesion kinase can also phosphorylate the serine and tyrosine residues of GEFs and 
activate them (Siehler, 2009).    
3.3. Rho-kinases 
     Rho-kinases are the ubiquitously expressed Ca2+-sensitizing serine-threonine 
kinases that were found to be the first downstream effectors of RhoA (Chikumi et al., 
2002). They are 40-50% homologous to other actin cytoskeleton kinases such as 
myotonic dystrophy kinase (DMPK), myotonic dystrophy-related Cdc42-binding 
kinase and citron kinase (Riento and Ridley, 2003). Rho-kinases have a 3 domain 
structure consisting of an amino-terminal kinase domain, followed by a mid-coiled-
coil-forming lesion containing a Rho-binding (RB) domain, and a carboxy-terminal 
cysteine-rich domain located within the pleck-strain homology (PH) motif. Rho-
kinase exists in 2 isoforms in the mammalian system; Rho-kinase-1 and Rho-kinase-2. 
Rho-kinase-1, also known as ROK-β and p160ROCK, is located on chromosome 18 
encoding a 1354 amino acids protein. On the other hand, Rho-kinase-2 also called 
ROK-α, is located on chromosome 12 and contains 1388 amino acids. Rho-kinase-1 is 
65% homologues to Rho-kinase-2 in amino acid sequence and 92% homologues in its 
kinase domain (Ishizaki et al., 1996, Matsui et al., 1996). The amino-terminal kinase 
domain has 72% amino acid sequence homology with the kinase domain of DMPK.  
     It has been observed that the binding of RB domain to GTP-RhoA enhances the 
Rho-kinase activity through depression of the carboxy-terminal RB-PH domain on the 
amino-terminal kinase domain, leading to an active “open” kinase conformation. 
Moreover, the lack of carboxy-terminal portion by cleavage also orientates Rho-
kinase to an open kinase conformation in a constitutively active form (Feng et al., 
1999b). By contrast, the kinase-activity-deficient form or the C-terminal fragments 
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lacking kinase domain, represent the dominant-negative form of Rho-kinase in cells 
(Leung et al., 1996, Amano et al., 1997, Amano et al., 1998). The dominant-negative 
form of Rho-kinase containing RB domain, specifically inhibits Rho-kinase activity 
and is used alongside several specific Rho-kinase inhibitors like Y-27632 and fasudil 
(HA1077) in many studies evaluating functional data in cells (Amano et al., 1999, 
Liao et al., 2007). 
     As mentioned earlier, Rho-kinases are ubiquitously expressed in mammals. In 
mouse tissues, Rho-kinase-1 mRNA was significantly expressed in lung, liver, spleen, 
kidney, and testis. In contrast, Rho-kinase-2 mRNA was highly expressed in the heart 
and brain (Nakagawa et al., 1996, Di Cunto et al., 2000). Moreover, the 
immunolocalization and cell fractionation studies have revealed that Rho-kinase-2 is 
distributed mainly in the cytoplasm, and is translocated to cell membrane after being 
activated by GTP-RhoA. In addition the subcellular localization of Rho-kinase-1 has 
been attributed to centrosomes (Kimura et al., 1996, Chevrier et al., 2002).  Since 
Rho-kinases control the actin cytoskeleton assembly and cellular contractility, they 
regulate cellular apoptosis, growth, migration, and metabolism by phosphorylation 
and inhibition of myosin phosphatase, phosphorylation of myosin light chain (MLC), 
and facilitating the interaction of myosin with F-actin, thereby initiating the formation 
of stress fibres and focal adhesion complexes (Uehata et al., 1997).                       
3.4. Myosin kinases 
     The phosphorylation of regulatory light chain of myosin-II molecule induces a 
change in its conformation and promotes the actomyosin filament assembly (van 
Nieuw Amerongen and van Hinsbergh, 2001). Rho-kinase-2 and myosin light chain 
kinases (MLCK) are responsible for this phosphorylation at Ser19 and Thr18 of MLC, 
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when induced by agonists that stimulate MLC phosphorylation (Amano et al., 1996). 
However, Rho-kinase-2-mediated phosphorylation of MLC was found to be ~3 times 
lower than that of MLCK, hence MLCK are considered to be principally responsible 
for MLC phosphorylation (Gong et al., 1996). The MLCK are Ca2+/calmodulin 
(CaM)-activated protein kinases which occur in several isoforms ranging from 130 to 
150 kDa in size (Gallagher et al., 1997). Studies on endothelial cells have reported 
few MLCK which are bigger in size and immunologically distinct from their original 
isoforms and are also regulated by Ca2+/CaM molecule (Gallagher et al., 1995, Garcia 
et al., 1997).          
3.5. RhoA/Rho-kinase regulated actomyosin contractility 
      It has been well documented that activated Rho-kinases control the 
polymerization/assembly of actin monomers and also regulate the cellular 
contractility. They do so by serine-threonine phosphorylation of their effectors like 
ezrin/radixin/moesin (ERM) proteins, LIM kinase (LIMK), α-adducin, MLC- 
phosphatase (MLCP), 17 kDa PKC-potentiated protein phosphatase-1 inhibitor 
protein (CPI-17), MLC and calponin (Kawano et al., 1999, Koyama et al., 2000, Sumi 
et al., 2001). These actin cytoskeletal proteins have consensus amino acid sequences 
for phosphorylation as R/KXS/T or R/KXXS/T (R: arginine; K: lysine; X: any amino 
acid; S: serine; T: threonine), and can also be phosphorylated by other serine-
threonine kinases like protein kinase A (PKA), PKC and G-kinases (Hartshorne, 
1998).       
3.5.1. Actin polymerization 
     Actin polymerization and reorganization are the pioneers in the cascade of events 
responsible for cellular contraction. The cellular protein cofilin binds to actin filament 
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and exhibits actin-depolymerizing activity (Carlier et al., 1997, Bamburg et al., 1999). 
This activity of cofilin is inhibited by phosphorylation at Ser3 by LIMK1 and LIMK2 
(Arber et al., 1998, Yang et al., 1998). It has been reported that Rho-kinase activates 
LIMK1 by phosphorylation at Thr508 and LIMK2 at Thr505, thereby curtailing the 
cofilin-mediated actin depolymerization (Ohashi et al., 2000, Sumi et al., 2001).  
     The ERM proteins are three closely related proteins, which function as cross-
linkers between plasma membrane proteins and actin filaments (Bretscher, 1983). 
Studies have shown that Rho-kinase phosphorylates ERM proteins at Thr567 of ezrin, 
Thr564 of radixin, and Thr558 of moesin. This results in the disruption of intermolecular 
head-to-tail association of ERM proteins and initiates actin cytoskeleton 
reorganization (Matsui et al., 1998). Studies have also shown that Rho-kinase-2 
phosphorylates and activates α-adducin, which assembles spectrin to the ends of actin 
filament, thereby increasing contractile response of actin cytoskeleton (Fukata et al., 
1999).  
3.5.2. Actomyosin contraction 
     The actomyosin contraction is corroborated by the formation of actomyosin 
bundles of anti-parallel actin filaments cross-linked by myosin-II, called as stress 
fibres (Narumiya et al., 2009). The formation and assembly of stress fibres is 
triggered by the Rho-kinase-mediated and MLCK-mediated phosphorylation of the 
regulatory subunit of MLC at Ser19. This causes major conformational changes within 
myosin molecule, and facilitates the cellular contraction by increasing actin-myosin 
interaction and propelling myosin to slide along the actin filaments (van Nieuw 
Amerongen and van Hinsbergh, 2001).  
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     Moreover, in many studies it was found that Rho-kinase further augments the 
MLC phosphorylation by inhibiting the MLC dephosphorylation activity of MLCP. 
MLCP holoenzyme is made of 3 subunits: a catalytic subunit (PP1δ), a myosin 
phosphatase targeting subunit-1 (MYPT1) composed of a 58 kDa head and 32 kDa 
tail region, and a small non-catalytic subunit, M21. Rho-kinase phosphorylates 
MYPT1 at Thr697, Thr855 and attenuates MLCP activity and in some studies, causes 
the dissociation of MLCP from myosin (Essler et al., 1998, Feng et al., 1999a, Fukata 
et al., 2001).  
      In another study, the inactivation of MLCP has also been attributed to CPI-17. 
CPI-17 is a phosphorylation-dependent inhibitory protein specific for MLCP. It was 
found that CPI-17 is also a downstream effector of Rho-kinase, and its 
phosphorylation increases the inhibitory effect of CPI-17 on MLCP activity (Koyama 
et al., 2000). Thus, Rho-kinase manoeuvres the MLC activity and actomyosin 
contractility by virtue of two processes: MLC phosphorylation and MLCP 
inactivation. In addition, calponin has also been reported as a downstream effector of 
Rho-kinase and plays a pivotal role in actin cytoskeleton remodelling. Calponin is an 
actin filament-associated protein and its binding to actin filament cast an inhibitory 
effect on the actin-activated myosin ATPase activity. Upon phosphorylation by 
various kinases like Rho-kinase, PKC and CaM-dependent protein kinase-II, the 
binding activity of calponin to actin filament gets significantly reduced, thereby 
regulating the actomyosin contractility (Kaneko et al., 2000). 
4. Ischaemic pathophysiology 
     Microglias are the resident immune cells in the brain that play a critical role in 
maintaining cerebral homeostasis and the BBB integrity (Gehrmann et al., 1995, 
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Hawkins and Davis, 2005). Upon activation following a cerebral injury like focal 
cerebral ischaemia, microglia migrate to the site of injury to exert a neuroprotective 
role through their ability to clear the dead tissue, inhibit excitotoxic neuronal damage 
and generate neuroprotective growth factors (Nakajima et al., 2001, Lu et al., 2005, 
Neumann et al., 2006, Turrin and Rivest, 2006, Ito et al., 2007). Contrary to this 
notion, previous in vitro studies under oxygen-glucose deprivation condition, which 
represents an aspect of ischaemia, have shown that the pharmacological inhibition of 
ischaemia-activated microglia attenuates the BBB disruption and the cerebral injury 
(Yenari et al., 2006). Activated microglia are implicated in the progression of cerebral 
neuro-inflammatory processes by increasing the production of pro-inflammatory 
cytokines such as interleukin-1β (IL-1β) and TNFα as well as chemokines, proteases, 
lipases, inducible nitric oxide synthase (iNOS), ROS and reactive nitrogen species 
which collectively compromise the BBB integrity and promote neuronal apoptosis 
(Wood, 1995, Flavin et al., 1997, del Zoppo et al., 2000, Wang et al., 2007). Indeed, a 
recent study focusing on an ischaemia-reperfusion (IR)-linked cerebral lesion, namely 
periventricular leukomalacia has shown that the activation of microglia is closely 
associated with increases in iNOS expression and activity (Haynes et al., 2009). 
Besides activated microglia, ischaemia-mediated astrocyte hyperactivity has also been 
linked to dramatic elevations in iNOS expression and activity and consequent cerebral 
damage further exacerbated by enhanced nitro-oxidative stress and increased infarct 
size, neuronal death and remodelling responses (Endoh et al., 1994, Yasuda et al., 
2004, Askalan et al., 2006, Haynes et al., 2009). In this context, inhibitions of iNOS 
and cyclooxygenases-2 (COX-2) activities via suppression of phosphoinositidyl 3-
kinase (PI3-K)/Akt, hypoxia inducible factor-1α (HIF-1α), nuclear factor-kappa B 
(NF-κB), Janus Kinase/Signal Transducer and Activator of Transcription 
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(JAK/STAT) and JNK/Stress-Activated Protein Kinase (SAPK) signalling pathways 
have been proposed as important molecular targets to mitigate the activated 
microglia-induced brain damage after ischaemia (Lu et al., 2006, Son et al., 2009, Oh 
et al., 2010, Kacimi et al., 2011). 
5. Alterations to BBB structure/function under ischaemic conditions  
     The detrimental effects of ischaemic stroke are brought upon the BBB as a result 
of cerebral thrombosis or embolism which decreases the blood supply to the CNS. 
This phenomenon evokes a cascade of deleterious biochemical events which include a 
rapid depletion of ATP molecules, activation of inflammatory processes, induction of 
proteases and oxidative stress (Assenza et al., 2009).     
     These events in turn disrupt extracellular matrix and contribute to the remodelling 
of endothelial cells thereby causing vasogenic oedema. Restoration of blood flow to 
ischaemic parts of brain is associated with enhanced tissue damage mediated partly by 
oxidative stress which results from the imbalance between generation and metabolism 
of superoxide anion (O2•−), the foundation molecule of other ROS (Raat et al., 2009). 
     It has been reported that in IR injury, the rapid ATP depletion impairs the 
Na+/K+ATPase in membrane and the Ca2+ATPase in endoplasmic reticulum, causing 
an increase in the intracellular Ca2+-concentration. Moreover, the influx of Ca2+ 
during reperfusion induces the activation of Ca2+-dependent enzymes and 
subsequently the actomyosin contractility (Solaini and Harris, 2005). Since rapid ATP 
depletion is also attributed to the ROS production, the ROS-mediated activation of 
RhoA has been demonstrated in vascular smooth muscles during IR injury (Ferrari et 
al., 1993, Jin et al., 2004). In recent years, the role of RhoA/Rho-kinase pathway has 
been studied in detail in cerebral and coronary vasospasm (Sato et al., 2000, 
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Masumoto et al., 2002). In various rat models of stroke, the inhibitors of RhoGTPase 
and Rho-kinase have been shown to improve the blood flow to ischaemic brain areas, 
decrease infarct volume, improve neurological functions and prevent neutrophil 
accumulation (Ohtaki and Tranmer, 1994, Satoh et al., 1999, Satoh et al., 2001). 
Recent studies using human endothelial cell lines have shown that protein levels of 
RhoA GTPase and Rho-kinase are increased significantly after 5 hours of hypoxia 
(Jin et al., 2006). Keeping that in mind our recent study has shown that ischaemia 
increases the expression and activity of RhoA GTPase and Rho-kinase, promotes the 
MLC2 phosphorylation and induces the actin stress fibre formation in human brain 
microvascular endothelial cells (HBMEC). By treating HBMEC with Y-27632 and 
electroporating with anti-RhoA-IgG, the effects of ischaemia were significantly 
attenuated. These observations were further substantiated by improved integrity and 
function of in vitro model of human BBB exposed to RhoA/Rho-kinase pathway 
inhibitors in the presence of OGD (Allen et al., 2010). A recent study has reported 
that during IR injury, ROS can directly activate RhoA in cells by oxidative 
modification of the critical cysteine residues within the redox-active motif of RhoA. 
Moreover, this mechanism of regulating RhoA/Rho-kinase pathway is independent 
but parallel to classical regulation by GEF and GAP (Aghajanian et al., 2009).  
6. Impact of hyperglycemia on BBB structure/function  
     Diabetes, a metabolic disorder associated with defects in either insulin production 
or utilisation, is one of the well-known risk factors for stroke. Approximately 40% of 
stroke patients have hyperglycaemia and nearly 50% of these patients have previously 
unrecognised glucose tolerance abnormalities. Hence, it is safe to state that 
hyperglycaemia plays an independent and possibly additive role in IR-mediated 
endothelial dysfunction during stroke (Goldstein et al., 2001, Allen and Bayraktutan, 
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2008). Hyperglycaemia-mediated endothelial dysfunction and injury has been 
attributed to increased oxidative stress, activation of polyol pathway, glucose auto-
oxidation, upregulation of diacylglycerol, activation of PKC, and the non-enzymatic 
glycation of proteins and lipids with the irreversible formation/deposition of advanced 
glycation endproducts (AGEs) in a variety of recent studies (Brownlee, 2001, 
Vlassara and Palace, 2002, Allen and Bayraktutan, 2009b). 
     It has been reported in many studies, that AGE in high concentration (≥ 0.6 µM) 
induce the formation and upregulation of hyperpermeability mediators like pro-
inflammatory cytokines e.g. TNF-α and IL-1 (Bonnardel-Phu et al., 1999, Otero et al., 
2001). Moreover, hyperglycaemia has also been reported to upregulate another 
hyperpermeability mediator namely vascular endothelial growth factor (VEGF) and 
its receptor VEGFR-2. These mediators are known to produce vasoactive and 
cytotoxic effects on vascular endothelium and activate a number of signalling 
pathways that promote endothelial remodelling and hyperpermeability (Caldwell et 
al., 2005, Kumar et al., 2009). In recent years, several studies have confirmed a direct 
relationship between diabetes and increased cerebrovascular RhoA/Rho-kinase 
activity. Moreover, the use of fasudil has shown to ameliorate hyperglycaemia-
induced microvascular damage in retinas of diabetic rats (Miao et al., 2002, Arita et 
al., 2009). The increased RhoA/Rho-kinase activity has also been confirmed by 
looking into the functional data from cerebral arterioles of type-2 diabetic mice which 
showed an enhanced dilator response to Y-27632 compared to control mice (Didion et 
al., 2005). Hence it is possible that through the activation and upregulation of 
RhoA/Rho-kinase pathway, hyperglycaemia augments the endothelial barrier 
dysfunction and remodelling thereby perturbing the BBB integrity and further 
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contributing to the vascular injury during ischaemic stroke (Srivastava and 
Bayraktutan, 2010).     
7. Drugs and inhibitors of Rho/Rho-kinase pathway 
     Aberrant Rho/Rho-kinase pathway activation has been reported in various 
cardiovascular, cerebrovascular, respiratory and dietary disorders. The Rho-kinase 
inhibitors have shown considerable improvement in Alzheimer’s disease, bronchial 
asthma, cancers, glaucoma and osteoporosis (Liao et al., 2007). Y-27632 has been 
used in several animal models as well as in our recent cell culture studies with 
HBMEC mainly because it is a small cell-permeable molecule. Another cell-
permeable Rho-kinase inhibitor, fasudil has been shown to prevent cerebral 
vasospasm after subarachnoid haemorrhage (Sato et al., 2000). Both of these 
inhibitors block the Rho-kinase activity by competing with ATP for binding and are 
therefore equipotent in inhibiting both isoforms of Rho-kinase. Moreover, higher 
concentrations of these inhibitors have been reported to inhibit other serine-threonine 
kinases, like PKA and PKC. On the contrary, the hydroxyl form of fasudil, 
hydroxyfasudil, is relatively more selective for Rho-kinases than fasudil and Y-27632 
and has a half-life greater than 5 hours compared to the extremely short half-life of 
fasudil (0.5 hours) (Rikitake et al., 2005).       
     In recent studies, RhoA GTPase has been targeted as an alternative to Rho-kinase 
inhibition to attenuate the Rho/Rho-kinase pathway. Ca2+-dependent enzyme, 
Transglutaminase2 (TGase2) catalyses the post-translational modification of RhoA by 
polyamination or deamidation at Gln63 and constitutively activates RhoA (Masuda et 
al., 2000, Singh et al., 2001). It has been reported that cystamine, an oxidized dimer of 
cysteamine and an inhibitor of TGase2 significantly prevented rat cardiomyocytes to 
IR-mediated injuries by inhibiting enhanced TGase-mediated RhoA/Rho-kinase 
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pathway during IR (Shin et al., 2008). C3-exoenzyme (transferase), another RhoA 
inhibitor has produced significant decreases in size of cerebral infarcts in mice models 
of middle cerebral artery occlusion (MCAO) (Laufs et al., 2000).  
     Moreover, the 3-hydroxy-3-methyl-glutarul coenzyme A (HMG-CoA) reductase 
inhibitors, commonly known as statins have been used to inhibit the RhoA/Rho-
kinase pathway. For many years, statins have been prescribed to reduce plasma 
cholesterol levels (Liao and Laufs, 2005). Recently, a number of pleiotropic effects of 
statins have been reported that extend beyond their cholesterol lowering activity. As 
indicated above statins block the cholesterol biosynthesis by inhibition of HMG-CoA 
reductase and subsequent synthesis of isoprenoid intermediate (farnesyl 
pyrophosphate or geranylgeranyl pyrophosphate). Importantly, the 
geranylgeranylation of RhoA is a prerequisite for Rho activation by facilitating its 
conformational change and interaction with plasma membrane where GDP-GTP 
exchange occurs. Hence, by inhibiting Rho isoprenylation, statins decrease membrane 
targeting and subsequent activation of RhoA GTPase (Takemoto and Liao, 2001).      
8. NADPH oxidase enzyme and superoxide anion metabolism 
     Cerebral reperfusion, achieved by the reestablishment of blood flow to ischaemic 
part of the brain is associated with enhanced tissue damage mediated in part by 
oxidative stress which emerges due to an imbalance between generation and 
metabolism of O2•–, the foundation molecule of all ROS (Raat et al., 2009). Although 
a number of enzymatic and nonenzymatic mechanisms (Figure 3) including leakage 
from the mitochondrial electron transport system, xanthine oxidase, COX, 
lipooxygenase, and uncoupled endothelial NOS may account for exaggerated 
production of O2•– in the brain, the nicotinamide adenine dinucleotide phosphate-
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oxidase (NADPH oxidase) has recently attracted much of the attention as it has been 
found to represent the major source of ROS in endothelial cells of different origins 
(Margaill et al., 2005, Selemidis et al., 2008). NADPH oxidase was first identified in 
phagocytic cells, and since then numerous isoforms of ‘classical’ NADPH oxidase 
have been identified in vascular cells which primarily differ in the nature of their 
catalytic ‘Nox’ subunit i.e. gp91-phox (Miller et al., 2006). To date, 7 other Nox 
isoforms have been discovered which are homologus to gp91-phox (Nox2), namely 
Nox1–Nox7. Among these Nox1, Nox2, Nox4, and Nox5 are highly expressed in 
vascular tissues and are the major source of ROS production in cardiovascylar system 
(Lassegue and Griendling, 2010). NADPH oxidase is a multi-component enzyme 
system comprising several cytosolic subunits such as small G protein Rac1, p47-phox, 
p67-phox and a membrane-bound cytochrome b558 domain consisting of gp91-phox 
and a stabiliser protein p22-phox that upon activation form functional enzyme 
complex. The O2•– produced from NADPH oxidase acts as a signalling molecule and 
activates a cascade of intracellular signalling mechanisms including mitogen-activated 
protein kinases (MAPK), PKC and PI3K. Furthermore, elevated levels of O2•– has also 
been implicated in the BBB hyperpermeability to large molecules in mice after IR 
injury (Stenmark et al., 2006, Chrissobolis and Faraci, 2008, Sandoval and Witt, 
2008).   
     The O2•– produced from various enzyme complexes is dismutased by antioxidant 
enzyme superoxide dismutase (SOD) to generate hydrogen peroxide (H2O2), another 
ROS. In physiological conditions, low levels of intracellular or extracellular ROS 
including O2•– and H2O2 participate in many cellular functions such as intracellular 
signalling and defence against invading microorganisms. However, high levels of 
ROS are implicated in the pathogenesis of many vascular complications which 
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include hypercholesterolemia, atherosclerosis, diabetes, hypertension, and myocardial 
infaction. In mammals, three isoforms of oxidoreductase SOD have been identified 
which are SOD1 (CuZn-SOD), SOD2 (Mn-SOD), and SOD3 (extracellular-SOD). 
The dismutation reactions vary slightly with these SOD isoforms because of different 
redox active transition metal required for the enzyme activity (Fukai and Ushio-Fukai, 
2011). The H2O2 generated after dismutation reaction is further metabolised to water 
and molecular oxygen by other antioxidant enzymes namely; catalase and glutathione 
peroxidase. It is of note here that recent in vivo studies using transgenic mice 
overexpressing catalase alone or with CuZn-SOD have been shown to be resistant to 
atherosclerosis due to their  vascular protective effects (Yang et al., 2004).     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
23 
 
NADPH oxidase
Xanthine 
oxidase
Lipooxygenase
Cyclooxygenase
eNOS
uncoupling
Mitochondrial 
electron transport
O2•–
H2O2
SODs (SOD1, 
SOD2, SOD3)
Catalase
H2O, O2H2O
Glutathione 
peroxidase
H2O2
ONOO–
NO•
OH•
Cu2+ Fe2+
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Metabolism of the reactive oxygen species (ROS). The prooxidant enzyme 
complexes (blue) generate ROS (O2•–), which under physiological conditions are 
rapidly converted into less toxic/non-toxic products by enzymatic and nonenzymatic 
protective mechanisms (green). ONOO–: peroxynitrite; NO•: Nitric oxide, O2•–: 
superoxide anion; H2O2: hydrogen peroxide; OH•: hydroxyl radical; H2O: water; O2: 
oxygen.   
9. Protein kinase C 
     The PKC is a family of enzymes that modulate the function of other proteins 
through phosphorylation of serine and threonine residues on them. The family 
possesses ten different isoforms that are classified into three different subfamilies, 
namely conventional (α, βI, βII and γ), novel (δ, ε, θ, η) and atypical (ζ and λ), on the 
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basis of their second messenger requirements (Geraldes and King, 2010). Due to the 
multiplicity of isozymes, the PKC is amenable to activation by many patho-
physiological stimuli and thus involved in a wide spectrum of functions ranging from 
the mediation of immune responses to modulation of cell growth, contractility and 
permeability. Recent data have shown that activation of PKC, especially its β isoform, 
results in vascular hyper-permeability in organs that present ischaemic injury- or 
diabetes-mediated damage such as heart and retina (Hink et al., 2001, Bayraktutan, 
2002, Geraldes and King, 2010). Specific increases in PKC-α and PKC-β protein 
expressions have also been reported in the brain infarcts of deceased ischaemic stroke 
patients (Xu et al., 2010). Given the profound involvements of PKC in the regulation 
of endothelial function and pathologies associated with barrier failure such as 
oxidative stress and inflammatory responses, it is safe to hypothesise that several PKC 
isoform(s) may be involved in the prevention or reversal of hyperglycaemia-evoked 
cerebrovascular damage (Stamatovic et al., 2006). In support of this notion, 
pharmacological inhibitions of PKC-α or PKC-β isoforms have previously been 
shown to exert vasculoprotection through negating the advanced glycation end 
products-induced inflammation and inhibitions of ZO-1 translocation, occludin 
phosphorylation and small GTP-binding protein RhoA glucosylation (Hink et al., 
2001, Chen et al., 2002, Harhaj et al., 2006, Stamatovic et al., 2006, Xu et al., 2010). 
10. Hypotheses          
    As mentioned earlier, occludins are implicated in increased tightness of the 
junctions and ZO-1 are known to anchor transmembrane proteins to endothelial cells 
(Furuse et al., 1998). Therefore, hyperglycaemia-induced putative changes in 
HBMEC phenotype and/or tight junction assembly may account for endothelial 
barrier hyperpermeability and endothelial-barrier dysfunction. Although several 
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mechanisms including the irreversible formation and accumulation of AGE, the 
activation of polyol pathway or stimulation of PKC have been implicated in diabetes-
mediated peripheral vascular pathologies, the mechanisms involved in 
hyperglycaemia-mediated cerebral barrier failure remain largely unknown 
(Bayraktutan, 2002). Recently, the roles of small GTP-binding protein RhoA and its 
effector Rho-kinase have been highlighted in several cerebrovascular pathologies 
including diabetes that are inextricably linked with cerebral barrier hyperpermeability. 
Once activated RhoA activates Rho-kinase which promotes MLC2 phosphorylation, 
actin stress fibre formation and mitigates the nitric oxide (NO) bioavailability (Van 
Aelst and D'Souza-Schorey, 1997, Takemoto et al., 2002). Since increased MLC2 
phosphorylation is linked to destabilization of the tight junction proteins and promote 
actomyosin contractility followed by hyperpermeability, it is possible that the 
suppression of RhoA/Rho-kinase pathway may be of clinical significance in reverting 
the hyperglycaemia-evoked barrier dysfunction by stabilising the endothelium 
effected by diabetes mellitus (Allen and Bayraktutan, 2009a). Thus, current thesis 
hypothesises that the activation of PKC and RhoA/Rho-kinase pathways under 
hyperglycaemia may perturb the physiological role of endothelial cells and 
compromise the BBB integrity. This may be due to enhanced cytoskeletal remodelling 
and modulation of junctional complexes. Studying these signaling pathways will 
enable us to identify new potential pharmacological targets/strategies for the stroke 
treatment.  
     Recent in vitro and in vivo studies on mice model of ischaemic stroke have shown 
that IR injury is associated with enhanced cytoskeletal remodelling and induction of 
oxidative stress which is responsible for the endothelial barrier hyperpermeability 
(Solaini and Harris, 2005, Raat et al., 2009). It has been shown that oxidative stress 
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modulates the tight junction and adherens junction proteins and disrupts the cerebral 
barrier integrity (Guntaka et al., 2011). However, the molecular mechanisms behind 
the  IR-mediated cerebral barrier faliure remain largly unexplored. Hence,  the current 
thesis also hypothesises that OGD±R may compromise the BBB integrity via 
enhanced cytoskeletal remodelling and induction of oxidative stress which could be 
associated with the RhoA/Rho-kinase pathway. This will lead to a better 
understanding of the signalling pathway and will help in identifing new molecular 
targets against oxidative stress-mediated pathologies which include ischaemic stroke 
and myocardial infarction.  
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General methods and approach 
     The following list of chemicals and equipment were used in various experimental 
methodologies outlined in this chapter. 
1. Chemicals and equipment 
 
Materials Company Origin 
Human brain microvascular endothelial cells ScienCell research Labs USA 
Human astrocytes ScienCell research Labs USA 
Dulbecco’s Modified Eagle’s Medium Sigma-Aldrich UK 
Bisindolylmaleimide-I Calbiochem (Merck) UK 
SB203580 Calbiochem (Merck) UK 
Y-27632 Calbiochem (Merck) UK 
LY333531 Calbiochem (Merck) UK 
Ro-32-0432 Calbiochem (Merck) UK 
CGP53353 Calbiochem (Merck) UK 
Rottlerin Calbiochem (Merck) UK 
His-RhoA-L63 Cytoskeleton USA 
Odyssey blocking buffer Li-Cor Biosciences Germany 
Rhodamine phalloidin dye Invitrogen UK 
Bovine serum albumin Sigma-Aldrich UK 
Foetal bovine serum (FBS) Sigma-Aldrich UK 
Leupeptin Sigma-Aldrich UK 
Aprotinin Sigma-Aldrich UK 
Trypsin 10X Sigma-Aldrich UK 
Protease cocktail inhibitor Sigma-Aldrich UK 
Phenylmethanesulfonyl fluoride (PMSF) Sigma-Aldrich UK 
Triton X-100 Sigma-Aldrich UK 
4',6-diamidino-2-phenylindole (DAPI) Sigma-Aldrich UK 
Formaldehyde Sigma-Aldrich UK 
Paraformaldehyde Sigma-Aldrich UK 
Tween-20 Sigma-Aldrich UK 
D-mannitol Sigma-Aldrich UK 
Evan's blue Sigma-Aldrich UK 
40% Acrylamide Sigma-Aldrich UK 
Sodium fluorescein Sigma-Aldrich UK 
Cytochrome C Sigma-Aldrich UK 
NADPH Sigma-Aldrich UK 
Lucigenin Sigma-Aldrich UK 
L-NAME Sigma-Aldrich UK 
Rotenone Sigma-Aldrich UK 
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Allopurinol Sigma-Aldrich UK 
Indomethacin Sigma-Aldrich UK 
Rho activation assay kit Upstate Millipore USA 
Non-radioactive Peptag total PKC activity kit Promega UK 
siRNA oligonucleotides (PKC-α, PKC-β) Dharmacon USA 
siRNA transfection reagents 1, 4 Dharmacon USA 
Antibodies   
Occludin Santa Cruz biotechnology Germany 
RhoA Santa Cruz biotechnology Germany 
Rho-kinase-2 Santa Cruz biotechnology Germany 
Myosin light chain-2 (MLC2) Santa Cruz biotechnology Germany 
p-MLC2Ser19 Santa Cruz biotechnology Germany 
p-MLC2Thr18/Ser19 Santa Cruz biotechnology Germany 
gp91-phox Santa Cruz biotechnology Germany 
Vinculin Santa Cruz biotechnology Germany 
PKC-α Santa Cruz biotechnology Germany 
PKC-βI Santa Cruz biotechnology Germany 
CuZn-SOD Sigma-Aldrich UK 
Catalase Sigma-Aldrich UK 
β-catenin Sigma-Aldrich UK 
β-actin Sigma-Aldrich UK 
Claudin-5 Abcam UK 
Zonula occludens-1 Abcam, Invitrogen UK 
α-tubulin Abcam UK 
Infrared (IR) dye 700/800 secondary antibody Li-Cor Biosciences Germany 
FITC-conjugated secondary antibody Axxora USA 
Equipment/apparatus   
6-well tissue culture plates Corning Life sciences UK 
12-well tissue culture plates Corning Life sciences UK 
96-well tissue culture plates Corning Life sciences UK 
Tissue culture flasks (T-25, T-75, T-225) Corning Life sciences UK 
12mm diameter, 0.4µm pore size, polyester 
membrane transwell inserts Corning Life sciences UK 
Cell scrappers TPP Switzerland 
8-chamber tissue culture slides BD Biosciences UK 
Fluorescence plate reader TECAN GENios USA 
Absorbance/luminescence plate reader BMG LABTECH Omega  USA 
Spectrophotometer Berthold Technologies USA 
Zeiss fluorescence microscope Carl Zeiss GmbH Germany 
Odyssey IR imaging system Li-Cor Biosciences Germany 
PAGE apparatus Bio-Rad UK 
Amersham hybond PVDF membrane GE Healthcare UK 
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O2-controlled hypoxic tissue culture incubator Sanyo USA 
CO2-controlled tissue culture incubator Sanyo USA 
N2 cylinders Airproducts UK 
Electroporator (1.8 kV) Equibio Easyject Prima USA 
Electroporation cuvettes Fisher scientific UK 
 
2. Human tissue culture 
     HBMEC and human astrocytes (HA) were cultured up to passage 7 to retain the 
barrier specific properties in Dulbecco’s Modified Eagle’s Medium (DMEM) 
containing 10% foetal bovine serum, penicillin (100 units/mL), and streptomycin (100 
µg/mL) in a humidified atmosphere (95% relative humidity) under normal conditions 
(70% N2, 25% O2, 5% CO2 and 5.5 mM D-glucose at 37ºC).  
2.1. Experiments under hyperglycaemic conditions 
     To study the effects of hyperglycaemia, HBMEC were exposed to 
normoglycaemia (5.5 mM D-glucose), hyperglycaemia (25 mM D-glucose), D-
mannitol (5.5 mM D-glucose + 19.5 mM D-mannitol) for 72 hours with media 
replacement every 24 hours to maintain the constant glucose levels. Experiments with 
D-mannitol were performed to assess how much of the putative changes that may be 
observed with hyperglycaemia could be attributed to an increase in osmolality. To 
determine the possible therapeutic effects of glucose normalisation on 
hyperglycaemia-mediated barrier dysfunction, in some experiments HBMEC were 
successively subjected to equal periods (72 hours) of hyperglycaemia followed by 
normoglycaemia (HG/NG). The relevance of Rho-kinase (Y-27632; 2.5 µM), 
p38MAPK (SB203580; 10 µM), PKC (Bis-I; 5 µM) and its specific isoforms PKC-α 
(Ro-32-0432; 1-5 µM), PKC-β (LY333531; 0.5-5 µM), PKC-βII (CGP53353; 1 µM), 
PKC-δ (rottlerin; 5 µM), to hyperglycaemia-mediated barr
31 
 
coexposure of HBMEC to hyperglycaemia and their specific inhibitors indicated in 
brackets.  
2.2. Experiments under oxygen-glucose deprivation condition  
     To study the effects of IR injury mimicked by OGD±R, the confluent HBMEC 
were cultured in glucose-free RPMI-1640 media under hypoxic (94% N2, 1% O2 and 
5% CO2 at 37ºC) conditions. To study the reperfusion-mediated pathological 
alterations, some of the HBMEC flasks were reintroduced to the normal conditions 
for 20 hours after exposure to OGD. HBMEC cultured under normal conditions 
served as controls. The therapeutic effects of Rho-kinase inhibition on HBMEC were 
studied by cotreatments with Y-27632 (10 µM) and OGD±R. The HA were cultured 
in DMEM under normal conditions and were used in establishing the in vitro models 
of human BBB. The normal morphologies of HBMEC and HA cultured on coverslips 
in complete DMEM have been illustrated in figure 4.  
 
 
 
 
 
 
                        HBMEC                                                                  HA 
 
Figure 4. HBMEC and HA cultured to subconfluence in complete DMEM as 
observed by 20X magnification on a light microscope. Bar scale: 50 m. 
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3. In vitro model of human blood-brain barrier 
     To generate an in vitro model of human BBB, HBMEC were cocultured with HA 
to maximum confluence. This enabled HBMEC to maintain their barrier specific 
properties. HA (~75,000 cells/150 µL DMEM) were seeded on the basolateral side of 
polyester membrane Transwell inserts (12 mm diameter, 0.4 µm pore size) directed 
upside down in the 6-well tissue culture plates. Following overnight adherence of HA 
to the membranes, the inserts were inverted the correct way in sterile 12-well tissue 
culture plates containing fresh DMEM (1.5 mL) and were kept under normal tissue 
culture conditions until attainment of ~90% confluence.  Thereafter, the HBMEC 
(~50,000 cells/150 µL DMEM) were seeded onto the inner part of the same inserts, 
and the cells were cultured to the maximum confluence under normal conditions 
before exposing the in vitro model of BBB to the experimental conditions. Equal 
number of HBMEC and HA used to start the preparation of the in vitro model of BBB 
were also seeded separately to form monolayers on the fresh inserts to monitor the 
cell proliferation rate and confluence simultaneously with the cocultures. A 
diagrammatic representation of the in vitro model of human BBB in a single well of a 
12-well plate is illustrated in figure 5.  
 
 
 
 
 
 
Figure 5. The in vitro model of human BBB consisting of HBMEC and HA 
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     To study the effects of hyperglycaemia on the BBB, HBMEC and HA cocultures 
were incubated for 72 hours under abovementioned conditions in the presence and 
absence of specific inhibitors outlined earlier in this chapter. Similarly, the cocultures 
were also exposed to OGD±R.  
3.1. Measurements of the in vitro blood brain-barrier integrity and function 
     The integrity and function of HBMEC and HA cocultures were assessed by 
measurements of transendothelial electrical resistance (TEER) and the flux of 
permeability markers sodium fluorescein (NaF; 376 Da), and Evan’s blue-labelled 
with 0.1% albumin (EBA; 67 kDa) across the barrier, respectively. After exposures to 
experimental conditions TEER across the cocultures were measured by EVOM 
electrodes on an EVOM resistance meter and expressed relative to the surface area of 
HBMEC monolayer in “cm2”. Thereafter, the inserts were transferred to the fresh 
wells in sterile 12-well plates containing Hank’s buffered salt solution (HBSS; 2 mL) 
in basolateral side. To the lateral side of the inserts, either NaF (10 µg/mL) or EBA 
(165 µg/mL; 0.5 mL) was gently added and the permeability of markers were 
analysed by carefully collecting the lateral and basolateral samples (400 µL) after 1 
hour of incubation. The concentration of EBA and fluorescein molecules in the 
samples were measured by using a BMG LABTECH Omega plate reader 
(absorbance: 610 nm) and fluorescent TECAN GENios plate reader (excitation: 440 
nm, emission: 525 nm) and the flux of permeability markers were calculated as 
cleared volume (µL) by the formula: Cleared volume = Concentration(basolateral reading) x 
Volume(basolateral) x Concentration(lateral reading)-1. The average cleared volumes were 
represented as histograms to display the NaF and EBA passage across the cocultures 
subjected to pathological versus normal conditions. A diagrammatic representation of 
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the TEER measurement and NaF, EBA flux across the in vitro model of human BBB 
is illustrated in figure 6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Measurements of the blood-brain barrier integrity and function by (A) 
TEER and (B) flux of NaF or EBA, respectively. 
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4. In-cell Western analysis 
     To detect the differences in the intracellular protein expressions, HBMEC (~5000 
cells/well) were seeded on sterile 96-well tissue culture plates and were exposed to 
normal tissue culture conditions to proliferate into subconfluent monolayers before 
subjecting to experimental and corresponding control conditions. For example, after 
treatment with hyperglycaemia in the presence or absence of inhibitors, the DMEM 
was aspirated carefully and the HBMEC monolayers were fixed in fixing solution 
composed of 3.7% formaldehyde/phosphate buffer saline (PBS), (20 minutes), 
followed by permeabilisation by Triton washing solution (0.1% Triton X-100/PBS, 20 
minutes) and blocking by either Odyssey blocking buffer or 1% BSA/PBS (1 hour) at 
room temperature. Following the blocking step, HBMEC were then successively 
incubated with primary antibodies (1-5 µg/mL, overnight at 4º C) raised against 
human RhoA, Rho-kinase-2, total MLC2, p-MLC2-Ser19, p-MLC2-Thr18/Ser19, 
occludin, ZO-1 and α-tubulin. Thereafter, the cells were washed with Tween washing 
solution (0.1% Tween-20/PBS, 25 minutes at room temperature) on an orbital shaker 
and incubated with species-specific infrared 700/800-dye-tagged secondary antibodies 
(1 hour, room temperature) in dark.  The cells were further washed as previously 
described and the plates were inverted to remove any residual washing solution. The 
plates were protected from light and were scanned on the Odyssey infrared imaging 
system to measure the infrared intensities corresponding to the intracellular protein 
levels in the HBMEC monolayer. Using the Li-Cor imaging software, the fold 
differences in the protein levels were calculated after normalisation against the 
infrared intensities corresponding to the internal control α-tubulin in the same well to 
eliminate the possibilities of unequal cell numbers.  
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5. Protein sample preparation and quantification 
     Firstly, the cells grown in cell culture flasks were washed twice with sterile PBS. 
The cells were dislodged from the flask by a sterile cell scrapper and were 
concentrated in the cell-lysis buffer (0.1% Triton X-100/PBS) containing protease 
cocktail inhibitor and phenylmethanesulfonyl fluoridePMSF). The cells were lysed 
by sonication and cell homogenates were collected in pre-cooled eppendorf tubes on 
ice. Half of the cell homogenates were aliquoted and stored at -80ºC and cell debris in 
the remaining protein samples were removed by centrifugation (12,000 rpm/10 
minutes) followed by storage at -80ºC. A small volume of protein samples and cell 
homogenates were used for protein quantification by Bradford assay using detergent-
sensitive Coomassie plus assay kit.      
     The total proteins in samples were quantified by Coomassie plus assay kit to 
ensure that equal amount of proteins are used in Western blottings and enzyme 
activity assays. Briefly, in a 96-well plate the bovine serum albumin (BSA) standards 
(10 µL) with known protein concentrations (0, 25, 125, 250, 500, 750, 1000, 1500 and 
2000 µg/mL) were mixed with Coomassie plus reagent (300 µL) in duplicates and a 
standard curve with its equation were derived from the absorbance values (610 nm) 
measured on the BMG LABTECH Omega plate reader after the colorimetric analysis. 
The figure 7 illustrates a representative standard curve and its equation used to 
quantify the protein levels in the unknown HBMEC samples. 
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Figure 7. The BSA standard curve and corresponding equation of a straight line for 
the protein quantification in tissue culture samples. 
 
6. Western blotting 
     Western blotting is a technique to resolve proteins depending on their molecular 
weight on polyacrylamide gels, and to compare the fold differences in their levels 
observed by immuno-specific reactions on the PVDF or nitrocellulose membranes. 
Various buffers including running buffer, transfer buffer, and washing buffer were 
used during Western blotting procedure to resolve and transfer the proteins onto the 
membranes followed by washing to remove excess of antibodies to minimise the 
background and maximise the signal intensity. A detailed recipe of these buffers and 
polyacrylamide gels are illustrated in appendix I.  
     Equal quantities of protein samples and cell homogenates were reduced (2-
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structures (100ºC, 5 minutes).  The samples were resolved on SDS-polyacrylamide 
gels (7.5-15%) and proteins were transferred on the methanol-activated PVDF 
membranes followed by blocking (either with 5% dry milk, or with 5% BSA/PBS; 1 
hour). The membranes were probed with primary antibodies against human antigens 
illustrated in appendix II followed by washing with the wash buffer (1X TBST). The 
membranes were subsequently probed with species-specific infrared 700/800-tagged 
secondary antibodies (1 hour) and were again washed to remove excessive antibodies 
to reduce the background and increase the signal intensities. The protein bands on the 
membrane were visualised by scanning on the Odyssey infrared imaging system and 
band intensities obtained by Li-Cor imaging software were used to calculate the 
relative band intensities between different treatment regimens after normalisation 
against the loading control β-actin. 
7. Rho activation assay  
    To measure the RhoA activity in HBMEC under abovementioned treatment 
regimens, the “Rho pulldown assay” was used to detect active RhoA-GTP isoform.. 
Briefly, the HBMEC were lysed in 1X Mg2+ lysis buffer in the presence of protease 
inhibitors aprotinin (10 µg/mL), leupeptin (10 µg/mL) and protease cocktail inhibitor 
at 4ºC. The cell homogenates were centrifuged (14,000 g for 5 minutes at 4ºC) and 
cell lysates were collected for total protein quantification by Bradford assay. Equal 
amount of protein samples were incubated with rhotekin-RhoA binding peptide 
immobilised on agarose beads (10 L) for 45 minutes at 4ºC with gentle shaking 
followed by centrifugation (14,000 g for 10 seconds at 4ºC).  The pellets were rinsed 
three times with 1X Mg2+ lysis buffer and dislodged in 2X laemmli reducing buffer 
(25 L). 20 µL of suspension samples were resolved on SDS-polyacrylamide gels 
(10%) followed by transfer of proteins on methanol-activated PVDF membranes. The 
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membranes were probed with primary antibody raised against human RhoA and 
subsequently with species-specific infrared 800-tagged secondary antibody. The 
protein bands on the membrane were visualised by scanning on the Odyssey infrared 
imaging system and band intensities obtained by Li-Cor imaging software were used 
to calculate the relative RhoA activities between different treatment regimens after 
normalisation against the total RhoA levels detected as described above. 
8. Immunocytochemistry  
     To analyse the cellular localisation of proteins of interest, the HBMEC were 
cultured on glass coverslips to subconfluence under experimental and corresponding 
control conditions. Following the treatments, the DMEM was carefully aspirated and 
the cells were fixed (4% paraformaldehyde/PBS, 15 minutes), permeabilised (0.1% 
Triton X-100/PBS, 15 minutes) and blocked (10% BSA/PBS, 1 hour) at room 
temperature. The cells were either incubated with Rhodamine-labelled phalloidin dye 
for F-actin staining (200 U/mL, 20 minutes, room temperature) or with primary 
antibodies against human tight junction proteins i.e. occludin (20 µg/mL) and ZO-1 (4 
µg/mL), human RhoA (2.5 µg/mL) and human Rho-kinase-2 (2.5 µg/mL) for 
overnight at 4º C in 1% BSA/PBS. The coverslips were washed by Tween washing 
solution (0.1% Tween-20/PBS, three times 5 minutes, room temperature) and the cells 
were incubated with FITC-labelled species-specific secondary antibody (1:100 in 1% 
BSA/PBS, 1 hour, room temperature) in dark. The coverslips were washed and 
incubated in 4',6-diamidino-2-phenylindole (DAPI) (5 minutes, room temperature) in 
dark. The excessive DAPI was removed by washing and the coverslips were mounted 
using glycerol/PBS (3:1), and the edges were sealed by nail polish. The cellular 
localisation of tight junction proteins and F-actin were observed under 40X 
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magnification on a Zeiss Axio Observer fluorescence microscope and pictures 
captured by Sony cybershot digital camera.  
9. Transfection experiments 
     To modulate the RhoA GTPase activity, HBMEC (~5x106) were resuspended in a 
FBS and antibiotics-free RPMI 1640 media (100 µL) in a pre-chilled sterile electrode 
cuvette. 3 µg/cuvette of either His-RhoA-L63 or anti-RhoA-IgG was added to the cell 
suspension before electroporation at 1.8 kV. Similar procedure with equal volume of 
ultrapure H2O served as electroporation controls. The viabilities of the electroporated 
cells were quickly analysed by trypan blue exclusion assay and the cells were quickly 
seeded in tissue culture flasks under normal tissue culture conditions. Once the 
electroporated cells were settled, they were subjected to experimental conditions 
followed by immunocytochemistry or the proteins harvestion to analyse the relative 
RhoA activities as previously described.      
10. siRNA gene knockdown studies 
     To substantiate the pharmacological inhibition data and to confirm the specific 
PKC isoform-mediated effects under hyperglycaemia, semiconfluent HBMEC were 
washed with sterile PBS to remove traces of antibiotics. The transfection media was 
prepared by diluting DharmaFECT siRNA transfection reagent 4 (containing 50-100 
nM of ON-TARGET plus SMART pool siRNA oligonucleotides against human PKC-
α and PKC-β isoforms) in antibiotics-free complete DMEM. The cells were incubated 
with equal volume of transfection media (2 mL) for 24 hours followed by the 
hyperglycaemia treatment. Similar procedure was adopted for tranfecting HBMEC 
with ON-TARGET plus Non-targetting siRNA pool, which served as negative 
controls before exposing them to the normal and hyperglycaemic treatments. The cells 
41 
 
were homogenised after 72 hours of treatment, and transfection efficiency followed 
by protein downregulation were confirmed by detecting human PKC-α and PKC-β 
isoforms by Western blotting. Since the amount of DharmaFECT reagent and siRNA 
used in this study were proportional to the transfected cell numbers (in accordance 
with the manufacturer’s guidelines), the cellular death rates observed appeared to be 
negligible. The appendix III shows the oligonucleotide sequences of the siRNA used 
to knockdown PKC isoforms. 
11. Total PKC activity assay 
     To evaluate the total PKC activities under hyperglycaemia and to delineate the 
PKC isoforms modulating the hyperglycaemic effects, the total PKC activity was 
measured in HBMEC lysates using the PepTag non-radioactive PKC activity assay 
kit. Briefly, HBMEC pellets were resuspended and homogenised in cold PKC 
extraction buffer prior to elution of PKC-containing fraction through the use of pre-
equilibrated Bio-spin columns with DEAE sepharose beads (1 mL). The eluted 
samples were mixed with PKC reaction mixture containing PepTag C1 peptide before 
loading onto 0.8% agarose/Tris-HCl (50 mM) gels to separate phosphorylated and 
nonphosphorylated PepTag peptide bands. The portion of the gel containing the 
phosphorylated bands was then excised and solubilised by melting (65ºC) followed by 
solubilisation in acetic acid. The samples (50 L) were aliquoted in duplicates on a 
96-well plate and absorbance (570 nm) was measured on a BMG LABTECH Omega 
plate reader. The absorbances were used to determine the relative PKC activities 
(units/mL) in accordance with the manufacturer’s guidelines by Beer’s law A=εBC, 
where A=absorbance of the samples, ε=the molar absorptivity of the peptide, B=the 
width of the light cell, C=the concentration of the peptide in mol/L of the sample read. 
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The appendix IV shows the detailed recipe of the buffers used in the total PKC 
activity assay.    
12. Total NADPH oxidase activity assay 
     The total NADPH oxidase activity was measured in HBMEC homogenates by 
lucigenin-enhanced chemiluminascent detection assay to address the role of NADPH 
oxidase enzyme complex in inducing the oxidative stress under OGD±R. The 
HBMEC were trypsinised and stored as pellets at -80ºC, and were homogenised only 
on the day of activity measurement to preserve maximum enzymatic activity. The 
HBMEC pellets were homogenised in phosphate lysis buffer (KH2PO4; 300 mM) 
containing ethylene glycol tetraacetic acid (EGTA; 50 mM) aprotinin, leupeptin, 
phenylmethylsulfonyl fluoride (PMSF) and protease cocktail inhibitors. Cell 
homogenates (50 L) were aliquoted in duplicates in a white 96-well plate containing 
reaction mixture (100 L) of phosphate buffer (50 mM), lucigenin (5 µM), sucrose 
(150 mM) and EGTA (1 mM).  To ascribe all the lucigenin-enhanced 
chemiluminescent to NADPH oxidase activity, specific inhibitors of other ROS 
genetating enzyme complexes and rections namely; L-NAME (100 µM, NOS 
inhibitor), indomethacin (50 µM, COX inhibitor), allopurinol (100 µM, xanthine 
oxidase inhibitor) and rotenone (50 µM, mitochondrial complex I inhibitor) were 
added simultaneously to aliquots. The plates were incubated in a temperature 
controlled BMG LABTECH Omega plate reader (37ºC) for 15 minutes and the 
reaction substrate NADPH (100 M; 100 L) was added to each well by injectors in 
the plate reader to initiate the reaction. The luminescence value was recorded after 
every minute from each well for 3 hours and average luminescence corresponding to 
different samples were calculated by Mars data analysis software. The relative 
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NADPH oxidase activities (units/g) were recorded by normalising the average 
luminescence values against the total protein levels in homogenates used. 
13. Total O2•– detection assay 
     The total O2•– levels were measured in HBMEC homogenates by lucigenin-
enhanced chemiluminescent detection assay. The HBMEC were trypsinised and 
stored as pellets at -80ºC, and were homogenised only on the day of activity 
measurement to preserve maximum enzyme activity. The HBMEC pellets were 
homogenised in phosphate lysis buffer (KH2PO4; 300mM) containing EGTA, 
aprotinin, leupeptin, PMSF and protease cocktail inhibitor. Cell homogenates (50 L) 
were aliquoted in duplicates in a white 96-well plate containing reaction mixture (100 
L) of lucigenin (5 µM), sucrose (150 mM), EGTA (1 mM). The plates were 
incubated in a temperature controlled BMG LABTECH Omega plate reader (37ºC) 
for 15 minutes and the reaction substrate NADPH (100 M; 100 L) was added to 
each well by injectors in the plate reader to initiate the reaction. The luminescence 
value was recorded after every minute from each well for 3 hours and average 
luminescence corresponding to different samples were calculated by Mars data 
analysis software. The relative O2•– levels (units/g) were recorded by normalising the 
average luminescence values against the total protein levels in homogenates used. 
14. Cytochrome C reduction assay 
The NADPH oxidase activity was measured in cell homogenates by colorimetric 
assay, which monitored the reduction of cytochrome C in the presence of electron rich 
NADPH substrate. HBMEC pellets comprising of 20 x106 cells were homogenised in 
cold HEPES buffer (20 mM, pH 7.2), containing EGTA (1 mM), mannitol (210 mM) 
and sucrose (70 mM). Equal volume (50 µL) of cell homogenate samples or positive 
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controls were added in 1 mL cuvette containing cytochrome C working solution (36 
µM, 950 µL) at 25°C. To ascribe all the cytochrome C reduction to NADPH oxidase, 
specific inhibitors of other ROS-generating enzymes including L-NAME (100 µM), 
rotenone (50 µM), allopurinol (100 µM), and indomethacin (50 µM) were added to 
the reaction mixture. The reaction components were mixed gently and the reaction 
was initiated by addition of NADPH working solution (0.85 mg/mL) just before 
measuring the absorbance values. The absorbance values were measured on a 
temperature controlled (25°C) spectrophotometer at 550 nM by initial delay of 5 
seconds followed by recordings of 7 readings with 10 seconds interval. The total O2•– 
anion levels were also measured by the cytochrome C reduction assay. Equal volume 
(50 µL) of HBMEC homogenates were added in 1 mL cuvette containing cytochrome 
C working solution (950 µL) at 25°C. The reaction was initiated by the addition of 
NADPH working solution followed by a gentle mix. The absorbance values were 
measured as previously described on a temperature controlled (25°C) 
spectrophotometer at 550 nM. The enzyme activities and total O2•– anion levels 
(units/µg) were measured following subtraction of background levels at 550 nm by 
following equation: 
Units/g= A550/min/(21.1 x amount of protein used (µg)), where A=absorbance at 
550nm. 
15. Cell counting and cell viability detection assay  
     The HBMEC or HA counting was regularly carried out either to seed accurate 
number of cells or to monitor the cellular viability rates after transfection 
experiments.  A small aliquot of cell suspension (10 L) was mixed with equal 
volume of 0.1% trypan blue for 5 minutes and the mixture was carefully pipetted on 
haemacytometer for cell counting. Cells situated on the 5 big grids were counted by 
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the aid of a light microscope, and cells/mL was calculated by the following formula: 
Total cells/mL = Average cells in each grid x dilution factor x 104; dilution factor = 
Total volume of cell suspension in trypan blue/original volume of cell suspension.  
     The viable cells were calculated by counting the cells which were not stained by 
trypan blue in 5 big grids, and total viable cells/mL was calculated as follows:  Total 
viable cells/mL = Average viable cells in each grid x dilution factor x 104. Hence, the 
cell viability was represented as percentage of viable cells by the following 
calculation: Cell viability = Total viable cells/mL x Total cells/mL-1 x 100 
16. Statistical analyses 
     Results were presented as mean±SEM. Statistical analysis was performed by using 
IBM SPSS 20.0 software and comparing the mean by student’s t-test and one-way 
analysis of variance (ANOVA) followed by Dunnet’s post hoc analysis. The P<0.05 
was considered to be significant in all the experiment. 
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Chapter 1 
 
 
 
OGD-evokes in vitro BBB disruption 
through regulation of  
RhoA/Rho-kinase pathway 
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1.1. Aims 
To study, 
1. whether OGD alters the in vitro model of human BBB integrity and function, 
2. whether RhoA and Rho-kinase play a significant role in the OGD-mediated 
hyperpermeability, 
3. the cellular localisation of RhoA and Rho-kinase during OGD, 
4. whether RhoA evokes cytoskeletal remodelling under OGD, 
5. whether specific inhibition of Rho-kinase exert any cerebrovascular protective 
effects. 
1.2. Results 
1.2.1. Effects of OGD on the in vitro cerebral-barrier integrity and function 
     To evaluate the effects of OGD on the integrity of an in vitro model of human 
BBB, HBMEC and HA cocultures were exposed to short and longer periods of OGD 
(4 and 20 hours) using a hypoxic chamber. The integrity of the cocultures were 
analysed by measuring TEER values which were indicative of physical disruption, 
and the flux of NaF which represented the functional impairment of the endothelial-
barrier. Our data have shown that OGD compromised the in vitro cerebral-barrier 
integrity as evidenced by time-dependent decreases in TEER values (P<0.05), and 
concomitant increases in the flux of NaF across cocultures compared to the cocultures 
exposed to normoxia which served as controls (P<0.05). Moreover, the cocultures 
exposed to longer periods of OGD further compromised the BBB integrity and 
function thereby showing the deleterious effects of OGD (P<0.05) (Figure 1.1A, B). 
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Figure 1.1. Effects of OGD on integrity and function of an in vitro model of human 
BBB. (A) Transendothelial electrical resistance (TEER) and (B) flux of sodium 
fluorescein (NaF) across the cocultures subjected to short and longer OGD (4 and 20 
hours). Data are expressed as mean±SEM from 5 different experiments. Statistical 
analysis was done using ANOVA with Dunnet’s post hoc test for multiple 
comparisons (A: P<0.0001, F=37.212, df1=2, df2=6), (B: P<0.0001, F=174.817, 
df1=2, df2=6). *P<0.05 compared to normoxia, †P<0.05 compared to OGD (4 hours). 
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1.2.2. RhoA and Rho-kinase are involved in OGD-mediated hyperpermeability 
     To evaluate the role of RhoA under OGD-mediated  barrier permeability, the 
cocultures were established using HBMEC electroporated with constitutively active 
human recombinant RhoA protein (His-RhoA-L63). Here, the cocultures developed 
by the HBMEC electroporated with either anti-human RhoA-IgG, or with ultrapure 
water served as electroporation controls to ensure that the changes observed were not 
dependent on electroporation-evoked cell death.  
     The studies investigating the effects of electroporation on the BBB function 
revealed no significant differences in the patterns of TEER and flux of NaF between 
the nonelectroporation controls and the electroporation controls as OGD disrupted the 
cerebral barrier measured by decreases in the TEER values and increases in the flux 
of NaF across the cocultures (P<0.05). These results indicate that the observed 
alterations to the coculture integrity are reflective of the treatments per se (Figure 
1.2A). The His-RhoA-L63 electroporation in HBMEC led to a marked decrease in the 
TEER values under normoxia and OGD, respectively (P<0.05). These data indicate 
that RhoA overexpression in HBMEC mediate and exacerbate the cerebral-barrier 
disruption under normoxia and OGD, respectively. Concomitant increases observed in 
the flux of NaF across the respective cocultures supported these findings (P<0.05) 
(Figure 1.2B). In contrast to these, the cocultures established with anti-human RhoA-
IgG electroporated HBMEC showed a significantly improved TEER and concurrent 
reduction in the flux of NaF after OGD compared to the respective cocultures 
subjected to normoxic conditions (P<0.05) (Figure 1.3A). These data indicate that 
inhibition of RhoA may be cerebral-barrier protective under OGD condition. 
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     In addition, cotreatment with Y-27632 (2.5 µM), a specific Rho-kinase inhibitor, 
during normoxia and OGD exposures appeared to blocked the synergistic effects of 
His-RhoA-L63 electroporation and OGD as confirmed by improvement in TEER 
values and decrease in the flux of NaF across these cocultures, thus suggesting a 
cerebral barrier protective role of the Rho-kinase inhibition during pathological 
conditions like OGD (P<0.05) (Figure 1.3B).  
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Figure 1.2. RhoA-mediated increase in the paracellular permeability under OGD. 
Transendothelial electrical resistance (TEER) and flux of sodium fluorescein (NaF) 
across cocultures established by HBMEC electroporated with (A) H2O which served 
as electroporation controls, and with (B) His-RhoA-L63 or H2O. Data are expressed 
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as mean±SEM from 5 different experiments. Univariate comparisons were made 
using Student’s t-test. *P<0.05 compared to normoxia in the same group, †P<0.05 
compared to normoxia in the electroporation control group, #P<0.05 compared to 
OGD in the electroporation control group. 
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Figure 1.3. RhoA/Rho-kinase-mediated increase in the paracellular permeability after 
OGD. Transendothelial electrical resistance (TEER) and flux of sodium fluorescein 
(NaF) across cocultures established by HBMEC electroporated with (A) Anti-RhoA-
IgG or H2O, and with (B) His-RhoA-L63 or H2O in the presence or absence of Y-
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27632. Data are expressed as mean±SEM from 5 different experiments. Univariate 
comparisons were made using Student’s t-test. *P<0.05 compared to normoxia in the 
same group, †P<0.05 compared to normoxia in the electroporation control group, 
#P<0.05 compared to OGD in the electroporation control group, $P<0.05 compared to 
the OGD in the His-RhoA-L63 electroporated group. 
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 1.2.3. Cellular localisation of RhoA and Rho-kinase  
      Small GTPase have been shown to localise to cytoplasm, hence the cellular 
localisation of RhoA and Rho-kinase proteins have been investigated in HBMEC 
exposed to normoxia and OGD (20 hours). Under normoxia, RhoA was uniformly 
distributed in the HBMEC cytoplasm as represented by faint intracellular stainings. 
However, after the OGD increased intracellular stainings of RhoA protein (arrows) 
marked by a relatively brighter stainings were recorded. In addition, the intracellular 
staining of Rho-kinase showed a faint uniform staining under OGD, which were 
similar to the Rho-kinase stainings observed under normoxic conditions (Figure 1.4).           
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Figure 1.4. Cellular localisation of RhoA (A, B)  and Rho-kinase-2 (C, D) in 
HBMEC exposed to normoxia and OGD (20 hours). Arrows indicate the effect of 
OGD on RhoA localisation. The cellular RhoA and Rho-kinase-2 levels were detected 
by primary antibodies against human RhoA and human Rho-kinase-2 followed by 
species specific secondary antibodies-tagged with FITC. The cells were incubated 
with DAPI and were identified by blue coloured nuclei by 40X magnification on a 
fluorescent microscope. Bar scale: 50 m.     
1.2.4. RhoA-induced cytoskeletal remodelling under OGD 
     To investigate whether the RhoA-evoked paracellular permeability may in part be 
due to OGD-induced cytoskeletal remodelling, the filamentous actin (F-actin) 
cytoskeletal detection were carried out in HBMEC electroporated with either H2O, 
His-RhoA-L63 or anti-RhoA-IgG before exposure to normoxia and OGD (20 hours), 
respectively. The H2O-electroporated HBMEC cultured under normoxia displayed 
marginal actin band distribution while OGD led to formation of stress fibres (arrows) 
and morphological changes characterised by cuboidal or elongated appearance. While 
RhoA overactivity induced by His-RhoA-L63 electroporation led to the formation of 
thick stress fibres similar to cells exposed to OGD, the inhibition of RhoA by anti-
human RhoA-IgG electroporation eradicated all phenotypic changes and produced 
morphologies resembling to those seen in normal HBMEC (Figure 1.5). 
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Figure 1.5. The F-actin stainings in HBMEC electroporated with H2O (A, B), His-
RhoA-L63 (C, D), and  anti-RhoA IgG (E, F) before exposure to normoxia and OGD. 
Arrows indicate the stress fibres. The F-actin were detected by Rhodamine-labelled 
phalloidin dye by 40X magnification on fluorescent microscope. Bar scale: 50 m.  
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1.2.5. Rho-kinase inhibition attenuate the cytoskeletal remodelling 
     Since the inhibition of Rho-kinase by Y-27632 abrogated RhoA-induced cerebral 
barrier, it was examined whether the cerebrovascular protective effects of Y-27632 
may in part be attributed to the regulation of the RhoA/Rho-kinase-mediated 
cytoskeletal remodelling. As described earlier, the HBMEC cultured under normoxia 
displayed marginal actin staining, while OGD promoted the formation of thick 
bundles of stress fibres. Cotreatment of HBMEC during OGD with Y-27632 
neutralised the effects of OGD on actin fibres and normalised the cellular morphology 
similar to those seen in normoxic HBMEC (Figure 1.6). 
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Figure 1.6. F-actin stainings with Rhodamine-labelled phalloidin dye in HBMEC 
exposed to normoxia (A, C) and OGD (20 hours) (B, D) in the absence and presence 
of Y-27632 (2.5 µM). Arrows represent the stress fibre formations. The F-actin 
stainings were observed by 40X magnification on a fluorescent microscope. Bar scale: 
50 m. 
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1.3. Discussion 
     Breakdown of the BBB, associated with formation of brain oedema, constitutes 
one of the leading causes of mortality after ischaemic strokes. Despite a consensus on 
endothelial cell dysfunction, the underlying mechanism(s) of this defect during 
ischaemic injury remains largely unknown (Hou and MacManus, 2002). Using an in 
vitro model of human cerebral barrier consisting of HBMEC and HA, the current 
study explored the involvement of RhoA in OGD-evoked barrier impairment and 
showed marked increase in intracellular levels of RhoA protein in OGD- versus 
normoxia-exposed HBMEC in consistence with our recent study (Allen et al., 2010). 
Similar increases in RhoA protein levels have previously been reported in stroke brain 
sections and in various cellular components of rodent cerebrovasculature after 
exposure to global ischaemia (Brabeck et al., 2003, Zhou et al., 2003). In the latter 
study, suppression of neuronal RhoA levels via hyperbaric oxygen confirms the 
ability of ischaemia to regulate GTPase expression (Zhou et al., 2003). 
     In previous in vitro studies, we have shown that OGD dramatically increases the 
activities of RhoA and Rho-kinase in HBMEC (Allen et al., 2010). Suppression of 
Rho-kinase activity in mice with fasudil or Y-27632, specific Rho-kinase inhibitors, 
before transient MCAO decreased infarct volume and kinase activity by ~50% and 
substantiated the relevance of Rho-kinase overactivity to ischaemic cerebral damage 
(Rikitake et al., 2005). As an inhibitor of Ca2+-dependent protein kinases (PKC and 
PKA) and an intracellular Ca2+ antagonist, it is possible that fasudil may attenuate 
Ca2+/calmodulin-dependent MLCK activity to reduce MLC phosphorylation and 
infarct volume. However, given the selection of relatively specific concentrations of 
fasudil for Rho-kinase, the protective effects observed are less likely to be due to 
inhibition of these secondary mechanisms (Rikitake et al., 2005). Other mechanisms 
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including vasodilation through activation of eNOS is more likely to contribute to 
beneficial effects of Rho-kinase inhibitors. Indeed, in eNOS-/- mice, Rho kinase 
inhibitors exerted no benefits on cerebral infarct size (Asano et al., 1989). 
          Several mechanisms including overt openings in paracellular pathways may 
compromise endothelial barrier function in the presence of OGD. TEER and NaF flux 
across HBMEC/HA cocultures were measured to assess the barrier function which 
showed OGD-evoked significant time-dependent decreases in TEER and increases in 
NaF flux thereby implying a physical breakdown and barrier impairments under 
OGD. To determine the actual relevance of RhoA to endothelial barrier integrity, 
HBMEC were transfected with anti-RhoA-IgG or constitutively active recombinant 
His-RhoA-L63 in that the former increased TEER and decreased paracellular 
permeability specifically in pathological conditions while the latter exerted the 
opposite effects. Taken together these findings verified the importance of RhoA in 
maintaining barrier integrity and showed a requirement for its adequate levels to 
preserve normal cellular activity (van Nieuw Amerongen et al., 2007). Attenuation of 
OGD-induced hyperpermeability by Y-27632 lent further support to the involvement 
of RhoA/Rho-kinase pathway in barrier disruption. Indeed, reduced tracer permeation 
in ischaemic brains and through endothelial monolayers have also been attributed to 
Rho-kinase inhibition (Takaishi et al., 1997). 
    The changes in cell morphology may also contribute to OGD-induced barrier 
failure. Experiments examining putative structural differences in microfilaments, a 
key component of cytoskeleton, (Davies et al., 2000) showed that HBMEC grown 
under normoxia possessed a marginal actin filament distribution while those exposed 
to OGD took up elongated and cuboidal appearance and developed stress fibres 
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traversing the cells. Transfection of HBMEC with His-RhoA-L63 or anti-RhoA-IgG 
induced thick stress fibre formation and preserved normal phenotype, respectively. 
Moreover, the inhibition of Rho-kinase activity also restored the cell morphology 
alongside reducing the stress fibres which was similar to the effects exhibited by 
RhoA inhibition. The cortical actin bands play a pivotal role in the prevention of 
paracellular flux by participating in formation and stabilisation of intercellular 
junctions. Once formed, stress fibres can generate a tensile centripetal force to pull 
junctional molecules inward to break up junctions and create intercellular gaps. 
Several mechanisms including activation of VEGF and transcriptional factors HIF-1 
and NF-κB have been implicated in OGD-mediated junctional disruptions (van 
Bruggen et al., 1999, Frixione, 2000).  
Enhanced phosphorylation of MLC triggered by RhoA/Rho kinase activity may also 
cause destabilisation of interendothelial cell junctions (Van Aelst and D'Souza-
Schorey, 1997, Sahai and Marshall, 2002). Indeed, previous studies including our own 
have shown that while activation of RhoA in HBMEC via His-RhoA-L63 transfection 
increased MLC2 phosphorylations  possibly through inhibition of myosin phosphatase 
or activation of MLCK, its inhibition via anti-RhoA-IgG dramatically decreased both 
phosphorylations (Tinsley et al., 2000, Mark and Davis, 2002, Allen et al., 2010). 
Given that activation of Rho kinase leads to phosphorylation of the ezrin-radixin-
moesin proteins and these in turn provide a regulated linkage between membrane 
proteins and the cortical cytoskeleton, this mechanism warrants further investigation 
(Amano et al., 1996, van Bruggen et al., 1999).  
     To summarise, this study has shown that OGD compromises the structural and 
functional capacities of an in vitro model of human cerebral barrier through the 
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activation of RhoA/Rho-kinase pathway and consequent induction of the cytoskeletal 
remodelling.  
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Chapter 2 
 
 
 
Mechanisms involved in Rho-kinase inhibition-
dependent normalisation of cerebral barrier 
under OGD±R 
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2.1. Aims 
1. To investigate whether Y-27632 treatment modulates the effects of OGD±R on 
pro-oxidant enzyme NADPH oxidase activity, total O2•– levels, and the protein levels 
of gp91-phox, antioxidant enzymes CuZn-SOD and catalase, 
2. To investigate whether Y-27632 treatment nullifies the effects of OGD±R on the 
protein levels of RhoA, Rho-kinase-2 and activity of RhoA, 
3. To investigate whether Y-27632 treatment restores the OGD±R-mediated 
modulation of junctional complex and protects the cerebral-barrier disruption.   
2.2. Results 
2.2.1. Effects of OGD±R in the absence or presence of Y-27632 on total O2•– levels 
and protein expressions and/or activity of pro-oxidant and antioxidant enzymes  
     Oxidative stress is an imbalance in the ROS metabolism caused by an aberration in 
the expression or activity of pro-oxidant and antioxidant enzymes resulting in an 
enhanced ROS production and accumulation. Hence, it was important to study the 
pro-oxidant and antioxidant parameters under same pathological condition to address 
the probable occurrence of an oxidative stress. Total proteins harvested from HBMEC 
exposed to OGD±R in the absence or presence of Y-27632 (10 µM) were used to 
detect the fold differences observed in the protein levels of gp91-phox, a membrane 
bound subunit of pro-oxidant NADPH oxidase, activity of NADPH oxidase enzyme, 
total O2•– levels and protein levels of antioxidant enzymes CuZn-SOD and catalase. 
Our results appeared to show a significant increase in the protein expression of gp91-
phox under OGD±R compared to the HBMEC cultured under normoxia which served 
as controls, after normalisation against β-actin (P<0.05). However, the Y-27632 
treatment neutralised the effects of OGD±R as the gp91-phox protein levels were 
normalised under OGD and significantly alleviated under OGD+R compared to the 
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controls (P<0.05). These results indicate that Y-27632 treatment neutralises the 
OGD±R-mediated elevation in gp91-phox protein levels (Figure 2.1A). 
     Since gp91-phox is pivotal for the NADPH oxidase enzyme activity, an increase in 
its protein expression may represent an increase in the activity of NADPH oxidase 
enzyme complex. Indeed, the exposure to OGD±R significantly increased the 
activities of NADPH oxidase enzyme compared to the enzyme activity measured in 
control HBMEC proteins (P<0.05). However, the Y-27632 treatment appeared to 
restore the OGD±R-mediated elevation in the NADPH oxidase enzyme activities 
(Figure 2.1B).  Since NADPH oxidase enzyme complex is one of the main producers 
of O2•–, an increase in its activity may increase an overall O2•– production. Indeed, the 
OGD±R significantly increased the total O2•– levels (P<0.05). However, Y-27632 
treatment abolished the OGD±R-mediated elevation in the total O2•– levels and 
restored their levels similar to controls (Figure 2.1C). These data indicate that Rho-
kinase activity may be involved in OGD±R-mediated upregulation in NADPH 
oxidase activity and O2•– production.  
     The protein levels of CuZn-SOD remained largely unchanged in HBMEC after 
OGD. However, a slight but insignificant reduction in its levels was observed after 
longer OGD+R compared to the controls. The Y-27632 treatment failed to alter the 
unchanged CuZn-SOD protein levels under OGD. However, its levels were 
significantly low under longer OGD+R (P<0.05) (Figure 2.2A). The protein levels of 
another antioxidant enzyme catalase were significantly higher in HBMEC subjected 
to OGD±R compared to the controls (P<0.05). However, the Y-27632 treatment 
abolished the OGD±R-mediated elevation in catalase protein levels and restored its 
levels similar to the controls. This result indicates that Rho-kinase activity may be 
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involved in upregulating the catalase protein expression as Y-27632 treated controls 
showed a significantly low catalase protein levels (P<0.05) (Figure 2.2B).  
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Figure 2.1. (A) Protein levels of gp91-phox, (B) NADPH oxidase enzyme activity 
(units/µg) and (C) total superoxide anion levels (units/µg) in HBMEC after OGD±R 
in the absence or presence of Y-27632 (10 µM). Data are expressed as mean±SEM 
from 6 different experiments. Statistical analysis was done using ANOVA with 
Dunnet’s post hoc test for multiple comparisons (Ai: P=0.022, F=3.937, df1=4, 
df2=15; Aii: P=0.046, F=3.193, df1=5, df2=12), (Bi: P=0.0015, F=10.21, df1=4, 
df2=10; Bii: P=0.378, F=1.169, df1=5, df2=12; Biii: P=0.0029, F=8.504, df1=4, 
df2=10; Biv: P=0.4634, F=0.9898, df1=5, df2=12), (Ci: P=0.0072, F=6.609, df1=4, 
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Figure 2.2. Protein levels of (A) CuZn-SOD and (B) catalase in HBMEC after 
OGD±R in the absence or presence of Y-27632 (10 µM). Data are expressed as 
mean±SEM from 3 different experiments. Statistical analysis was done using 
ANOVA with Dunnet’s post hoc test for multiple comparisons (Ai: P=0.80, 
F=0.4022, df1=4, df2=10; Aii: P=0.0011, F=8.711, df1=5, df2=12), (Bi: P=0.006, 
F=6.842, df1=4, df2=10; Bii: P=0.063, F=2.849, df1=5, df2=12). *P<0.05 compared 
to the controls. 
2.2.2. Effects of OGD±R in the absence or presence of Y-27632 on RhoA, Rho-
kinase-2 protein expressions and RhoA activity 
     HBMEC subjected to OGD±R showed no significant alteration in the total RhoA 
protein levels. However, their protein levels dramatically decreased after Y-27632 
treatment during OGD±R and in Y-27632 treated controls compared to the untreated 
controls (P<0.05) (Figure 2.3A). Since RhoA-GTP levels represent active RhoA 
isoform, the RhoA activity was measured after normalising RhoA-GTP protein levels 
against unchanged total RhoA protein levels in HBMEC. A marked increase in the 
RhoA activity was recorded in HBMEC subjected to OGD±R (P<0.05). Since Y-
27632 treatment attenuated the total RhoA protein levels, the RhoA activity was 
measured by normalising RhoA-GTP levels with loading control β-actin in Y-27632 
treated HBMEC. The Y-27632 treatment abrogated the OGD±R-mediated increase in 
the RhoA activity and normalised the RhoA-GTP levels similar to the controls. In 
addition, the Rho-kinase inhibitor treatment significantly attenuated the RhoA activity 
in HBMEC exposed to short OGD+R (P<0.05) (Figure 2.3A). These data indicate that 
inhibition of Rho-kinase activity may modulate RhoA protein expression as well as 
activity.  
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     Since Rho-kinase is the main effector protein of RhoA, the OGD±R-mediated 
alterations in RhoA expression or activity may induce alterations in Rho-kinase 
protein levels. Our results show no significant difference in the Rho-kinase-2 protein 
levels under OGD. However, OGD+R induced an increase in the Rho-kinase-2 levels 
which were significantly higher only after longer OGD+R compared to the controls 
(P<0.05). In addition, the Y-27632 treatment had no effect on the Rho-kinase-2 
protein levels under OGD, but it abolished the OGD+R-mediated elevation and 
normalised Rho-kinase-2 levels similar to the controls (Figure 2.3B).  These results 
indicate that Y-27632 can regulate the expression of Rho-kinase.    
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Figure 2.3. (A) Protein expression and activity of RhoA and (B) protein levels of 
Rho-kinase-2 in HBMEC after OGD±R in the absence or presence of Y-27632 (10 
µM). Data are expressed as mean±SEM from 4 different experiments. Statistical 
analysis was done using ANOVA with Dunnet’s post hoc test for multiple 
comparisons (Ai: P=0.0001, F=34.4, df1=4, df2=10; Aii: P=0.0045, F=6.234, df1=5, 
df2=12; Aiii: P=0.0173, F=4.341, df1=5, df2=12), (Bi: P=0.0018, F=9.765, df1=4, 
df2=10; Bii: P=0.707, F=0.5916, df1=5, df2=12). *P<0.05 compared to the controls, 
#P<0.05 compared to the OGD (4hr)+R. 
2.2.3. Effects of OGD±R in the absence or presence of Y-27632 on junctional 
complex and cerebral-barrier integrity 
     Since tight junction and adherens junction proteins seal the adjacent endothelial 
cells making the cerebral barrier impermeable to the blood driven solutes, the effects 
of OGD±R in the presence or absence of Y-27632 were studied on the expressions of 
tight junction proteins occludin and claudin-5, adherens junction protein β-catenin and 
focal adhesion protein vinculin. OGD±R did not significantly affect the occludin 
protein expression in HBMEC compared to the control cells cultured under normoxic 
conditions. However, the Y-27632 treatment during OGD±R and normoxia 
significantly increased the occludin protein levels compared to the levels in untreated 
control cells (P<0.05) (Figure 2.4A). In addition, OGD increased the claudin-5 protein 
levels in a time-dependent manner which appeared to be significantly elevated after 
longer periods of OGD and OGD+R (P<0.05). In contrast, the Y-27632 treatment 
neutralised the OGD±R-mediated elevation in the claudin-5 protein levels and 
restored its levels similar to the control cells (Figure 2.4B). These results indicate that 
OGD±R can modulate the tight junction protein expression via Rho-kinase activity. 
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     The protein levels of β-catenin did not appear to significantly alter in HBMEC 
subjected to OGD. However, a marked rise in the β-catenin protein levels was 
observed after OGD+R compared to the control cells (P<0.05). Moreover, the Y-
27632 treatment did not alter the β-catenin levels under OGD, but it attenuated its 
levels after OGD+R and normalised it to the levels observed in control cells (Figure 
2.5A). The vinculin protein levels appeared to remain unchanged after OGD±R in the 
absence or presence of Y-27632 and indicate that OGD±R may not affect the levels of 
focal adhesion protein (Figure 2.5B).  
     To study the significance of OGD±R mediated modulation of aforementioned 
proteins on the BBB, the integrity and function of the in vitro model of human BBB 
were measured by TEER and flux of EBA, respectively. OGD decreased the TEER 
readings in a time-dependent manner compared to the cocultures exposed to normoxia 
which served as controls, indicating the physical breakdown of the endothelial barrier 
(P<0.05). Reperfusion after OGD further diminished the coculture integrity (P<0.05). 
These findings were further confirmed by dramatic increases in the flux of EBA 
across the cocultures compared to the controls (P<0.05). These data demonstrate that 
OGD±R can compromise the cerebral-barrier integrity (Figure 2.6A). 
     Treatment with Y-27632 improved the TEER readings after short OGD±R. These 
results were substantiated by concurrent decreases in the flux of EBA across the 
cocultures which appeared to be similar to flux measured across the cocultures 
exposed to normoxia in the absence or presence of Y-27632. However, Y-27632 had 
no affect on the barrier integrity after longer OGD±R as dramatic decrease in TEER 
readings and concomitant increases in the flux of EBA were recorded across the 
cocultures compared to the respective measurements across the cocultures exposed to 
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normoxia and short OGD±R (P<0.05) (Figure 2.6B). These results indicate that Y-
27632 is cerebral-barrier protective under short OGD±R.   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Protein expressions of (A) occludin and (B) claudin-5 in HBMEC after 
OGD±R in the absence or presence of Y-27632 (10 µM). Data are expressed as 
mean±SEM from 3 different experiments. Statistical analysis was done using 
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ANOVA with Dunnet’s post hoc test for multiple comparisons (Ai: P=0.1448, 
F=2.18, df1=4, df2=10; Aii: P=0.0105, F=4.992, df1=5, df2=12), (Bi: P<0.0001, 
F=23.07, df1=4, df2=10; Bii: P=0.7944, F=0.4661, df1=5, df2=12). *P<0.05 
compared to the controls, #P<0.05 compared to the OGD (4hr)+R. 
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Figure 2.5. Protein expressions of (A) β-catenin and (B) vinculin in HBMEC after 
OGD±R in the absence or presence of Y-27632 (10 µM). Data are expressed as 
mean±SEM from 3 different experiments. Statistical analysis was done using 
ANOVA with Dunnet’s post hoc test for multiple comparisons (Ai: P=0.0007, 
F=12.42, df1=4, df2=10; Aii: P=0.1936, F=1.770, df1=5, df2=12), (Bi: P=0.3645, 
F=1.213, df1=4, df2=10; Bii: P=0.0404, F=3.338, df1=5, df2=12). *P<0.05 compared 
to the controls. 
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Figure 2.6. Measurement of cerebral-barrier integrity by TEER readings (cm2), and 
flux of EBA (µL) across an in vitro model of human BBB after OGD±R in the (A) 
absence or (B) presence of Y-27632. Data are expressed as mean±SEM from 4 
different experiments. Statistical analysis was done using ANOVA with Dunnet’s 
post hoc test for multiple comparisons (Ai: P<0.0001, F=65.645, df1=4, df2=10; Aii: 
P<0.0001, F=173.5, df1=4, df2=10), (Bi: P<0.0001, F=88.892, df1=5, df2=12; Bii: 
P<0.0001, F=53.853, df1=5, df2=12). *P<0.05 compared to the controls, †P<0.05 
compared to longer OGD, #P<0.05 compared to short OGD±R. 
 
 
2.3. Discussion 
     The main findings of this study were that in HBMEC, OGD±R accounted for the 
enhanced activity of pro-oxidant enzyme NADPH oxidase and consequent generation 
of O2•–, a marker of oxidative stress. OGD±R also upregulated the RhoA activity, and 
protein expressions of Rho-kinase-2 and antioxidant enzyme catalase. In addition, 
OGD also altered the endothelial-barrier integrity preserved by tightly sealed HBMEC 
by modulating the expressions of tight junction protein claudin-5 and adherens 
junction protein β-catenin. Taken together, these events may in part be responsible for 
the OGD±R-mediated disruption of the endothelial barrier associated with BBB 
hyperpermeability. Cotreatment with Y-27632 reversed the OGD±R-mediated affects 
marked by the normalisation of gp91-phox, catalase, caludin-5, β-catenin and Rho-
kinase-2 protein levels, NADPH oxidase and RhoA activities, and total O2•– levels. 
Moreover, the Y-27632 treatment in part proved to be cerebral barrier protective by 
attenuating BBB hyperpermeability under short OGD±R.   
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     During physiological conditions, low levels of ROS are known to act as secondary 
messengers in maintaining the cellular homeostasis. However, under pathological 
condition, many ROS generating enzyme complexes including xanthine oxidase, 
COX, mitochondrial electron transport chain, NOS and NADPH oxidase are activated 
and generate ROS in abundance leading to oxidative stress. Among these enzyme 
complexes, NADPH oxidase has attracted much of the attention mainly due to its role 
in generating O2•–, the foundation molecule of all ROS. Previous studies in our group 
have shown that HBMEC express p22-phox protein which is a pivotal subunit of 
NADPH oxidase enzyme complex and enhances the enzyme activity and the O2•– 
production under hyperglycaemia (Allen and Bayraktutan, 2009a). In this study we 
have shown that HBMEC express gp91-phox protein which is also important for the 
NADPH oxidase enzyme activity and OGD±R enhances its expression which 
correlates with increases in the NADPH oxidase activity. Since NADPH oxidase 
activity was measured in the presence of inhibitors for other ROS generating 
enzymes, it is safe to suggest that NADPH oxidase plays a big role during OGD±R 
injury. Previous studies also support this rationale and associate the vascular O2•– 
produced by NADPH oxidase with the endothelial dysfunction. Moreover, it has been 
shown that inhibition of NADPH oxidase by apocynin reduces the infarction in 
animal model of ischaemic stroke (Guzik et al., 2000, Kahles et al., 2007).     
     Previous research in our group had shown that RhoA and subsequent Rho-kinase 
activations modulate cytoskeletal-remodelling and impair the coculture integrity 
under OGD conditions. We had shown that low concentration of Y-27632 (2.5 µM) 
was ineffective in improving the coculture integrity under OGD±R (Allen et al., 
2010). Therefore in this study, the HBMEC were exposed to higher dose of Y-27632 
(10 µM) where the cell death was found to be negligible, thus eliminating the cellular 
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toxicity that may be induced by high dose of Y-27632. Our Y-27632 dosage selection 
is consistent with the results from a recent study, which demonstrates 10 µM to be the 
optimal concentration for Y-27632 to exhibit the barrier protective effects on rat 
BMEC (Ma et al., 2012). To monitor the prophylactic and therapeutic effects of Rho-
kinase inhibition, HBMEC were treated with Y-27632 during exposures to different 
periods of OGD alone and during reperfusion following OGD, respectively. The Y-
27632 treatment normalised the gp91-phox protein levels in HBMEC exposed to 
OGD. However, pronounced decreases in its levels were recorded under short and 
long OGD±R. The gp91-phox data was substantiated by NADPH oxidase activity, 
which showed basal NADPH oxidase activities under the influence of Y-27632 
during OGD±R and were similar to control HBMEC cultured under normoxia. These 
data demonstrate the antioxidant properties of Y-27632 and emphasise the Rho-
kinase-mediated increase in the expression and activity of the NADPH oxidase 
enzyme complex. Indeed, a previous study on rat neonatal cardiac myocytes have 
shown that activated Rho-kinase mediates angiotensin II-induced Rac1 activation and 
concomitant Rac1-dependent ROS production by NADPH oxidase enzyme activation 
(Nishida et al., 2005). Our data go hand in hand with the results from study with Dahl 
salt-sensitive hypertensive rats, which showed that Y-27632 treatment inhibited the 
increased expression of NADPH oxidase subunits (p22-phox, p47-phox and gp91-
phox) in heart tissues from the left ventricle hypertrophy stage and exhibited the 
cardioprotective mechanisms of Rho-kinase inhibition by suppression of oxidative-
stress mediated vascular lesion formations which included medial thickness and 
perivascular fibrosis (Mita et al., 2005). Recent studies with rat model of angiotensin 
II-induced cardiovascular hypertrophy, Dahl salt-sensitive hypertensive rats and rat 
model of liver transplantation with IR injury have demonstrated the dramatic 
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increases in the vascular NADPH oxidase expressions and endothelial O2•– 
production, which were significantly supressed by another Rho-kinase inhibitor, 
fasudil, and further exhibit the cardioprotective and hepatoprotective effects of Rho-
kinase inhibition (Higashi et al., 2003, Shiotani et al., 2004, Takeshima et al., 2012). 
In support of these studies, the total O2•– levels measured in HBMEC exposed to 
OGD±R with Y-27632 treatment also showed basal levels of O2•– which were similar 
to the controls and suggest that the Rho-kinase inhibition attenuates NADPH oxidase-
derived O2•– as well as it may also supress other O2•– generating enzymatic complexes 
like lipooxygenase-1 and COX-2 (Schmeck et al., 2003, Mita et al., 2005).  
     Since impaired cellular antioxidant mechanisms may also account for the oxidative 
stress, it was important to delineate the OGD±R-mediated modulation of antioxidant 
enzymes CuZn-SOD and catalase in HBMEC. Previous studies have shown that the 
levels of CuZn-SOD can dictate the extent of an NADPH oxidase-induced oxidative 
stress in murine coronary arteries subjected to hypoxia-reoxygenation. Indeed, 
transgenic mice overexpressing human CuZn-SOD reduced NADPH oxidase-derived 
O2•– levels along with completely blocking the coronary vasoconstriction (Liu et al., 
2004). Hence, the protein level of CuZn-SOD was explored in HBMEC that revealed 
no change or insignificant reduction under OGD±R. These results were consistent 
with studies on bovine pulmonary microvascular endothelial cells, which showed a 
two-fold increase in the O2•– production along with unchanged CuZn-SOD levels after 
hypoxia-reoxygenation. However, only after treatment with CuZn-SOD (100 
units/mL) during hypoxia prevented the O2•– generation and attenuated the 
hyperpermeability (Lum et al., 1992). Since in our experiment the OGD±R resulted in 
hyperpermeability, the existing CuZn-SOD protein levels may not be sufficient to 
dismutate the excessive O2•– generated. Studies on rats with transient focal cerebral 
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ischaemia followed by reperfusion have also shown a reduced CuZn-SOD 
immunoreactivity in the ipsilateral striatum along with a reduced antioxidant activity 
of total SOD and CuZn-SOD in plasma and blood cells reiterating a weak dismutase 
activity (Matsuda et al., 2009, Kravcukova et al., 2010). The Y-27632 treatment 
during OGD and short OGD+R had no significant effect on the CuZn-SOD protein 
levels. However, a significant reduction in its protein level was recorded under long 
OGD+R. These data indicate the inability of Rho-kinase inhibition to alter CuZn-
SOD protein levels, but it may modulate the antioxidant enzyme activity. Indeed, 
studies with rat model of intestinal IR support this hypothesis, as fasudil 
hydrochloride, a derivative of fasudil, significantly increased the IR-attenuated SOD 
antioxidant activity. Similarly in rat MCAO model of focal cerebral IR, the presence 
of fasudil mesylate, a derivative of fasudil, has been recently shown to increase the 
SOD activity by 50% in ischaemic cortex and by 58% in ischaemic hippocampus 
regions of the brain alongside improving the neurological deficits and reduction in 
cerebral infarct volume (Huang et al., 2008, Li et al., 2009, Li et al., 2011b). Further 
studies are required to measure the CuZn-SOD activity in HBMEC.      
     The dismutation of O2•– by CuZn-SOD and Mn-SOD results in the production of 
H2O2 in cytoplasm and mitochondria, respectively (Gao et al., 2009). However, under 
physiological state the H2O2 accumulation is averted by another antioxidant enzyme 
catalase, which breaks down H2O2 into H2O. Previous studies in our group have 
shown that HBMEC express functionally active catalase (Allen and Bayraktutan, 
2009a). In this study we have found that the protein levels of catalase increase in 
HBMEC after OGD±R. The increase in catalase protein levels may be in response to 
an increased intracellular H2O2 levels. Indeed, study with bovine aortic endothelial 
cells has shown that an increase in the intracellular O2•– levels leads to elevations in 
85 
 
intracellular H2O2 levels (Quijano et al., 2007). In addition, studies with rat skeletal 
muscle IR injury model support this hypothesis as an elevated tissue catalase activity 
was observed in this group compared with the sham group (Ozkan et al., 2012). 
However, recent studies with rat MCAO model of focal cerebral ischaemia have 
shown a significant reduction in the catalase activity in the brain cortex compared 
with that of the sham group (Liu et al., 2012). Since in our experiments, the OGD±R 
increased the BBB permeability, the increased catalase levels may not be sufficient to 
attenuate the H2O2 accumulation. Indeed, recent study on the mitochondrial oxidative 
stress demonstrated the inability of overexpressed catalase in alleviating the oxidative 
stress-induced cell death triggered after IR injury (Loor et al., 2011). Moreover, 
external supplementation with only high dose of catalase (1000 units/mL), which may 
be beyond physiological levels, have been previously shown to inhibit the 
reoxygenation-induced hyperpermeability in bovine pulmonary microvascular 
endothelial cells after hypoxic exposures, further suggesting the importance of H2O2 
in mediating the response (Lum et al., 1992). As stated earlier, the intracellular levels 
of H2O2 are dependent on the intracellular levels of O2•–. Hence, the Y-27632-
mediated normalisation of O2•– levels may also reduce the H2O2 levels and subsequent 
catalase protein expression or activity. Our data is supportive of this notion as the Y-
27632 treatment normalised the catalase protein levels in HBMEC exposed to 
OGD±R. Thus, treatment with Y-27632 has been shown to regulate the ROS 
metabolism in HBMEC by limiting elementary ROS i.e. O2•– production and 
modulate HBMEC to adjust the cellular antioxidant machinery to maintain cellular 
homeostasis. Indeed, studies on porcine brain capillary endothelial cells supports our 
rationale, as Y-27632 treatment completely prevented H2O2 (100 µM)-induced actin 
polymerisation and monolayer permeability (Kahles et al., 2007).  
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     In our previous study, we found that RhoA and its downstream effector Rho-kinase 
are expressed in HBMEC (Allen et al., 2010). In this study we have observed that the 
total RhoA levels measured in HBMEC homogenates remained mostly unchanged 
after OGD±R. However, the relative RhoA activities, measured by RhoA-GTP/total 
RhoA ratio, were significantly elevated during OGD±R. Our results are consistent 
with previous studies with human pulmonary artery endothelial cells, human 
pulmonary artery smooth muscle cells and porcine pulmonary artery smooth muscle 
cells where RhoA activity appeared to be upregulated in a time-dependent manner 
under hypoxia (Bailly et al., 2004, Wojciak-Stothard et al., 2012). SinceY-27632 
inhibits Rho-kinase activity; we examined its possible role in modulating the RhoA 
expression and activity to demonstrate the Y-27632 inhibitory effects are not limited 
to Rho-kinase per se, but might also affect RhoA. Our data show a dramatic reduction 
in the total RhoA protein levels in HBMEC under Y-27632 treatment during OGD±R. 
Studies with rat model of diabetes mellitus and Dahl salt-sensitive hypertensive rats 
are in agreement with our findings and also demonstrate the Y-27632-mediated 
reduction in RhoA protein expression in heart tissues (Mita et al., 2005, Soliman et 
al., 2012). In addition, our study has also shown that Y-27632 alleviates the RhoA 
activity marked by normalised RhoA-GTP levels in HBMEC exposed to OGD±R, 
which is also consistent with a previous in vitro study on mouse BMEC (Stamatovic 
et al., 2003). Taken together, Y-27632 also appears to regulate the Rho-kinase activity 
by modulating the expression and activity of RhoA.  
     Earlier we had shown that RhoA overactivity and subsequent Rho-kinase 
activation are associated with the stress-fibre formations in HBMEC resulting in 
increased actin filament contractility and impaired endothelial-barrier function (Allen 
et al., 2010). Since Rho-kinase-2 is highly expressed in heart and brain tissues, we 
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investigative the levels of this particular isoform in HBMEC exposed to OGD±R and 
showed selective increases only in OGD+R groups. However, the unchanged protein 
levels in OGD may not be representative of level of change in the activity. Indeed, 
recent studies confirm increased Rho-kinase activities measured by elevated adducin 
and MYPT phosphorylations, substrates of Rho-kinase, in endothelial cells from 
ischaemic lesions after focal cerebral ischaemia in rat and mice, respectively. 
Moreover, the increased Rho-kinase activity was associated with infarct expansion 
and neurological deficits in these rodents (Rikitake et al., 2005, Yagita et al., 2007). 
The Y-27632 treatment normalised the OGD+R-mediated increase in Rho-kinase-2 
protein levels without altering those in the OGD groups. These data are in partial 
agreement with previous in vivo studies where Rho-kinase inhibition by Y-27632 and 
fasudil have been shown to supress the Rho-kinase gene expression and activation, 
which resulted in the inhibition of infarct expansion and subsequently improved the 
neurological deficits (Mita et al., 2005, Yagita et al., 2007). These results suggest that 
Y-27632 is a potent inhibitor of RhoA/Rho-kinase signalling pathway. 
     The vasogenic oedema emerging from the disruption of the BBB represents one of 
the most severe outcomes of ischaemic stroke. Since the tight junction proteins and 
adherens junction proteins tightly seal the adjacent endothelial cells to restrict the 
paracellular permeability, it is possible that the disruption of the BBB may reflect the 
ischaemia-mediated modulation of these proteins. In this context, our data confirm the 
ischaemia-mediated modulation of tight junction proteins given the time-dependent 
increase in claudin-5 protein levels under OGD±R. It is of vital importance that the 
increases in the claudin-5 protein levels may not be reflective of its peripheral 
localisation which is critical element for the assembly of tight junctions and the 
barrier integrity. Recent studies with female Sprague-Dawley rats exposed to either 
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chronic inflammatory pain, hypoxia or hypoxia-reoxygenation have shown that 
increased claudin-5 levels in cerebral microvessels are associated with increased 
paracellular permeability and a loss of BBB function (Brooks et al., 2005, Willis et 
al., 2010). In addition, the Y-27632 treatment normalised the OGD±R-mediated 
increases in the claudin-5 protein levels in HBMEC. Since increased claudin-5 protein 
expressions are associated with barrier dysfunction, the normalisation of claudin-5 
levels under OGD±R may suggest an improved endothelial-barrier function. These 
results indicate that Rho-kinase is involved in modulation of claudin-5 protein 
expression. Indeed, a previous study has demonstrated the direct correlation of Rho-
kinase overactivity with enhanced claudin-5 phosphorylation and subsequent BBB 
dysfunction (Yamamoto et al., 2008). 
     Unlike claudin-5 protein levels, our results show no significant differences in the 
occludin protein expression in HBMEC exposed to normoxic versus OGD±R 
conditions. Similar to our data, a recent study with rat treated with λ-carrageenan, an 
inflammatory pain inducer, led to increased substrate permeability across the BBB 
without altering the β-occludin protein levels in cerebral microvessels. However, the 
α-occludin levels were decreased by 1.3-fold in the same study (Ronaldson et al., 
2009). Studies with rat model of subarachnoid haemorrhage have also shown a 
reduction in the occludin protein levels in the ipsilateral brain hemisphere 
emphasising possibility of protein degradation with cerebrovascular pathology. 
Recent in vitro and in vivo studies on mice brain endothelial cells and mice model of 
acute liver failure, respectively, have confirmed that the degradation of occludin 
proteins is due to an endogenous overexpression of MMP-9 (Chen et al., 2009, Fujii 
et al., 2012). However, the similar levels of occludin before and after exposure to 
OGD±R highlight the possible phosphorylation and subsequent disassembly of this 
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particular transmembrane protein. Indeed, a recent study with rat-MCAO model of 
global cerebral ischaemia supports this hypothesis, as ischaemic injury increased the 
BBB breakdown mediated through acute disassembly of occludin protein triggered by 
its increased phosphorylation (Kaur et al., 2011).  
     Treatment with Y-27632 during OGD±R increased occludin protein levels in 
HBMEC. Since occludin is one of the major transmembrane tight junction protein 
responsible for sealing the gaps between the adjacent endothelial cells, an increase in 
its levels under the influence of Y-27632 may reflect an improved endothelial barrier 
integrity. Indeed, recent in vitro and in vivo studies have shown that the inhibition of 
Rho-kinase improves the total occludin protein levels and the endothelial-barrier 
tightness (Fujii et al., 2012, Xie et al., 2012). Moreover, studies with mouse BMEC 
and bovine retinal endothelial cells have revealed that RhoA, Rho-kinase and PKC-β 
activations phosphorylate occludin at more than one sites and potentiate the tight 
junction trafficking, which is accompanied by the functional impairment of the 
endothelial barrier and prevented by specific inhibitor of aforementioned molecules 
(Hirase et al., 2001, Yamamoto et al., 2008, Murakami et al., 2012). Hence, further 
studies are required to examine the phosphorylation status of claudin-5 and occludin 
and their cellular localisation in HBMEC to investigate the tight junction trafficking 
under pathological conditions. 
          Apart from the transmembrane tight junction proteins, the endogenous adherens 
junction proteins like β-catenin, the primary canonical Wnt pathway activator, also 
regulates the endothelial permeability and intercellular signalling (Bazzoni and 
Dejana, 2004, Aisagbonhi et al., 2011). In this study we found that β-catenin levels 
remain unchanged in HBMEC after short and longer periods of exposures to OGD. 
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However, their levels elevated after OGD+R. These results illustrate the reperfusion-
mediated modulation of the adherens junction proteins. Recent findings from 
hypoxia-reoxygenation studies on proximal tubular epithelial rat cell line concur with 
our data, as β-catenin protein levels remain unchanged during hypoxia and hypoxia 
followed by short phases of reoxygenation (1-6 hours) (Saenz-Morales et al., 2006). 
Moreover, study on mouse model of myocardial infarction have shown a dramatic 
activation of canonical Wnt signalling in endothelial cells surrounding infarct area 
after 4 days of myocardial infarction emphasising the enhanced β-catenin induction 
during the later stages of pathology. In addition, this study also showed that canonical 
Wnt/β-catenin signalling triggers the transition of bovine aortic endothelial cells into 
mesenchymal cells indicated by phenotype modifications and loss of endothelial-cell-
specific signature gene CD31 (Aisagbonhi et al., 2011). Since β-catenin supports the 
transmembrane adherens junction protein VE-cadherin and anchors the focal adhesion 
complex to actin (Bazzoni and Dejana, 2004), its dissociation from VE-cadherin may 
introduce gaps and increase paracellular permeability. Indeed, recent studies on 
human pulmonary microvascular endothelial cells have suggested the ROS-mediated 
dissociation of β-catenin from VE-cadherin as one of the reasons behind the enhanced 
endothelial permeability (Makarova et al., 2011). In addition, using transgenic mice 
and primary brain endothelial cells it has been shown that stabilisation of VE-
cadherin-β-catenin complex is pivotal in maintaining the BBB integrity (Liebner et 
al., 2008).  
     In the current study, we observed that Y-27632 treatment restored the increased 
total β-catenin levels during OGD+R conditions which may be related to the stability 
of the VE-cadherin-β-catenin complex. Furthermore, it has been shown that synthesis 
and release of growth factors and cytokines destabilise the VE-cadherin adhesion 
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complex by increasing β-catenin phosphorylation. Hence by regulating the synthesis 
of cytokines and growth factor, Rho-kinase inhibition may attenuate β-catenin 
phosphorylation and subsequent dissociation from the VE-cadherin adhesion 
complex, thereby improving the barrier integrity (Vogelmann et al., 2005). Further 
studies are required to evaluate the β-catenin phosphorylations levels in HBMEC after 
OGD±R.     
     The vinculin, a subunit of focal adhesion complex, protein levels were also 
investigated in the current study which remained similar in HBMEC exposed to 
normoxia versus OGD±R conditions. These data are in coherence with results from 
studies with coronary endothelial cells which illustrated an unchanged vinculin 
protein levels, and proposed the association of increased vinculin phosphorylation 
levels with the progression of hyperpermeability during energy depletion in these 
cells (Muhs et al., 1997). Recent hypoxia-reoxygenation study has also shown 
unchanged paxillin, another subunit of focal adhesion complex, protein levels in 
proximal tubular epithelial rat cell line exposed to different hypoxia-reoxygenation 
combinations (Saenz-Morales et al., 2006). These results suggest that the focal 
adhesion protein levels are not altered under pathological conditions. Similarly, the Y-
27632 treatment did not change the vinculin protein levels in HBMEC under OGD±R. 
These results suggest that vinculin protein levels are not modulated by either Rho-
kinase activation or inhibition. However, phosphorylations of vinculin protein are 
known to be associated with the hyperpermeability (Muhs et al., 1997). Therefore, 
further studies are required to delineate the vinculin phosphorylations and their 
association with OGD±R-mediated hyperpermeability in HBMEC.  
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     Overwhelming evidence exists regarding the critical role of endothelial-barrier in 
restricting the paracellular permeability and therefore maintaining proper barrier 
function. In final part of this section, the possible alterations in BBB integrity were 
assessed by TEER and flux of EBA after exposure to OGD±R using an in vitro model 
of human BBB consisting of HBMEC and HA. We have previously shown that 
astrocytes are not as dormant as they were initially thought, in that they also possess 
increased RhoA activity and Rho-kinase expression after OGD±R (Allen et al., 2010). 
Therefore increased ROS production from astrocytes might also augment the 
oxidative stress-mediated BBB disruption. A time-dependent decrease in TEER and 
concurrent increase in the flux of EBA were recorded across the cocultures under 
OGD. The reperfusion after OGD exacerbated the BBB damage and further reduced 
the TEER and increased the flux of EBA across the cocultures. This may in part be 
due to the enhanced oxidative stress-mediated endothelial cell apoptosis (Kahles et 
al., 2007, Connell et al., 2011, Genovese et al., 2011). The Y-27632 treatment with 
OGD±R showed cerebral-barrier protective effects as the Rho-kinase inhibitor 
preserved the coculture integrity during short OGD±R which was confirmed by TEER 
readings and flux of EBA similar in the cocultures exposed to normoxia versus short 
OGD±R conditions. However, the Y-27632 treatment was ineffective in protecting 
the cerebral barrier integrity under longer OGD±R which showed decreased TEER 
readings and concomitant increase in the flux of EBA. Thus, cocultures exposed to 
short OGD±R with Y-27632 treatment appeared to have improved integrity and 
function compared to the cocultures exposed to OGD±R without Y-27632. This may 
be due to the inhibition of Rho-kinase-mediated induction of apoptosis in HBMEC 
under OGD±R. It has been shown that RhoA/Rho-kinase pathway is associated with 
the upregulation of proapoptotic protein Bax which activates the mitochondrial death 
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pathway and induce apoptosis in cardiomyocytes. Moreover fasudil mesylate has been 
shown to protect the oxidative stress-mediated apoptosis in rat PC12 cell line derived 
from rat pheochromocytoma (Del Re et al., 2007, Li et al., 2011a).  
     In conclusion, the current study has shown that Rho-kinase inhibitor Y-27632 may 
demonstrate antioxidant properties by attenuating the OGD±R-mediated increase in 
expression and activity of NADPH oxidase enzyme complex and preventing the 
excessive ROS formation and accumulation. Y-27632 may also be considered a 
cerebral barrier protective agent as it has improved the endothelial-barrier integrity 
and function. Lastly, the RhoA/Rho-kinase signalling pathway appears to orchestrate 
the endothelial-barrier dysfunction in part by modulating the pro-oxidant, antioxidant 
enzymes and junctional protein complexes.  
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Chapter 3 
 
 
Studies focusing on the molecular 
mechanisms behind cerebro 
protective effects of fasudil after 
ischaemic injury in mice  
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     Previous in vivo studies have shown that fasudil, a specific Rho-kinase inhibitor, 
treatment attenuates the IR-mediated injury by reducing the cerebral infarct volume 
and exhibit the neuroprotective properties following cerebral ischaemia (Rikitake et 
al., 2005, Yagita et al., 2007). Hence, the current study was designed to investigate 
the molecular mechanisms behind cerebro protective effects of fasudil after ischaemic 
injury in mice. Ischaemic stroke was induced in male mice by MCAO for 60 minutes 
and the animals received either fasudil or vehicle after ischaemia at: onset of 
reperfusion, 6 hours post reperfusion and 24 hours post reperfusion. The mice were 
sacrificed 48 hours after ischaemia and their brain tissues were collected, sliced and 
homogenised for in vitro experiments.  
3.1. Aims 
To investigate,  
1. whether fasudil modulates the IR-mediated effects on cerebral RhoA and Rho-
kinase-2 protein levels and RhoA activity, 
2. whether fasudil alters the IR-mediated effects on cerebral pro-oxidant enzyme 
NADPH oxidase expression and activity, total O2•– levels, antioxidant enzymes CuZn-
SOD and catalase protein levels, 
3. whether cerebral junctional complex proteins are regulated by fasudil after IR 
injury. 
3.2. Results 
3.2.1. Effects of fasudil on cerebral RhoA and Rho-kinase-2 protein expressions 
and RhoA activity 
     The homogenised brain sections from a mice model of ischaemic stroke were used 
to study the effects of fasudil on the RhoA protein expression, activity and Rho-
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kinase-2 protein levels after normalisation against β-actin levels. The results have 
been generated from (a) comparison between protein levels in the contralateral and 
ipsilateral brain sections from either vehicle-treated group or fasudil-treated group of 
mice, and (b) comparison of fold differences (ipsilateral/contralateral) in protein 
expression between vehicle-treated and fasudil-treated mice. Our results appear to 
show no significant difference in total RhoA protein levels between contralateral and 
ipsilateral brain sections in either vehicle-treated or fasudil-treated mice.  In addition, 
there was no significant fold difference in the total RhoA levels observed between 
these mice groups (Figure 3.1). These data appear to indicate that the cerebral total 
RhoA levels remain unchanged in vehicle-treated and fasudil- treated animals after IR 
injury.  
     The total RhoA activity was analysed by measuring the RhoA-GTP/total RhoA 
ratio in brain sections from vehicle-treated and fasudil-treated groups of mice. There 
were no significant differences in the total RhoA activities between contralateral and 
ipsilateral brain sections from either vehicle-treated or fasudil-treated mice. In 
addition, the fold differences in the total RhoA activities also remain unchanged 
between these groups (Figure 3.2). These results may indicate that the total RhoA 
activity does not change in brain sections after IR injury, and fasudil treatment may be 
ineffective in modulating the RhoA activity.    
     Similarly, the Rho-kinase-2 levels were also detected in mice brain tissue from the 
contralateral and ipsilateral sections of vehicle-treated group and fasudil-treated group 
of mice. No significant differences were observed in the Rho-kinase-2 protein levels 
between contralateral and ipsilateral brain sections of either vehicle- or fasudil-treated 
mice. Moreover, the fold difference in the Rho-kinase-2 protein levels also remained 
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unchanged between these mice groups (Figure 3.3). These results seem to indicate 
that Rho-kinase-2 protein levels do not change in brain sections after IR injury, and 
fasudil treatment has no effect on Rho-kinase-2 protein levels in brain sections of 
mice.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Total RhoA protein levels mice brain sections. (A-D) Representative 
Western blots and densitometric analyses of RhoA protein expression in contralateral 
and ipsilateral brain sections of mice model of ischaemic stroke treated with either 
Animal Group Contralateral (c)  Ipsilateral (i) Fold difference (i/c) 
1 Vehicle 0.68 0.72 1.06 
2 Vehicle 1.64 1.77 1.08 
3 Vehicle 1.54 1.68 1.09 
4 Fasudil 1.15 1.17 1.02 
5 Fasudil 0.78 0.78 1.00 
6 Fasudil 1.11 1.18 1.06 
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fasudil or vehicle. Univariate comparisons were made using Student’s t-test. Data are 
expressed as mean±SEM, n=3 in each group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Total RhoA activity in mice brain sections. (A-D) Representative Western 
blots and densitometric analyses of RhoA-GTP/total RhoA ratio in contralateral and 
Animal Group Contralateral (c)  Ipsilateral (i) Fold difference (i/c) 
1 Vehicle 17.89 6.56 0.37 
2 Vehicle 0.31 12.1 39.03 
3 Vehicle 16.53 16.4 0.99 
4 Fasudil 0.4 1.53 3.83 
5 Fasudil 1.54 5.65 3.67 
6 Fasudil 1.99 13.12 6.59 
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ipsilateral brain sections of mice model of ischaemic stroke treated with either fasudil 
or vehicle. Univariate comparisons were made using Student’s t-test. Data are 
expressed as mean±SEM, n=3 in each group. 
 
Animal Group Contralateral (c)  Iipsilateral (i) Fold difference (i/c) 
1 Vehicle 6.7 6.7 1.00 
2 Vehicle 7.3 7.3 1.00 
3 Vehicle 6.9 6.8 0.99 
4 Fasudil 6.7 6.7 1.00 
5 Fasudil 6.1 6.1 1.00 
6 Fasudil 6.3 5.8 0.92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Rho-kinase-2 protein levels in mice brain sections. (A-D) Representative 
Western blots and densitometric analyses of Rho-kinase-2 protein expression in 
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contralateral and ipsilateral brain sections of mice model of ischaemic stroke treated 
with either fasudil or vehicle. Univariate comparisons were made using Student’s t-
test. Data are expressed as mean±SEM, n=3 in each group. 
3.2.2. Effects of fasudil on cerebral gp91-phox protein levels, NADPH oxidase 
activity, total O2•–levels and antioxidant enzyme expressions 
     Our data show a slight but insignificant reduction in the gp91-phox protein levels 
in ipsilateral sections compared to contralateral sections in vehicle-treated mice 
group, which remained unchanged between respective sections in fasudil-treated mice 
group. Moreover in the ipsilateral brain sections, the fasudil treatment dramatically 
increased the gp91-phox protein levels compared to the ipsilateral brain sections of 
vehicle-treated mice (P<0.05). There was no significant variation in the fold 
difference in gp91-phox protein levels in brain sections between these mice groups 
(Figure 3.4). These results seem to indicate that gp91-phox protein levels do not 
change between the contralateral and ipsilateral sections of mice brain after IR injury 
in the presence or absence of fasudil. 
     In parallel with the gp91-phox data, the total NADPH oxidase enzyme activities 
measured by lucigenin-enhanced chemiluminescent detection of O2•– assay indicate a 
slight but insignificant reduction in the enzyme activity in ipsilateral section 
compared to contralateral section in vehicle-treated animals. However, the enzyme 
activities seemed to be similar in respective brain sections of fasudil-treated mice. 
There was no significant fold difference in the enzyme activities from ipsilateral and 
contralateral sections of fasudil-treated mice compared to the vehicle-treated mice 
(Figure 3.5). These results seem to indicate that the NADPH oxidase enzyme activity 
does not vary in different sides of mice brain after IR insult, and the fasudil treatment 
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may be ineffective in modulating the enzyme activities in brain sections of ischaemic 
mice. 
     To substantiate the differences or similarities observed in NADPH oxidase 
activity, total O2•– levels were also measured in the same homogenates of contralateral 
and ipsilateral brain sections from vehicle-treated and fasudil-treated mice groups via 
lucigenin-enhanced chemiluminescent detection of O2•–. No significant difference was 
recorded in the total O2•– levels between contralateral and ipsilateral brain sections 
from aforementioned mice groups. In addition, similar fold differences in the total 
O2•– levels were recorded between these groups of mice (Figure 3.6). These results 
indicate that the total O2•– levels appeared to remain unchanged in different sides of 
mice brain after IR insult and may also reflect the inefficiency of fasudil in 
modulating the total O2•– levels in brain sections of ischaemic mice. 
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Figure 3.4. The gp91-phox protein levels in mice brain sections. (A-D) 
Representative Western blots and densitometric analyses of gp91-phox protein 
expression in contralateral and ipsilateral brain sections of mice model of ischaemic 
Animal Group Contralateral (c)  Ipsilateral (i) Fold difference (i/c) 
1 Vehicle 0.053 0.054 1.02 
2 Vehicle 0.05 0.052 1.04 
3 Vehicle 0.048 0.045 0.94 
4 Vehicle 0.04 0.02 0.50 
5 Vehicle 0.08 0.06 0.75 
6 Vehicle 0.24 0.04 0.17 
7 Fasudil 0.047 0.09 1.91 
8 Fasudil 0.145 0.15 1.01 
9 Fasudil 0.061 0.117 1.92 
10 Fasudil 0.021 0.102 4.86 
11 Fasudil 0.091 0.11 1.21 
12 Fasudil 0.15 0.079 0.53 
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stroke treated with either fasudil or vehicle. Univariate comparisons were made using 
Student’s t-test. Data are expressed as mean±SEM, n=6, *P<0.05 compared to the 
ipsilateral section in vehicle group. 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. The cerebral NADPH oxidase enzyme activity (units/µg). (A-C) Relative 
NADPH oxidase activity and fold difference in contralateral and ipsilateral brain 
sections of mice model of ischaemic stroke treated with either fasudil or vehicle. 
Univariate comparisons were made using Student’s t-test. Data are expressed as 
mean±SEM, n=3 in each group. 
  
 
Animal Group Contralateral (c)  Ipsilateral (i)  Fold difference (i/c) 
1 Vehicle 1.28 1.28 1.00 
2 Vehicle 1.42 1.07 0.75 
3 Vehicle 1.37 1.14 0.83 
4 Fasudil 1.05 1.27 1.21 
5 Fasudil 1.14 1.1 0.96 
6 Fasudil 1.18 0.93 0.79 
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Animal Group Contralateral (c)  Ipsilateral (i)  Fold difference (i/c) 
1 Vehicle 0.77 0.84 1.09 
2 Vehicle 0.7 0.81 1.16 
3 Vehicle 0.79 0.72 0.91 
4 Fasudil 0.63 0.91 1.44 
5 Fasudil 0.8 0.7 0.90 
6 Fasudil 0.63 0.75 1.19 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. The cerebral O2•– levels (units/µg). (A-C) Relative O2•– levels and fold 
difference in contralateral and ipsilateral brain sections of mice models of ischaemic 
stroke treated with either fasudil or vehicle. Univariate comparisons were made using 
Student’s t-test. Data are expressed as mean±SEM, n=3 in each group. 
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     Moreover, our data show no significant variations in the antioxidant enzyme 
CuZn-SOD protein levels between contralateral and ipsilateral brain sections of either 
vehicle-treated group or fasudil-treated group of mice. In addition, the fold difference 
in CuZn-SOD levels was similar in these mice groups (Figure 3.7). These data may 
indicate that the protein levels of CuZn-SOD do not change after IR insult in mice, 
and fasudil treatment does not modulate the CuZn-SOD levels.   
     Similarly, the protein levels of another antioxidant enzyme catalase were also 
analysed in the brain sections of these mice groups. There was no significant 
difference observed in the catalase levels between contralateral and ipsilateral brain 
sections of either vehicle-treated or fasudil-treated mice. A similar fold difference in 
the catalase levels was also recorded between these mice groups (Figure 3.8). Taken 
together, these results indicate that IR injury seems to have no effect on the catalase 
protein levels, and fasudil treatment appears to be largely ineffective in modulating 
the catalase levels. 
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Animal Group Contralateral (c)  Ipsilateral (i)  Fold difference (i/c) 
1 Vehicle 9.06 8.57 0.95 
2 Vehicle 8.27 7.9 0.96 
3 Vehicle 9.02 9.79 1.09 
4 Fasudil 8.5 9.3 1.09 
5 Fasudil 8.1 7.90 0.98 
6 Fasudil 10.63 7.84 0.74 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. CuZn-SOD protein levels in mice brain sections. (A-D) Representative 
Western blots and densitometric analyses of CuZn-SOD protein expression in 
contralateral and ipsilateral brain sections of mice model of ischaemic stroke treated 
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with either fasudil or vehicle. Univariate comparisons were made using Student’s t-
test. Data are expressed as mean±SEM, n=3 in each group. 
 
 
Animal Group Contralateral (c)  Ipsilateral (i)  Fold difference (i/c) 
1 Vehicle 2.94 2.87 0.98 
2 Vehicle 3.09 3.09 1.00 
3 Vehicle 2.97 3.19 1.07 
4 Fasudil 2.46 2.72 1.11 
5 Fasudil 2.4 2.44 1.02 
6 Fasudil 2.8 3.32 1.19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Catalase protein levels in mice brain sections. (A-D) Representative 
Western blots and densitometric analyses of catalase protein expression in 
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contralateral and ipsilateral brain sections of mice model of ischaemic stroke treated 
with either fasudil or vehicle. Univariate comparisons were made using Student’s t-
test. Data are expressed as mean±SEM, n=3 in each group. 
 
3.2.3. Effects of fasudil on cerebral occludin and claudin-5 protein levels 
     Tight junction proteins like occludin and caludin-5 restrict the paracellular 
permeability and prevent the cerebral oedema formation. Hence, the cerebral levels of 
these proteins were detected in vehicle-treated and fasudil-treated groups of mice 
model of ischaemic stroke. There were no significant differences observed in the 
occludin protein levels between contralateral and ipsilateral brain sections in either of 
the mice groups. In addition, similar fold difference in the occludin levels was 
observed between these mice groups (Figure 3.9).  
     Similarly, the cerebral claudin-5 levels were also detected in the same mice 
groups. Our data show no significant difference in the claudin-5 levels between 
contralateral and ipsilateral sections of either vehicle-treated or fasudil-treated mice 
groups. However, a significant reduction in the claudin-5 levels was observed in 
contralateral and ipsilateral sections after fasudil treatment compared to the vehicle 
treatment (P<0.05). Moreover, the fold difference in the claudin-5 levels also 
remained unchanged between the mice groups (Figure 3.10). These results indicate 
that IR injury appears to have no significant effect on the cerebral occludin and 
claudin-5 protein levels, and fasudil may supresses the claudin-5 levels in mice brain. 
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1 Vehicle 0.1 0.11 1.10 
2 Vehicle 0.1 0.1 1.00 
3 Vehicle 0.08 0.09 1.13 
4 Fasudil 0.07 0.07 1.00 
5 Fasudil 0.08 0.07 0.88 
6 Fasudil 0.1 0.1 1.00 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3.9. Cerebral occludin protein levels in mice. (A-D) Representative Western 
blots and densitometric analyses of occludin protein expression in contralateral and 
ipsilateral brain sections of mice model of ischaemic stroke treated with either fasudil 
or vehicle. Univariate comparisons were made using Student’s t-test. Data are 
expressed as mean±SEM, n=3 in each group. 
A 
B C 
D 
Contralateral        +        -         +       -   
Ipsilateral             -         +        -       + 
R
el
at
iv
e 
ba
n
d 
in
te
n
sit
y 
Vehicle              +              -        
Fasudil               -              +        
Fo
ld
 
di
ffe
re
n
ce
 
(i/
c) 
Occludin (78kDa)     
β-actin (44kDa)  
Contralateral            +       -        +      -         +       -   
Ipsilateral                 -       +        -      +         -       + 
 
Vehicle-treated             1                2                3 Fasudil-treated           4               5              6 
Vehicle Fasudil 
Occludin (78kDa)     
β-actin (44kDa)  
Contralateral           +     -        +     -       +     -   
Ipsilateral                -      +        -     +      -     + 
 
110 
 
0.0
0.1
0.2
0.3
0.4
0.5
0.0
0.5
1.0
1.5
 
Animal Group Contralateral (c)  Ipsilateral (i)  Fold difference (i/c) 
1 Vehicle 0.42 0.4 0.95 
2 Vehicle 0.43 0.29 0.67 
3 Vehicle 0.32 0.29 0.91 
4 Fasudil 0.11 0.15 1.36 
5 Fasudil 0.19 0.16 0.84 
6 Fasudil 0.18 0.15 0.83 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. Cerebral claudin-5 protein levels in mice. (A-D) Representative Western 
blots and densitometric analyses of claudin-5 protein expression in contralateral and 
ipsilateral brain sections of mice model of ischaemic stroke treated with either fasudil 
or vehicle. Univariate comparisons were made using Student’s t-test. Data are 
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expressed as mean±SEM, n=3 in each group, *P<0.05 compared to same sections in 
vehicle group.  
3.3. Discussion 
     In this study, the brain tissue homogenates obtained from mice subjected to 
MCAO and treated with either vehicle or fasudil, a specific Rho-kinase inhibitor, 
were used to assess the effects of IR injury and Rho-kinase inhibition on RhoA/Rho-
kinase, pro-oxidant enzyme, antioxidant enzyme and junctional complex proteins. Our 
results show that IR injury had no significant effects on the protein expressions of 
RhoA, Rho-kinase-2, gp91-phox, CuZn-SOD, catalase, occudin and claudin-5; RhoA 
and NADPH oxidase enzyme activities and total O2•– levels. Although fasudil 
treatment supressed the claudin-5 protein levels, it was ineffective in modulating 
either expression or activities of other aforementioned proteins. Thus, it appears that 
different types of cells constituting the complex cerebral tissues maybe stimulated in a 
different manner under IR stress.   
     Our previous studies have shown that the activation of RhoA/Rho-kinase 
modulates the cytoskeletal components like MLC2 and actin, and enhances the 
cytoskeletal remodelling under IR pathology in HBMEC and HA (Allen et al., 2010). 
Here, we investigated the expression of RhoA and RhoA-GTP in brain tissues from 
mice model of ischaemic stroke which were found to remain unchanged after IR 
injury. Results from previous studies do not support this data as a marked increase in 
RhoA protein levels have been reported in stroke brain sections and in cellular 
components of rodent cerebrovasculature after global ischaemia (Brabeck et al., 2003, 
Zhou et al., 2003). Although the unaltered total RhoA protein data in brain samples 
were similar to our in vitro data observed in HBMEC exposed to OGD±R, the RhoA 
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activity data were different as two-fold increases were recorded in HBMEC subjected 
OGD±R. In addition, the fasudil treatment neither affected the RhoA levels nor its 
activity. These results indicate that the IR injury may not modulate the RhoA activity 
in the similar manner in all the brain cells. Since cerebral tissues constitute neurons, 
astrocytes, pericytes, microglia, macrovascular endothelial cells, microvascular 
endothelial cells and blood cells, an IR-mediated alteration in microvascular 
endothelial cells may not be reflected in data obtained from complete cerebral tissues. 
The brain sections from mice treated with either fasudil or vehicle had no difference 
in the Rho-kinase-2 protein levels, which were consistent with our previously 
discussed in vitro data in HBMEC. However, the unchanged Rho-kinase-2 protein 
levels may not be representative of change in its activity. Indeed, recent studies 
confirm increased Rho-kinase activities in the cerebral tissues from ischaemic lesions 
after focal cerebral ischaemia in rodents (Rikitake et al., 2005, Yagita et al., 2007). 
Moreover, suppression of Rho-kinase activity by fasudil or Y-27632 in mice models 
of global ischaemia decreased the kinase activity and the infarct volume and 
substantiated the role of Rho-kinase to ischaemic cerebral damage (Rikitake et al., 
2005). 
     Oxidative stress, an imbalance in ROS metabolism, exacerbates the cerebral 
damage under IR injury. Since pro-oxidant NADPH oxidase enzyme complex is one 
of the major sources of O2•– production, the expression of gp91-phox, a pivotal 
subunit of NADPH oxidase, and enzyme activity were studied in brain sections of 
experimental mice treated with either fasudil or vehicle. Our data show no significant 
changes in the gp91-phox protein levels, NADPH oxidase activities and total O2•– 
levels in mice brain sections after IR injury regardless of the treatment regimen. 
Recent in vivo studies on rat models of liver transplantation with IR injury, 
113 
 
angiotensin II-induced cardiovascular hypertrophy and Dahl salt-sensitive 
hypertensive rats with cardiovascular abnormalities does not support the current in 
vivo data as marked increase in the gp91-phox protein levels, NADPH oxidase 
activities and total O2•– levels were observed in respective tissues under the 
pathological conditions. In addition, Rho-kinase inhibition either by fasudil or Y-
27632 completely suppressed the elevation in gp91-phox protein levels, NADPH 
oxidase activities and total O2•– levels (Higashi et al., 2003, Shiotani et al., 2004, 
Takeshima et al., 2012). Taken together these data indicate that under pathological 
conditions, Rho-kinase activity may induce oxidative stress by substantially 
upregulating NADPH oxidase expression, activity and ROS production in different 
tissues. Since brain is a complex tissue constituting different cell types it is possible 
that IR injury may not have induced dramatic NADPH oxidase activation in all the 
cells simultaneously. Indeed, microglia and astrocytes are known to produce enhanced 
levels of reactive nitrogen species which include nitric oxide and peroxynitrite under 
IR stress conditions (Askalan et al., 2006, Haynes et al., 2009).  
    The alteration in physiological levels of antioxidant enzymes like CuZn-SOD and 
catalase are key determinants of ROS and overall oxidative status. Hence, the protein 
expressions of CuZn-SOD and catalase were detected in brain sections of ischaemic 
mice treated with either vehicle or fasudil. Our results show no significant differences 
in the CuZn-SOD protein levels in the ipsilateral and contralateral brain sections of 
vehicle-treated and fasudil-treated ischaemic mice. These results are in agreement 
with our in vitro data where protein expression of CuZn-SOD remained unchanged in 
HBMEC under OGD±R. These results also go hand in hand with a previous in vitro 
study on bovine pulmonary microvascular endothelial cells which showed unchanged 
CuZn-SOD levels after hypoxia-reoxygenation (Lum et al., 1992). On the contrary, 
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recent studies on rat models of focal cerebral IR have shown a reduced CuZn-SOD 
immunoreactivity in the ipsilateral striatum (Matsuda et al., 2009, Kravcukova et al., 
2010). In addition, recent studies on rat models of intestinal IR and focal cerebral IR 
have shown that fasudil treatment ameliorated the SOD activity alongside improving 
neurological deficits and reducing the cerebral infarction (Huang et al., 2008, Li et al., 
2009, Li et al., 2011b). Further experiments are required to measure the CuZn-SOD 
activity in brains sections of ischaemic mice, and to evaluate the influence of fasudil 
treatment on enzyme activity.    
     The antioxidant enzyme catalase is also important in the ROS metabolism as it 
reduces the excessive H2O2 into water and oxygen. Hence, the catalase protein levels 
were studied in brain sections from ischaemic mice. Our results show no significant 
difference in the catalase protein expression in the brain sections of vehicle-treated 
mice and also remain unchanged in brain sections of fasudil-treated mice. These 
results are different from our in vitro data which showed a dramatic increase in the 
catalase protein expression in HBMEC after OGD±R, and were normalised with Y-
27632 treatment. The difference in the catalase protein expression in our in vitro and 
in vivo experiments may be due to the variation in the catalase expression in different 
cellular components of the brain. Since brain is a complex tissue made up of different 
kinds of cells, the OGD±R-mediated modulation of catalase in microvascular 
endothelial cells may not be similar in other cells of brain. Hence, further experiments 
are required to measure catalase protein levels and activity in different cellular 
components of brain from ischaemic mice.   
     As discussed in earlier chapters, the integrity of the BBB is heavily dependent on 
the expression, localisation and stability of tight junction proteins. Variation in these 
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parameters due to the pathological conditions, destabilise the tight junction protein 
complexes and compromise the tightness and integrity of the BBB. Therefore, this 
study investigated the protein levels of tight junction components occludin and 
claudin-5 in brain sections of mice model of IR treated with either vehicle or fasudil. 
In addition, the effects of fasudil treatment on the tight junction protein levels were 
also observed in these in vivo samples. There were no significant differences observed 
in the protein levels of occludin in the brain sections from contralateral and ipsilateral 
sides of the experimental mice and remained unchanged after fasudil treatment. These 
results indicate that the total occludin protein levels do not change after IR injury 
which is consistent with our in vitro data from HBMEC exposed to OGD±R. Recent 
in vivo studies with rat models of subarachnoid haemorrhage and acute liver failure 
have shown a decrease in the occludin levels in the brain samples and do not support 
the current in vivo data (Chen et al., 2009, Fujii et al., 2012). The unchanged occludin 
level observed in the current study does not dismiss the possibility of occludin 
phosphorylation and subsequent destabilisation. Indeed, recent in vivo studies with 
rodents have shown that ischaemia-mediated BBB breakdown is due to the acute 
disassembly of occludin triggered by Rho-kinase-mediated occludin phosphorylation 
(Yamamoto et al., 2008, Kaur et al., 2011). Although the fasudil treatment did not 
alter the total ocludin protein levels, it may have decreased the IR-mediated occludin 
phosphorylation and contributed to stabilise the BBB.     
     Similarly, the claudin-5 protein expressions were investigated in the in vivo brain 
sections form the experimental mice and the effects of IR injury and fasudil treatment 
were studied. Our data show no significant difference in the claudin-5 protein levels 
between the contralateral and ipsilateral brain sections from these mice. Recent in 
vivo data from rat models of chronic inflammatory pain and global hypoxia have 
116 
 
shown an increase in claudin-5 levels in the cerebral microvessels under pathological 
conditions (Brooks et al., 2005, Willis et al., 2010). These results indicate that the 
protein levels of caludin-5 vary in different cellular components of brain and this 
variability may not be reflected in brain tissue which constitutes different kinds of 
cellular components. Although the claudin-5 protein levels remain unchanged 
between contralateral and ipsilateral brain sections of fasudil-treated mice, a dramatic 
reduction in its levels was recorded after the fasudil treatment compared to the vehicle 
treatment. These results indicate that Rho-kinase modulates the claudin-5 protein 
level which is consistent with our in vitro data in HBMEC exposed to the 
experimental conditions. In addition, recent in vivo studies with rodents have shown 
that activated Rho-kinase phosphorylates claudin-5 proteins and potentiate the tight 
junction protein trafficking under pathological conditions (Yamamoto et al., 2008, 
Kaur et al., 2011). 
     In conclusion, the data collected from this particular study showed no significant 
difference in RhoA and NADPH oxidase activities, O2•– production and RhoA, Rho-
kinase-2, gp91-phox, CuZn-SOD, catalase, occludin and claudin-5 protein levels 
between contralateral and ipsilateral brain sections obtained from mice subjected to 
MCAO and treated with either vehicle or fasudil. These results were somewhat 
expected considering the complexity of the brain tissue which comprises of different 
kinds of cells as mentioned before. All of these cells may not respond to the IR stress 
simultaneously and in a similar manner. In addition, our in vitro data were collected 
from brain microvascular endothelial cells which are the cellular components of the 
BBB and may be less than 1% of total brain tissue (Bar, 1983, del Zoppo and 
Mabuchi, 2003, Cipolla, 2009).                     
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Chapter 4 
 
 
 
Studies focusing on the effects of 
hyperglycaemia on BBB integrity 
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4.1. Aims 
     To examine the association of hyperglycaemia with cerebral barrier dysfunction, 
this study was designed to elucidate, 
1. whether hyperglycaemia modulates the RhoA/Rho-kinase/MLC2 pathway, 
cytoskeletal organisation, junctional complex protein expressions or  localisation 
and cerebral barrier integrity, 
2. whether PKC and p38MAPK signalling pathways are involved in the 
hyperglycaemia-mediated effects, 
3. whether inhibition of RhoA/Rho-kinase activities and specific PKC isoforms  
modulate the hyperglycaemia-mediated PKC overactivity,  
4. whether specific PKC-α and PKC-β inhibitors restore the hyperglycaemia-
mediated alterations to the RhoA/Rho-kinase/MLC2 pathway, cytoskeletal 
reorganisation, junctional complex protein expressions or  localisation and 
cerebral barrier integrity, 
5. whether PKC-α and PKC-β siRNA protein knockdown attenuate the 
hyperglycaemic effects on the RhoA activity, MLC2 phosphorylation, junctional 
complex protein expression and cytoskeletal remodelling. 
4.2. Results 
4.2.1. Effects of hyperglycaemia on RhoA/Rho-kinase/MLC2 signalling pathway, 
cytoskeletal reorganisation and junctional complex 
   The cellular protein levels in HBMEC subjected to different treatments were 
detected by in-cell Western analysis after normalisation against the α-tubulin levels 
which served as internal controls. In-cell Western analyses is a new technique to 
detect and quantify the proteins present in the monolayer of cells in an attempt to 
minimise the variations in protein levels caused by artifacts in ordinary Western 
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blotting technique. Hyperglycaemic exposure (25 mM D-glucose) to HBMEC 
increased the protein expressions of RhoA and Rho-kinase-2 compared to the 
HBMEC under normoglycaemia (5.5 mM D-glucose) which served as controls 
(P<0.05). However after the glucose normalisation, the hyperglycaemia mediated 
increase in these proteins was restored (P<0.05). The equimolar D-mannitol treatment 
did not introduce any significant difference in the protein levels and thus eliminated 
the effects of hyperosmolality playing its part in the hyperglycaemia-mediated 
alterations. Cotreatment with low dosage of Y-27632 (2.5 µM) under hyperglycaemia 
appeared to have no effect on the increased protein expressions of RhoA and Rho-
kinase-2 and supports the fact that Y-27632 is an inhibitor of Rho-kinase activity 
(Figure 4.1A, B). Since the total RhoA levels measured in HBMEC homogenates 
remained largely unchanged among various treatment regimens after normalisation 
against the β-actin, the relative RhoA activities  were calculated after normalising 
total RhoA-GTP isoforms levels against the total RhoA protein levels (RhoA-
GTP/total RhoA ratio). Hyperglycaemia introduced a 2-fold increase in the RhoA 
activity compared to the controls (P<0.05), which was independent of a rise in 
osmolality and were effectively neutralised by glucose normalisation and inhibition of 
RhoA by electroporation of anti-RhoA-IgG to HBMEC (P<0.05). In contrast, the 
treatment with low dose of Y-27632 with hyperglycaemia failed to restore the 
elevated RhoA-GTP levels in HBMEC (Figure 4.1C). These results indicate that 
hyperglycaemia modulates RhoA/Rho-kinase signalling and glucose normalisation 
abrogated the hyperglycaemia-mediated alterations.  
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Figure 4.1. Hyperglycaemia modulates RhoA/Rho-kinase signalling. Representative protein levels and corresponding densitometric analyses of 
(A) RhoA, (B) Rho-kinase-2 and (C) RhoA activities in HBMEC after normalisation against α-tubulin and β-actin. HBMEC were exposed to 
NG (5.5 mM D-Glucose), HG (25 mM D-glucose), D-M (5.5 mM D-glucose+19.5 mM D-mannitol), Y-27632 (2.5 µM)+HG and electroporated 
with anti-RhoA-IgG before HG. Data are expressed as mean±SEM from 4 different experiments. Statistical analysis was done using ANOVA 
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with Dunnet’s post hoc test for multiple comparisons (A: P<0.0001, F=18.07, df1=4, 
df2=15), (B: P<0.0001, F=12.737, df1=4, df2=15), (C: P<0.0001, F=61.285, df1=5, 
df2=12) *P<0.05 versus NG, †P<0.05 versus HG.  
     Since MLC2 is one of the known downstream targets of Rho-kinase, a change in 
their phosphorylation status may be an indication of the Rho-kinase activity under 
hyperglycaemia. There were no significant changes in the total MLC2 protein levels 
in HBMEC treated with hyperglycaemia alone or in the presence of Y-27632 and in 
HBMEC treated with D-mannitol compared with the controls. However, 
hyperglycaemia increased the levels of MLC2 mono-phosphorylation (p-MLC2-Ser19) 
and di-phosphorylation (p-MLC2-Thr18/Ser19) in HBMEC measured after 
normalisation against the total MLC2 protein levels which appeared to be unaffected 
by hyperglycaemic challenge (P<0.05). The hyperglycaemia-induced increases in the 
levels of MLC2-mono/di-phosphorylations were independent of hyperosmolality and 
were restored by glucose normalisation and treatment with Y-27632 (P<0.05). As 
MLC2 phosphorylations are dependent on Rho-kinase activity, these results illustrate 
the role of hyperglycaemia-mediated Rho-kinase overactivity in modulating the 
MLC2 phosphorylation levels (Figure 4.2).  
     To examine the effects of hyperglycaemia-mediated MLC2 phosphorylations on 
HBMEC architecture, the actin filaments were detected by Rhodamine-labelled 
phalloidin dye. While cells cultured under normoglycaemia and D-mannitol displayed 
a cortical actin stainings, those exposed to hyperglycaemia developed stress fibres 
traversing across the cells and acquired morphological changes characterised by 
cuboidal or elongated appearances. Normalisation of glucose levels reinstated cortical 
actin staining and cellular morphology which were fully preserved by inhibition of 
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RhoA and Rho-kinase by anti-RhoA-IgG electroporation and Y-27632 treatment, 
respectively, during hyperglycaemic insult (Figure 4.3). These results suggest that 
hyperglycaemia induces the cytoskeletal remodelling by activation of RhoA/Rho-
kinase signalling pathway.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Representative in-cell Westerns and densitometric analyses of (A) p-
MLC2-Ser19, and (B) p-MLC2-Thr18/Ser19 in HBMEC after normalisation against 
total MLC2 and α-tubulin. HBMEC were exposed to NG (5.5 mM D-Glucose), HG 
(25 mM D-glucose), D-M (5.5 mM D-glucose + 19.5 mM D-mannitol) and cotreated 
with Y-27632 (2.5 µM) plus HG. Data are expressed as mean±SEM from 4 different 
experiments. Statistical analysis was done using ANOVA with Dunnet’s post hoc test 
for multiple comparisons (A: P<0.0001, F=21.312, df1=4, df2=15), (B: P<0.0001, 
F=37.151, df1=4, df2=10). *P<0.05 compared to NG, †p<0.05 compared to HG. 
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Figure 4.3. Actin microfilament stainings in HBMEC exposed to normoglycaemia 
(NG; 5.5 mM D-glucose), hyperglycaemia (HG; 25 mM D-glucose), D-mannitol (D-
M; 5.5 mM D-glucose + 19.5 mM D-mannitol), HG followed by NG, HG+Y-27632 
(2.5 µM) and electroporated with anti-RhoA-IgG (3 µg) before HG. The cells were 
fixed, permeabilised, blocked, and incubated with Rhodamine-labelled phalloidin dye. 
Arrows represent the stress fibre formations during hyperglycaemic exposure. Data 
are collected from 3 different experiments. Bar scale: 50 m. 
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     Given the effects of hyperglycaemia on cytoskeleton, it was highly likely that 
hyperglycaemia could compromise the expression and respective localisation of tight 
junction proteins occludin and ZO-1. In support this notion the in-cell Western 
analyses showed that hyperglycaemia reduced the occludin protein levels in HBMEC 
compared to the normoglycaemic controls (P<0.05). Where the increases in 
osmolality failed to affect the occludin levels. However, the decreases in occludin 
levels were restored by normalisation of glucose levels and supression of Rho-kinase 
activity via Y-27632 (P<0.05) (Figure 4.4A). In addition, the cellular levels of ZO-1 
protein remained unchanged in HBMEC treated with hyperglycaemia alone or in the 
presence of Y-27632. Similarly, the ZO-1 protein levels also remained unaffected by 
hyperosmolality and the glucose normalisation (Figure 4.4B) 
     These data were corroborated with studies focusing on the cellular localisations of 
occludin and ZO-1 in that while complete peripheral stainings were observed under 
normoglycaemic conditions, hyperglycaemia disrupted the uniform peripheral 
occludin and ZO-1 stainings observed by partial disappearance of occludin and 
regular introduction of gaps in ZO-1 stainings by either relocalisation or degradation 
of these proteins at cell borders (Figure 4.5 A, B). These changes in the occludin and 
ZO-1 localisations were independent of hyperosmolality. Moreover, the complete 
peripheral stainings of these proteins were restored after glucose normalisation and 
inhibition of RhoA and Rho-kinase by anti-RhoA-IgG electroporation and Y-27632 
treatment, respectively, during hyperglycaemia. These results indicate that 
hyperglycaemia modulates tight junction complex in part via RhoA/Rho-kinase 
signalling pathway. 
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Figure 4.4. Representative in-cell Westerns and densitometric analyses of (A) 
occludin, and (B) ZO-1 in HBMEC after normalisation against α-tubulin. HBMEC 
were exposed to NG (5.5 mM D-Glucose), HG (25 mM D-glucose), D-M (5.5 mM D-
glucose + 19.5 mM D-mannitol) and cotreated with Y-27632 (2.5 µM) plus HG. Data 
are expressed as mean±SEM from 4 different experiments. Statistical analysis was 
done using ANOVA with Dunnet’s post hoc test for multiple comparisons (A: 
P<0.0001, F=10.548, df1=4, df2=15), (B: P=0.848, F=0.339, df1=4, df2=15). *P<0.05 
compared to NG, †P<0.05 compared to HG. 
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Figure 4.5. Hyperglycaemia disrupts tight junction complex. (A) occludin and (B) 
ZO-1 localisation in HBMEC detected by FITC-stainings. Arrows represent the gap 
formations after hyperglycaemic exposures. HBMEC were subjected to 
normoglycaemia (NG; 5.5 mM D-glucose), hyperglycaemia (HG; 25 mM D-glucose), 
D-mannitol (D-M; 5.5 mM D-glucose + 19.5 mM D-mannitol), HG followed by NG, 
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HG+Y-27632 (2.5 µM) and electroporated with anti-RhoA-IgG (3 µg) before 
exposing to HG. Data are collected from 3 different experiments. Bar scale: 50 m. 
     The functional outcome of the hyperglycaemia-mediated changes observed in the 
aforementioned proteins were studied by measuring TEER values and the flux of 
permeability marker EBA across an in vitro model of human BBB. Hyperglycaemia 
compromised the in vitro cerebral-barrier integrity as evidenced by decrease in TEER 
values, and concomitant increase in the flux of EBA compared to those observed 
across cocultures subjected to normoglycaemia which served as controls (P<0.05) 
(Figure 4.6 A, B). However, suppression of RhoA and Rho-kinase activities by anti-
RhoA-IgG electroporation and Y-27632, respectively, abrogated these defects and 
improved the cerebral-barrier function as observed by improvement in the TEER 
readings and concurrent reduction in the flux of EBA across the cocultures (P<0.05). 
Furthermore during hyperglycaemia, inhibitions of PKC and p38MAPK signalling 
pathways in HBMEC by cotreatments with a general PKC inhibitor Bis-I (5 µM) and 
a p38MAPK inhibitor SB203580 (10 µM), respectively, have also been shown to be 
cerebral-barrier protective as they maintained the normal barrier function similar to 
those observed in normoglycaemic cocultures (Figure 4.6 A, B). Taken together, these 
data indicate the involvements of RhoA, Rho-kinase, PKC and p38MAPK in the 
pathogenesis of hyperglycaemia-mediated cerebral-barrier breakdown. 
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Figure 4.6. Measurement of integrity and function of an in vitro model of human 
BBB. (A) Transendothelial electrical resistance (TEER) (cm2) and (B) flux of EBA 
(µL) across the cocultures after exposures to normoglycaemia (NG; 5.5 mM D-
Glucose), hyperglycaemia (HG; 25 mM D-glucose) alone or in the presence of 
inhibitors against Rho-kinase (Y-27632; 2.5 µM), PKC (Bis-I; 5 µM), p38MAPK 
(SB203580; 10 µM), and establishing cocultures with anti-RhoA-IgG (3µg) 
electroporated HBMEC before exposing to HG. Data are expressed as mean±SEM 
from 6 different experiments. Statistical analysis was done using ANOVA with 
Dunnet’s post hoc test for multiple comparisons (A: P<0.0001, F=32.597, df1=5, 
df2=30), (B: P<0.0001, F=23.589, df1=5, df2=30). *P<0.05 compared to NG, †P<0.05 
compared to HG. 
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4.2.2. PKC-mediated modulation of RhoA/Rho-kinase/MLC2 pathway under 
hyperglycaemia 
     Since the inhibitions of RhoA/Rho-kinase, PKC and p38MAPK pathways exerted 
cerebral-barrier protective effects, in subsquent studies we aimed to determine the 
possible existence of a cross-talk between them. In relation to this, the cotreatment of 
HBMEC with either Bisindolylmaleimide-I (Bis-I) or SB203580 under 
hyperglycaemia did not alter the hyperglycaemia-mediated elevations observed in 
cellular RhoA protein levels. However, only the treatment with Bis-I normalised the 
Rho-kinase-2 protein levels (P<0.05). These data indicate that PKC signalling might 
be upstream to the Rho-kinase-2. In addition, cotreatment with SB203580 under 
hyperglycaemia did not affect the hyperglycaemia evoked Rho-kinase-2 levels 
(Figure 4.7 A, B). To further explore the link between these particular signalling 
pathways and RhoA/Rho-kinase/MLC2 system, the levels of MLC2 phosphorylation 
were observed in cells treated with PKC and p38MAPK inhibitors. It is of note here 
that the total MLC2 protein levels were unaffected in cells exposed to hyperglycaemic 
conditions in the absence or presence of Bis-I and SB203580. The treatment with Bis-
I but not SB203580 attenuated the hyperglycaemia-evoked MLC2 mono- and di-
phosphorylations when normalised against total MLC2 levels (P<0.05), thereby 
confirming the PKC-mediated modulation of Rho-kinase expression and activity 
(Figure 4.8 A, B).  
     To elucidate the effects of PKC-mediated modulation of RhoA/Rho-kinase/MLC2 
signalling on HBMEC architecture, the cytoskeletal component, F-actin, was 
visualised. As stated before, the cells cultured under normoglycaemia displayed 
cortical actin stainings while those exposed to hyperglycaemia developed stress fibres 
traversing across the cells and acquired morphological changes characterised by 
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cuboidal or elongated appearances. Cotreatment with Bis-I reinstated cortical actin 
staining and dramatically reduced stress fibres alongside restoring the cellular 
morphology similar to that of HBMEC subjected to normoglycaemic conditions 
(Figure 4.8C). As the treatments with SB203580 slightly reduced the MLC2 
diphosphorylation levels, it is safe to suggest that a separate pathway may be involved 
in p38MAPK inhibitor-dependent cerebral-barrier protection (P<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. PKC modulates RhoA/Rho-kinase pathway. Representative in-cell 
Westerns and densitometric analyses of (A) RhoA, and (B) Rho-kinase-2 proteins in 
HBMEC after normalisation against α-tubulin. HBMEC were exposed to 
normoglycaemia (NG; 5.5 mM D-Glucose), hyperglycaemia (HG; 25 mM D-glucose) 
alone and in the presence of either Bis-I (5 µM) or SB203580 (10 µM). Data are 
expressed as mean±SEM from 4 different experiments. Statistical analysis was done 
using ANOVA with Dunnet’s post hoc test for multiple comparisons (A: P=0.001, 
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Figure 4.8. PKC modulates MLC2 mono/di- phosphorylations. Representative in-cell 
Westerns and densitometric analyses of (A) p-MLC2-Ser19, and (B) p-MLC2-
Thr18/Ser19 in HBMEC after normalisation against total MLC2 and α-tubulin. (C) F-
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actin stainings with Rhodamine-labelled phalloidin dye. HBMEC were exposed to 
normoglycaemia (NG; 5.5 mM D-Glucose), hyperglycaemia (HG; 25 mM D-glucose) 
alone and cotreated with either Bis-I (5 µM) or SB203580 (10 µM). Arrows represent 
stress fibre formations. Data are expressed as mean±SEM from 3 different 
experiments. Statistical analysis was done using ANOVA with Dunnet’s post hoc test 
for multiple comparisons (A: P=0.002, F=12.857, df1=3, df2=8), (B: P=0.003, 
F=11.102, df1=3, df2=8). *P<0.05 compared to NG, †P<0.05 compared to HG, 
#P<0.05 compared to HG+Bis-I. Bar scale: 50 m. 
4.2.3. Effects of RhoA/Rho-kinase and isoform-specific PKC inhibitors on total 
PKC activity  
     In order to assess the effects of RhoA and Rho-kinase on total PKC activity, to 
further address the crosstalk between these signalling molecules, and to determine the 
relative contributions of specific PKC isoforms to the hyperglycaemia-mediated 
changes observed in PKC activity, the total PKC activities (units/mL) were measured 
in HBMEC exposed to normoglycaemia versus hyperglycaemia alone and in the 
presence of specific inhibitors for PKC-α, PKC-β, PKC-βII, and PKC-δ isoforms. It 
was observed that hyperglycaemia significantly increased the total PKC activity 
(P<0.05), which was normalised by inhibition of RhoA and Rho-kinase by anti-
RhoA-IgG electroporation and Y-27632 treatment, repectively, thus confirming the 
existence of the cross-talk and interdependence between these signalling pathways 
(P<0.05) (Figure 4.9A). The specific inhibitors of PKC-α (Ro-32-0432, 1 µM), PKC-
β (LY333531, 0.5 µM), PKC-βII (CGP53353, 1 µM) and PKC-δ (rottlerin, 5 µM) also 
attenuated the hyperglycaemia-mediated increases in the total PKC activity (P<0.05). 
Moreover, a dramatic attenuation was observed with PKC-α, PKC-β and PKC-δ 
inhibitors that reduced the PKC activity below the levels observed in normal cells 
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which might indicate the inhibition of constitutive activity as well (P<0.01) (Figure 
4.9B). These data indicate that the bulk of PKC activity is governed by PKC-α, PKC-
β and PKC-δ isoforms.  
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Figure 4.9. Inhibition of RhoA/Rho-kinase signalling and PKC isoforms attenuate the 
PKC overactivity under hyperglycaemia. (A) Total PKC activity (units/mL) measured 
in HBMEC subjected to normoglycaemia (NG; 5.5 mM D-glucose), hyperglycaemia 
(HG; 25 mM D-glucose) alone and in the presence of Y-27632 (2.5 µM), and anti-
RhoA-IgG electroporation (3 µg) before HG. (B) Total PKC activity was measured in 
HBMEC exposed to NG, HG alone and with inhibitors of PKC-α (Ro-32-0432; 1 
µM), PKC-β (LY333531; 0.5 µM), PKC-βII (CGP53353; 1 µM), and PKC-δ 
(rottlerin; 5 µM). Data are expressed as mean±SEM from 5 different experiments. 
Statistical analysis was done using ANOVA with Dunnet’s post hoc test for multiple 
comparisons (A: P=0.006, F=8.894, df1=3, df2=8), (B: P<0.0001, F=51.767, df1=5, 
df2=12). *P<0.05 compared to NG, †P<0.05 compared to HG, ††P<0.01 compared to 
HG. 
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4.2.4. Effects of PKC-α and PKC-β inhibitors on the BBB integrity, RhoA/Rho-
kinase/MLC2 pathway, cytoskeletal reorganisation and junctional complex  
     Since we examined the effects of specific PKC isoform inhibitors in attenuating  
the hyperglycaemia-mediated PKC overactivity, these inhibitors were used to study 
their cerebral-barrier protective effects under hyperglycaemia. Despite reducing total 
PKC activity, the specific inhibitors of PKC-βII and PKC-δ appeared to be inaffective 
in improving the hyperglycaemia-induced barrier damage which was confirmed by a 
marked decrease in the TEER values and concomitant increases in the flux of EBA 
across the cocultures (P<0.05) (Figure 4.10 A, B). However, the inhibition of PKC-α 
or PKC-β isoforms in cocultures exposed to hyperglycaemia improved the coculture 
integrity and function by increasing TEER and decreasing flux of EBA across the 
cocultures compared to the cocultures under hyperglycaemia (P<0.05) (Figure 4.10 A, 
B). This data substantiated our previous results and strengthened the focus on PKC-α 
and PKC-β isoforms in the forthcoming studies. 
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Figure 4.10.  Effects of isoform-specific PKC inhibitors on the integrity and function 
of an in vitro model of human BBB. (A) Transendothelial electrical resistance 
(TEER) (cm2) and (B) flux of EBA (µL) across the cocultures after exposures to 
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normoglycaemia (NG; 5.5 mM D-glucose), hyperglycaemia (HG; 25 mM D-glucose), 
and HG with inhibitors of PKC-α (Ro-32-0432; 1 µM), PKC-β (LY333531; 0.5 µM), 
PKC-βII (CGP53353; 1 µM), and PKC-δ (rottlerin; 5 µM). Data are expressed as 
mean±SEM from 5 different experiments. Statistical analysis was done using 
ANOVA with Dunnet’s post hoc test for multiple comparisons (A: P<0.0001, 
F=18.874, df1=5, df2=12), (B: P<0.001, F=16.245, df1=5, ddf2=12). *P<0.05 
compared to NG, †P<0.05 compared to HG. 
      Having investigated the effects of inhibitors for PKC-α and PKC-β isoforms in 
attenuating the PKC overactivity and improving the coculture integrity, we aimed to 
elucidate whether these inhibitors regulate the RhoA/Rho-kinase signalling pathway. 
The use of rottlerin was discontinued in further experiements because of its multiple 
specificities for other kinase enzymes. It was observed that specific inhibition of 
PKC-α and PKC-β isoforms decreased the cellular RhoA protein levels in a dose-
dependent manner, where statistical significance was achieved only with the highest 
doses of inhibitors used in the study (5 µM) (P<0.05) (Figure 4.11A). In addition, 
cotreatment with these inhibitors attenuated the hyperglycaemia-mediated 2-fold 
increase in the relative RhoA activities (P<0.05). These results indicate that PKC-α 
and PKC-β isoforms are involved in hyperglycaemia-mediated RhoA activation in 
HBMEC (Figure 4.11B). However, the effects of these inhibitors on Rho-kinase-2 
protein levels were different. While different doses of PKC-β inhibitor and low doses 
of PKC-α inhibitor appeared to be ineffective against the hyperglycaemia-mediated 
increases in Rho-kinase-2 protein levels, only the high dose of PKC-α inhibitor (5 
µM) normalised the Rho-kinase-2 levels and indicates that PKC activity regulates the 
Rho-kinase-2 expression (Figure 4.11C). 
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Figure 4.11. PKC-α and PKC-β isoforms-modulate RhoA/Rho-kinase signalling pathway. Representative Western blots and densitometric 
analyses of (A) RhoA protein levels, (B) RhoA activities and (C) Rho-kinase-2 protein levels in HBMEC exposed to normoglycaemia (NG; 5.5 
mM D-glucose), hyperglycaemia (HG; 25 mM D-glucose), and HG with inhibitors of PKC-β (LY333531; 0.5-5 M) and PKC-α (Ro-32-0432; 
1-5 M) after normalisation against β-actin. Data are expressed as mean±SEM from 5 different experiments. Statistical analysis was done using 
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ANOVA with Dunnet’s post hoc test for multiple comparisons (A: P<0.0001, 
F=8.771, df1=7, df2=16), (B: P<0.0001, F=27.706, df1=3, df2=8), (C: P=0.002, 
F=5.979, df1=7, df2=16). *P<0.05 compared to NG, †P<0.05 compared to HG. 
     To further study the importance of PKC-α and PKC-β isoforms in regulating the 
RhoA/Rho-kinase pathway, we investigated the levels of MLC2 mono- and di-
phosphorylations. There were no significant differences in the total MLC2 protein 
levels in HBMEC exposed to varying doses of PKC-α and PKC-β isoform specific 
inhibitors. However, a dose-dependent decrease in the hyperglycaemia-evoked p-
MLC2-Ser19 levels were recorded after normalisation against total MLC2 levels in 
HBMEC cotreated with these inhibitors under hyperglycaemia (P<0.01). In addition, 
the effects of these inhibitors on MLC2 di-phosphorylation levels (p-MLC2-
Thr18/Ser19) were different. While inhibitors for PKC-β attenuated the 
hyperglycaemia-evoked p-MLC2-Thr18/Ser19 levels in a dose-dependent manner 
(P<0.05), varying doses of PKC-α inhibitor appeared to be inaffective in modulating 
the p-MLC2-Thr18/Ser19 levels (Figure 4.12 A, B).  
     To elucidate the effects of PKC-α and PKC-β-mediated modulation of RhoA/Rho-
kinase/MLC2 signalling on cellular architecture, actin filaments was visualised in 
HBMEC exposed to hyperglycaemia in the absence or presence of PKC-α and PKC-β 
inhibitors. While the cells cultured under normoglycaemia displayed cortical actin 
stainings, those exposed to hyperglycaemia developed thick bundles of stress fibres 
and acquired elongated morphological appearances. Cotreatment with either PKC-α 
or PKC-β inhibitors reinstated cortical actin staining and dramatically reduced stress 
fibres alongside restoring the cellular morphology similar to that of HBMEC 
subjected to normoglycaemic conditions. (Figure 4.12C). Thus, these results indicate 
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that both PKC-α and PKC-β isoforms regulate the cytoskeletal remodelling. However, 
the therapeutic effects of the PKC-β inhibition appear to be more sustainable during 
the hyperglycaemic insult.    
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Figure 4.12. Effect of PKC-α and PKC-β inhibitors on MLC2 phosphorylation and 
cytoskeletal reorganisation. Representative Western blots and densitometric analyses 
of (A) p-MLC2-Ser19, (B) p-MLC2-Thr18/Ser19 in HBMEC subjected to 
normoglycaemia (NG; 5.5 mM D-glucose), hyperglycaemia (HG; 25 mM D-glucose), 
and HG with inhibitors of PKC-β (LY333531; 0.5-5 M), PKC-α (Ro-32-0432; 1-5 
M) after normalisation against total MLC2 levels and β-actin. (C) F-actin stainings 
in HBMEC exposed to aforementioned conditions. Following the treatments, the cells 
were fixed, permeabilised, blocked, incubated with Rhodamine-labelled phalloidin 
dye and identified by 40X magnification on fluorescent microscope. Arrows represent 
the stress fibre formations. Data are expressed as mean±SEM from 5 different 
experiments. Statistical analysis was done using ANOVA with Dunnet’s post hoc test 
for multiple comparisons (A: P<0.0001, F=37.543, df1=7, df2=16), (B: P<0.0001, 
F=8.564, df1=7, df2=16). *P<0.05 compared to NG, †P<0.05 compared to HG. Bar 
scale: 50 m. 
     Given the effects of PKC-α and PKC-β inhibitors in improving the integrity and 
function of cerebral barrier under hyperglycaemia, it was highly likely that these 
effects emerge from the induction of tighter assembly of junctions via regulation of 
tight junction proteins. In support of this notion, treatment with different doses of 
PKC-α and PKC-β inhibitors appeared to abolish the hyperglycaemia-mediated 
supression of occludin protein expression in HBMEC and improved its levels to that 
observed in HBMEC under normoglycaemic condition (P<0.05) (Figure 4.13A). 
However, the effects of these inhibitors on ZO-1 protein levels was slightly different. 
While the PKC-β inhibitor increased the ZO-1 protein levels in a dose-dependent 
manner (P<0.05), the varying doses of PKC-α inhibitor appeared to be ineffective in 
modulating the ZO-1 protein levels compared to the ZO-1 levels observed in HBMEC 
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under normoglycaemia (Figure 4.13B). These data indicate the clinical importance of 
the PKC-β inhibition in improving the tight junction protein levels and indeed the 
cerebral-barrier integrity. 
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Figure 4.13. PKC-α and PKC-β inhibitors improve tight junction protein levels. Representative Western blots and densitometric analyses of (A) 
occludin, (B) ZO-1 in HBMEC subjected to normoglycaemia (NG; 5.5 mM D-glucose), hyperglycaemia (HG; 25 mM D-glucose), and HG with 
inhibitors of PKC-β (LY333531; 0.5-5 M) and PKC-α (Ro-32-0432; 1-5 M) after normalisation against β-actin. Data are expressed as 
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mean±SEM from 5 different experiments. Statistical analysis was done using 
ANOVA with Dunnet’s post hoc test for multiple comparisons (A; P=0.002, F=5.572, 
df1=7, df2=16), (B: P=0.005, F=4.651, df1=7, df2=16). *P<0.05 compared to NG, 
†P<0.05 compared to HG. 
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4.2.5. Effects of PKC-α and PKC-β protein knockdown by siRNA transfection on 
the RhoA activity, MLC2 phosphorylation, cytoskeletal reorganisation and 
junctional complex  
     Although the PKC isoform inhibitors used in this study have high specificity for 
PKC-α and PKC-β isoforms, they are also specific for other PKC isoforms with low 
IC50 values. Hence to eliminate the non-target specific effects of these inhibitors, the 
siRNA gene knockdown studies were carried out to confirm the effects of these 
pharmacological inhibitors. Under normal and hyperglycaemic conditions, HBMEC 
were transfected with equal amounts (50-100 nM) of either non-target, PKC-α or 
PKC-β siRNA oligonucleotides via lipid based transfection reagents. The successful 
siRNA transfection and protein knockdown were confirmed by a dramatic reduction 
in the protein levels of PKC-α and PKC-β isoforms by 80% and 50%, respectively, 
compared to the non-target siRNA transfected HBMEC which served as negative 
controls (P<0.05) (Figure 4.14A). The decrease in protein levels of either isoforms 
alleviated the relative RhoA activities as a marked reduction in the RhoA-GTP levels 
were recorded after normalisation against total RhoA levels (P<0.05) (Figure 4.14B). 
These results confirm the role of PKC-α and PKC-β isoforms in the activation of 
RhoA-driven signalling pathways. 
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Figure 4.14. PKC-α and PKC-β gene knockdown and their effect on the relative 
RhoA activity. Representative Western blots and densitometric analyses of (A) PKC-
α and PKC-β, and (B) relative RhoA activities in HBMEC transfected with PKC-α, 
PKC-β and non-target siRNA before exposure to normoglycaemia (NG; 5.5 mM D-
glucose) and hyperglycaemia (HG; 25 mM D-glucose) for 72 hours. Data are 
expressed as mean±SEM from 4 different experiments. Statistical analysis was done 
using ANOVA with Dunnet’s post hoc test for multiple comparisons (Ai: P<0.0001, 
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F=793.944, df1=3, df2=8; Aii: P<0.0001, F=44.8, df1=3, df2=8), (Bi: P=0.006, 
F=9.214, df1=3, df2=8, Bii: P<0.0001, F=20.75, df1=3, df2=8). *P<0.05 compared to 
NG, †P<0.05 compared to HG. 
     The role of PKC isoforms in hyperglycaemia-evoked MLC2 phosphorylation was 
further studied in PKC-α or PKC-β knockdown HBMEC. A dramatic reduction in the 
p-MLC2-Ser19 and p-MLC2-Thr18/Ser19 protein levels were recorded in PKC-β 
knockdown HBMEC compared to the negative controls under hyperglycaemic 
conditions (P<0.05) (Figure 4.15A). These results confirm that PKC-β plays a pivotal 
role in enhanced MLC2 mono- and di-phosphorylations under hyperglycaemia. The 
PKC-α knockdown significantly decreased the hyperglycaemia-evoked p-MLC2-Ser19 
levels in HBMEC compared to the negative controls (P<0.05). However, the PKC-α 
knockdown was ineffective in modulating the hyperglycaemia-evoked MLC2 di-
phosphorylation (Figure 4.15B). These results go hand in hand with the previous 
pharmacological data and highlight the significance of PKC-β inhibition. 
      Since MLC2 phosphorylations enhance the cytoskeletal reorganisation, the effects 
of PKC-α and PKC-β isoforms were studied by exploring the F-actin localisation in 
siRNA transfected HBMEC to investigate their role in the hyperglycaemia-evoked 
cytoskeletal remodelling. The HBMEC serving as negative controls showed faint 
marginal F-actin stainings with spindle shape cellular morphology under 
normoglycaemia. However, hyperglycaemic exposure induced thick bundles of stress 
fibre formations traversing across the cells along with cells attaining an elongated 
morphology. The PKC-α knockdown in HBMEC induced thick cortical F-actin 
stainings under normoglycaemia and appeared to reduce the stress fibre formations 
and restore the cellular morphology under hyperglycaemia. However, a dramatic 
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reduction in the stress fibre formation along with thick cortical stainings and cobble-
stone or spindle cellular morphologies were recorded in the PKC-β knockdown 
HBMEC under hyperglycaemia which seemed identical to the siRNA transfected 
HBMEC under normoglycaemia (Figure 4.16). Thus, these results confirm the 
therapeutic potential of PKC-β knockdown in attenuating the hyperglycaemia-evoked 
cytoskeletal remodelling. 
     To demonstrate whether formation of compact junctional complexes is involved in 
PKC-α and PKC-β inhibition-mediated protection of cerebral barrier integrity, the 
levels of occludin and ZO-1 proteins were investigated in non-target versus PKC-α 
and PKC-β siRNA-transfected HBMEC. Exposure of HBMEC to hyperglycaemia 
markedly decreased occludin protein expression without significantly altering the ZO-
1 protein levels. However, inhibition of PKC-β dramatically enhanced the expressions 
of both occludin and ZO-1 under hyperglycaemic conditions while selectively 
improving occludin levels under normoglycaemia (P<0.05) (Figure 4.17A). Inhibition 
of PKC-α on the other hand, prevented hyperglycaemia-mediated decreases in 
occludin expression without affecting that of ZO-1 (Figure 4.17B). These data 
reiterate the clinical importance of PKC-β inhibition in improving the tight junction 
protein levels and indeed the cerebral barrier integrity.    
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Figure 4.15. PKC-α and PKC-β gene knockdown attenuates the MLC2 
phosphorylations. Representative Western blots and densitometric analyses of p-
MLC2-Ser19 and p-MLC2-Thr18/Ser19 levels in (A) PKC-β, and (B) PKC-α 
knockdown HBMEC. The cells were transfected with PKC-α, PKC-β and non-target 
siRNA before exposure to normoglycaemia (NG; 5.5 mM D-glucose) and 
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hyperglycaemia (HG; 25 mM D-glucose) for 72 hours. Data are expressed as 
mean±SEM from 5 different experiments. Statistical analysis was done using 
ANOVA with Dunnet’s post hoc test for multiple comparisons (Ai: P<0.0001, 
F=47.581, df1=3, df2=8; Aii: P<0.0001, F=32.65, df1=3, df2=8), (Bi: P=0.001, 
F=17.021, df1=3, df2=8; Bii: P=0.010, F=7.539, df1=3, df2=8). *P<0.05 compared to 
NG, †P<0.05 compared to HG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. PKC-α and PKC-β gene knockdown studies to investigate the 
hyperglycaemia-induced cytoskeletal remodelling. HBMEC were transfected with 
PKC-α siRNA (50 nM), PKC-β siRNA (100 nM) and non-target siRNA (50-100 nM) 
Normoglycaemia Hyperglycaemia 
Non-target siRNA 
PKC-α siRNA 
PKC-β siRNA 
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before exposure to normoglycaemia (5.5 mM D-glucose) and hyperglycaemia (25 
mM D-glucose) for 72 hours. Following the treatments, the cells were fixed, 
permeabilised, blocked, and incubated with Rhodamine-labelled phalloidin dye. The 
cells were incubated with DAPI and were identified by 40X magnification on 
fluorescent microscope. Arrows represent the stress fibre formations after the 
hyperglycaemia exposure. Data are collected from 5 different experiments. Bar scale: 
50 m. 
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Figure 4.17. PKC-α and PKC-β gene knockdown modulate tight junction complex. 
Representative Western blots and densitometric analyses of occludin and ZO-1 
protein levels in (A) PKC-β, and (B) PKC-α knockdown HBMEC. The cells were 
transfected with PKC-α, PKC-β and non-target siRNA before exposure to 
normoglycaemia (NG; 5.5 mM D-glucose) and hyperglycaemia (HG; 25 mM D-
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glucose) for 72 hours. Data are expressed as mean±SEM from 3 different 
experiments. Statistical analysis was done using ANOVA with Dunnet’s post hoc test 
for multiple comparisons (Ai: P=0.003, F=11.484, df1=3, df2=8; Aii: P=0.004, 
F=10.193, df1=3, df2=8), (Bi: P=0.522, F=0.813, df1=3, df2=8; Bii: P=0.077, 
F=3.328, df1=3, df2=8). *P<0.05 compared to NG, †P<0.05 compared to HG. 
4.3. Discussion 
    Brain oedema emerging from disruption of the BBB constitutes one of the leading 
causes of mortality after a stroke and appears to be more prevalent in stroke patients 
with diabetes than those without thereby implying a prominent role for 
hyperglycaemia in the BBB breakdown (Ergul et al., 2009). The current study 
investigated whether the overactivation of RhoA/Rho-kinase/MLC2 pathway is 
implicated in hyperglycaemia-mediated barrier damage. Using a microplate-based 
immunocytochemical assay i.e. in-cell Western analysis, designed to detect proteins 
in their cellular context to produce more relevant results via elimination of cell lysis-
derived artefacts, this study has shown that hyperglycaemia elicits significant 
increases in HBMEC RhoA and Rho-kinase-2 protein expressions and RhoA activity. 
Since equimolar concentrations of D-mannitol did not affect cell viability, protein 
expression or enzyme activity, it is safe to suggest that all the aforementioned 
alterations are a consequence of hyperglycaemia itself rather than a rise in osmolality 
or cell death. It is of note that the presence of such close link between hyperglycaemia 
and RhoA/Rho-kinase pathway overactivity is also documented in basilar artery 
sections of type-1 diabetic rats and in endothelial cells originated from different 
species and parts of vascular tree such as human saphenous vein and bovine aorta 
(Miao et al., 2002, Rikitake and Liao, 2005b, Iwasaki et al., 2008).  
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     Hyperglycaemia represents a common phenomenon in stroke patients, with up to 
~65-70% of patients known to manifest hyperglycaemia at some stage within 48 
hours of stroke onset as a result of diabetes or acute stress response. Clinical evidence 
regarding the extent of glycaemic control in acute ischaemic stroke patients is limited. 
However, given the close correlation between hyperglycaemia and poor outcomes, 
typically defined by enhanced mortality or dependence 90 days after the event, it 
remains important to monitor and reduce blood glucose levels in an effective manner 
(Capes et al., 2001, Baird et al., 2002). Indeed, normalisation of glucose levels in the 
current study returned the increases observed in RhoA, Rho-kinase-2 protein 
expression and RhoA activity to the levels obtained in control groups and provided 
some mechanistic evidence for the benefits that may be produced by efficacious 
glycaemic control. Unlike glycaemic control, the specific inhibition of Rho-kinase-2 
by Y-27632, a competitive-ATP inhibitor, failed to normalise the expression and 
activity of RhoA and Rho-kinase-2. Thus, ruling out the existence of a negative 
feedback mechanism by which the bioavailability of Rho-kinase may influence RhoA 
expression and activity. Since equimolar concentrations of D-mannitol did not alter 
protein expressions and activity, it is safe to suggest that the outlined alterations are 
due to glucose per se rather than a glucose-mediated rise in osmolality. Similarly, 
these alterations cannot be attributed to differences in cell numbers and viability 
because the protein levels observed in each experiment were normalised against α-
tubulin that was detected concurrently as an internal standard. Moreover, as the 
electroporation process diminished cell viability by ~23%, the number of cells seeded 
were increased by 30% following this procedure to enable all experimental groups to 
reach confluence simultaneously. 
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     Studies investigating the effects of hyperglycaemia on in vitro barrier integrity and 
function demonstrated substantial decreases in the TEER values which were 
indicative of the physical disruptions to the endothelial barrier and lead to 
concomitant rise in the EBA flux across the cocultures. In addition, the inhibitions of 
signalling molecules like Rho-kinase (Y-27632), PKC (Bis-I), and p38MAPK 
(SB203580) improved the coculture integrity by attenuating the hyperglycaemia-
induced endothelial-barrier disruptions characterised by an improved TEER and 
reduced EBA flux; and demonstrated the detrimental effects of these signalling 
pathways under hyperglycaemia. Since changes in cytoskeleton may contribute to the 
hyperglycaemia-induced barrier failure, the status of actin filament formation and 
distribution was comparatively studied. Cells cultured under normoglycaemic 
conditions displayed a cortical actin staining while those subjected to hyperglycaemia 
possessed actin stress fibres traversing the cells and appeared predominantly 
elongated and somewhat cuboidal. The appearance of stress fibres coincided with 
enhanced MLC2 mono- and di-phosphorylation at Ser19 and/or Thr18 possibly through 
the activations of MLCK and Rho-kinase, and/or inhibition of MLCP (Fukata et al., 
2001, van Nieuw Amerongen and van Hinsbergh, 2001). Once the actin stress bundles 
are formed, they lead to the intercellular gap formations by compromising tight 
junctions via generation of a tensile centripetal force to pull the tight junction proteins 
inward (Sumi et al., 2001, Allen et al., 2010). Normalisation of glucose levels along 
with inhibition of RhoA or Rho-kinase before and during hyperglycaemic challenge 
by anti-RhoA-IgG electroporation and Y-27632, respectively, prevented stress fibre 
formation, restored actin staining in cell periphery and abolished the barrier disruptive 
effects of hyperglycaemia. Despite significantly reducing p-MLC2-Ser19 levels 
compared with normoglycaemia and hyperglycaemia HBMEC, Y-27632 cotreatments 
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normalised the p-MLC2-Thr18/Ser19 levels and  failed to affect total MLC2 
expression, suggesting the notion that diphosphosphorylated isoform may make up 
the main constituent of total MLC2 under hyperglycaemic conditions. Apart from 
MLC2, RhoA/Rho-kinase pathway can also phosphorylate adducin, LIMK and ERM 
proteins which link a number of proteins such as spectrin and cofilin to cortical actin 
and modulate actin filament (de)stabilisation (Matsui et al., 1998, Ohashi et al., 2000, 
Sumi et al., 2001). Moreover, RhoA/Rho-kinase pathway-mediated changes in actin 
cytoskeleton are also implicated in diminished expression, phosphorylation (at 
Ser1177) and activity of eNOS and thus reduced availability of NO, a barrier protective 
agent, while inhibition of Rho activity by statins are known to produce the opposite 
effects (Rikitake and Liao, 2005a). 
    Impaired organisation of the tight junction proteins which seal the edges between 
adjacent endothelial cells to control paracellular permeability may also be a key 
determinant of hyperglycaemia-evoked barrier failure. Indeed, a discontinuous pattern 
of the transmembrane occludin and the cytoplasmic ZO-1 staining at cell borders 
coupled with the reduced expressions of the occludin in hyperglycaemic cells 
confirmed this hypothesis. Normalisation of glucose levels and inhibition of RhoA or 
Rho-kinase-2 significantly improved the occludin protein levels and restored the 
occludin and ZO-1 staining to the cell periphery. These concurred with the findings of 
previous in vivo studies which correlated the levels of tight junction proteins with 
enhanced retinal hyperpermeability, and insulin-mediated glycaemic control of 
diabetic animals significantly ameliorated the reduced cerebral contents of occludin 
and ZO-1 (Antonetti et al., 1998, Chehade et al., 2002, Barber and Antonetti, 2003, 
Hawkins et al., 2007). More importantly the inhibition of RhoA/Rho-kinase pathway 
is clinically relevant in restoring the occludin and ZO-1 levels and cytoplasmic 
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trafficking under hyperglycaemia. This might also be due to an increased RhoA/Rho-
kinase-mediated phosphorylation of tight junction proteins triggering their 
cytoplasmic trafficking. Recent in vitro and in vivo studies on brain endothelial cells 
supports this hypothesis and demonstrates three specific sites of phosphorylation on 
occludin and claudin-5 after RhoA/Rho-kinase activation which were accompanied by 
functional impairment of barrier and prevented by specific Rho-kinase inhibitor 
(Yamamoto et al., 2008). However, the contribution of increased matrix 
metalloproteinase activities to diabetes-induced loss of cerebral tight junction proteins 
and subsequent BBB hyperpermeability cannot be dismissed (Hawkins et al., 2007). 
    After having established a critical role for RhoA/Rho-kinase pathway in 
hyperglycaemia-mediated cerebral-barrier damage, the aforementioned cerebral-
barrier protection by inhibition of the PKC and p38MAPK signalling were further 
studied since recent research on these signalling pahways have documented the 
hyperglycaemia-mediated increases in both kinase activities. (Geraldes and King, 
2010, Rane et al., 2010). To address whether regulation of RhoA/Rho-kinase pathway 
may in part be involved in the aforementioned barrier protective effects, the level of 
RhoA and Rho-kinase-2 protein expressions, p-MLC2-Ser19 and p-MLC2-Thr18/Ser19 
were investigated in HBMEC subjected to hyperglycaemia in the absence and 
presence of Bis-I or SB203580. Although RhoA protein levels were not modified by 
either compound, Rho-kinase-2 expression, p-MLC2-Ser19 and p-MLC2-Thr18/Ser19 
were significantly diminished by Bis-I alone, thereby indicating that PKC is 
modulating the RhoA/Rho-kinase pathway to deteriorate barrier function. Enhanced 
expression, translocation and activity of several PKC isoforms, namely PKC-α, PKC-
βI, PKC-βII and PKC-δ have previously been observed in hyperglycaemic retinal 
endothelial cells amongst which PKC-βII is closely linked to the occludin 
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phosphorylation and blood-retinal barrier hyperpermeability in diabetic rats (Park et 
al., 2000, Harhaj et al., 2006). In addition, the inhibition of PKC also reduced the 
hyperglycaemic stress fibre formations and restored the endothelial morphology, 
thereby confirming the PKC-driven cytoskeletal reoganisation to be in part 
responsible for the endothelial hyperpermeability.  
    Despite the inability of SB203580 to suppress RhoA/Rho-kinase protein 
expressions and MLC2 mono- and di-phosphorylations in hyperglycaemic cells, the 
inhibition of p38MAPK has been extremely efficacious in preventing 
hyperglycaemia-induced barrier dysfunction. These data imply that p38MAPK exerts 
its deleterious effects on the in vitro barrier utilising mechanisms other than 
RhoA/Rho-kinase pathway but do not dismiss the possibility that p38MAPK may act 
downstream of Rho-kinase. In fact, RhoA/Rho-kinase complex-mediated stimulation 
of linear kinase cascades leading to p38MAPK activation has recently been shown in 
endothelial cells, supporting the hypothesis that this pathway may act upstream of 
p38MAPK (Marinissen et al., 2001, Edlund et al., 2002, Shimada and Rajagopalan, 
2010). Besides, mitogen activated protein-extracellular signal-regulated kinase (ERK) 
kinase kinase-1 molecules including ERK and p38MAPK may directly regulate 
MLC2 phosphorylation and impair endothelial function and cytoskeleton (Usatyuk 
and Natarajan, 2004, Deng et al., 2011). In the latter study, inhibitions of ERK and 
p38MAPK have been shown to partially attenuate 4-hydroxy-2-nonenal-mediated 
barrier disruption and actin remodelling in bovine lung microvascular endothelial 
cells (Usatyuk and Natarajan, 2004). 
     Hence, to further explore the abovementioned PKC modulation of RhoA/Rho-
kinase pathway, the present study investigated the molecular mechanisms by which 
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hyperglycaemia-evoked PKC activity was linked with the cytoskeletal remodelling 
and the HBMEC barrier dysfunction. The results show that hyperglycaemia 
dramatically increases the total PKC activity and different PKC isoforms have 
variable sensitivity and activity under hyperglycaemic pathology where PKC-α, PKC-
β and PKC-δ are highly sensitive as reported previously in retinal endothelial cells 
(Park et al., 2000). Moreover, the PKC-α and PKC-β isoforms are key signalling 
molecules modulating the hyperglycaemia-mediated endothelial-barrier dysfunction 
as inhibition of their activity by specific inhibitors Ro-32-0432 (PKC-α) and 
LY333531 (PKC-β) attenuated the hyperglycaemia-evoked total PKC activity 
possibly by competitive inhibition with respect to ATP, and the hyperglycaemia-
induced hyperpermeability by restoring the endothelial-barrier integrity as observed 
by the coculture data across the in vitro model of human BBB.  
     These results are consistent with the recent findings which also demonstrated that 
by knocking down PKC-α expression and by blocking the PKC-β activity 
(LY333531), both mouse BMEC and HUVEC showed an improvement in their 
barrier functionality in part by improving the cell antioxidant and antiapoptotic ability 
(Stamatovic et al., 2003, Stamatovic et al., 2006, Wei et al., 2010a, Xu et al., 2010). 
Our results have shown that although the treatment with specific inhibitor CGP53353 
(PKC-βII) under hyperglycaemia normalised the total PKC activity, it was ineffective 
in improving the endothelial-barrier integrity compared with LY333531 which was 
used half of CGP53353 dosage. The answer may be in the IC50 values of these 
molecules, i.e. CGP53353 has the IC50 values of 3,800 nM and 410 nM for PKC-βI 
and PKC-βII, respectively, and LY333531 has the IC50 values of 4.7 nM and 5.9 nM 
for PKC-βI and PKC-βII, respectively. Although rottlerin, an alleged PKC-δ-specific 
inhibitor, has been shown to alleviate the total PKC activity under hyperglycaemia, 
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there are questions about its specificity because it inhibits many other protein kinases 
as explained in detail in a recent review (Davies et al., 2000). These results have 
shown that Y-27632 treatment normalised the hyperglycaemia-evoked total PKC 
activity indicating a Rho-kinase-dependent PKC activation under hyperglycaemia. 
However like other PKC isoform specific inhibitors, Y-27632 attenuates the activity 
of its target molecules by competing with ATP and also has a lower affinity for PKC 
isoforms. This might be the reason for the abovementioned phenomenon but our 
recent RhoA knockdown studies examining the crosstalk between RhoA/Rho-kinase 
and PKC pathways have found that an inverse crosslink does exists between RhoA 
protein levels and PKC-α activity only under pathological condition like 
hyperglycaemia. This data substantiates the therapeutic importance of the multiple 
target drugs which can reduce the side effects of their other constituents. In addition 
for the first time a direct crosslink was also observed between RhoA protein level and 
PKC-β activity indicating inter-dependent mechanistic cascades under 
hyperglycaemic stress (Srivastava and Bayraktutan, 2010, Srivastava et al., 2012).  
     Previous studies in our group have shown the hyperglycaemia-mediated disruption 
of the in vitro BBB integrity which was restored by the non-specific PKC inhibitor 
(Bis-I) (Allen and Bayraktutan, 2009a). Hence, the current studies have identified the 
hyperglycaemia-evoked conventional PKC isoforms i.e. PKC-α and PKC-β to be in 
part responsible for the endothelial-barrier dysfunction as the effects of 
hyperglycaemia i.e. decreased TEER values and hyperpermeability across the 
coculture models were reverted under the influence of Ro-32-0432 and LY333531 
respectively, and highlights the therapeutic potential of these inhibitors. Our results 
are in coherence with previous findings and point to the PKC-α and PKC-β-mediated 
endothelial barrier dysfunction (Mehta et al., 2001, Wei et al., 2010b). 
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     The exposure of bovine aortic endothelial cells to hyperglycaemia has been linked 
with barrier hyperpermeability and dysfunction due to an increased activity of the 
components of plasminogen-plasmin system which are regulated in part by the 
activated RhoA/Rho-kinase pathway (Iwasaki et al., 2008). This study has shown that 
hyperglycaemia-evoked PKC overactivity is in part associated with the activation of 
RhoA/Rho-kinase pathway. The dose-dependent decrease in total RhoA, Rho-kinase 
levels and a significant decrease in the total RhoA activity in HBMEC under 
treatment with PKC-α and PKC-β inhibitors further substantiates this hypothesis and 
demonstrates the importance of the pharmacological intervention of PKC-α and PKC-
β isoforms as a tool in modulating the components of RhoA/Rho-kinase pathway. Our 
gene knockdown studies involving PKC-α and PKC-β siRNA transfection in HBMEC 
confirms the above findings and demonstrate the PKC-mediated RhoA activation.  
These results are consistent with recent findings where PKC-α was shown to 
phosphorylate the Rho-GDI resulting in its dissociation from RhoA-GDP which 
facilitated in the RhoA activation by p115Rho-GEF (Mehta et al., 2001, Peng et al., 
2011). Recent in vitro studies on mesangial cells are consistant with the current study 
and manifest the PKC-βI-mediated RhoA activation in part by the ROS formation and 
accumulation under hyperglycaemia (Zhang et al., 2011).    
     Consistent with the previous findings, the decrease in the intracellular RhoA and 
RhoA-GTP levels had a direct impact in reducing the hyperglycaemia-evoked MLC2 
mono- and di-phosphorylation (p-MLC2-Ser19, p-MLC2-Thr18/Ser19) levels under the 
influence of isoform-specific PKC inhibitors. Since the isoform-specific PKC 
inhibitors have multiple targets of varying specificity, as indicated by Ro-32-0432 
having 4-fold specificity for PKC-β isoform, it was imperative to find the most 
important PKC isoform between α and β for therapeutic importance. Hence the gene 
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knockdown studies have shown that although both PKC-α and PKC-β gene 
knockdown resulted in protein reductions by approximately 80% and 50%, 
respectively,  and attenuated the RhoA activity, it was the PKC-β knockdown which 
normalised the hyperglycaemia-evoked MLC2 mono- and di-phosphorylation levels, 
albeit PKC-α knockdown reduced only the hyperglycaemia-evoked MLC2 mono-
phosphorylation levels. Thus, these data emphasise on the therapeutic importance of 
PKC-β inhibition under hyperglycaemia.   
     The F-actin staining results substantiated the reduction in MLC2 phosphorylation 
as hyperglycaemia-mediated stress fibre formations were mitigated under the 
influence of general PKC and isoform-specific PKC inhibitors for PKC-α and PKC-β, 
and replaced with a thick and prominent cortical stainings. The modulation of these 
cytoskeletal components i.e. MLC2 and actin reverted the hyperglycaemia-mediated 
morphological changes in HBMEC and the cells resumed their typical cobblestone 
morphology similar to control cells under normoglycaemia. This might be due to the 
decrease in the inward force exerted by stress fibres under hyperglycaemia since most 
of the filamentous-actin reverted back to their granular-actin form. These results were 
further substantiated by gene knockdown studies as PKC-β gene knockdown-HBMEC 
displayed a thick cortical staining with reduction in stress fibres whereas, the effects 
of hyperglycaemia prevailed in the PKC-α knockdown HBMEC. Interestingly, these 
data highlight the importance of PKC-β and MLC2 di-phosphorylation levels in 
modulating the hyperglycaemia-mediated stress fibre formation and disappearance. 
     To further support the coculture results, the hyperglycaemia-mediated 
downregulation of the transmembrane tight junction protein occludin was attenuated 
by cotreatment with either PKC-α or PKC-β inhibitors under hyperglycaemia. The 
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total occludin protein levels were either normalised or upregulated under the dose-
dependent treatment of these inhibitors. The significance of these results was 
exemplified by increased coculture barrier integrity. However, the cytoplasmic 
component of the tight junction complex i.e. ZO-1 showed significant increase only 
under the influence of PKC-β inhibitor. These data confirms the role of PKC-α and 
PKC-β isoforms in modulating the tight junction protein expression and their 
overactivity is in part involved in the degradation and/or disruption of tight junction 
protein complexes. Since the PKC-α and PKC-β isoform-specific inhibitors also 
target other PKC isoforms with low specificity and selectivity, these data were further 
substantiated with gene knockdown studies which highlighted the therapeutic 
importance of PKC-β knockdown as the protein levels of occludin and ZO-1 
significantly improved under hyperglycaemia compared with the PKC-α knockdown. 
This improvement in the occludin protein levels by PKC-β protein knockdown under 
hyperglycaemia may be due to a decrease in occludin ubiquitination as explained in 
detail in recent in vitro and in vitro studies which concluded that inhibition of PKC-β 
activation blocks occludin phosphorylation, ubiquitination and tight junction protein 
trafficking in bovine retinal vascular endothelial cells resulting in a decreased 
vascular permeability (Murakami et al., 2012). These results are also in coherence 
with previous studies showing the degradation of tight junction proteins under the 
influence of Acanthamoeba metabolite and the attenuation in Clostridium difficile 
toxin A-mediated tight junction translocation when subjected to PKC-α and PKC-β 
antagonists. Consistent to the earlier results the inhibition of RhoA and Rho-kinase 
activity has also been shown to be pivotal in preventing the monocyte chemoattractant 
protein-1-induced reorganization of tight junction proteins and alterations in 
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endothelial permeability (Chen et al., 2002, Stamatovic et al., 2003, Khan and 
Siddiqui, 2009).  
     In conclusion, the current study has shown that hyperglycaemia disrupts the 
endothelial-barrier function by potentiating the MLC2 phosphorylation-mediated 
cytoskeletal remodelling and disrupting the tight junction protein assembly. Inhibition 
of RhoA, Rho-kinase and PKC signalling molecules restored the aforementioned 
hyperglycaemic effects and demonstrated the cerebrovascular protection by 
ameliorating the endothelial-barrier integrity. A schematic representation of the 
proposed PKC/RhoA/Rho-kinase signalling pathway is shown in figure 4.18.  
     After successfully evaluating the significance of PKC-β overactivity in 
hyperglycaemia-evoked PKC/RhoA/Rho-kinase pathway, it will be interesting to 
further study the role of specific PKC-β isoforms (βI, βII) in modulating the NF-κB, a 
transcription factor, activation which may induce the RhoA overactivity as recently 
reported in the BMEC (He et al., 2011). 
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Figure 4.18. The hyperglycaemia-evoked PKC/RhoA/Rho-kinase signalling pathway 
modulating the BBB integrity via modulation of cytoskeletal remodelling and tight 
junction localisation. MLC2: Myosin light chain-2; p-MLC2: phosphorylated-MLC2. 
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     The endothelial cells form the innermost layer of all the blood vessels and 
synthesise a number of physiological elements such as nitric oxide to maintain 
vascular homeostasis. In brain, the microvascular endothelial cells form tightly sealed 
barrier termed as the BBB, which limit the paracellular permeability to a number of 
selective blood-driven solutes. However, the pathological conditions like IR and 
hyperglycaemia alter the physiological functions of the endothelial cells by activating 
many intercellular stress-sensitive and inflammation-sensitive signalling pathways 
which collectively threaten the integrity of the BBB.   
     The outlined studies in the thesis set out to highlight the molecular mechanisms of 
hyperglycaemia and ischaemia-mediated BBB disruption, a characteristic feature of 
ischaemic stroke, by investigating the OGD±R-activated RhoA/Rho-kinase signalling 
cascade, which is related to both the oxidant-dependent and oxidant-independent 
mechanisms of injury. Tissue oedema has been reported as a result of IR injury in 
many organs including brain which is a leading cause of death after ischaemic stroke 
(Bounds et al., 1981, McCord, 1985, Werns and Lucchesi, 1990). Hence, the current 
OGD studies focused on some of the key molecular mechanisms responsible for the 
brain oedema which include cytoskeletal remodelling, activation of prooxidant 
NADPH oxidase enzyme complex, induction of the oxidative stress, and modulation 
of the tight junction and adherens junction proteins. Moreover the significance of 
these molecular mechanisms were also studied by evaluating their effects on the BBB 
integrity and the functionality.  
     The overall results generated throughout these studies confirm these hypotheses 
and have shown that OGD compromises the BBB integrity by activation of RhoA-
GTPase.  The activation of these molecular switches disseminate the stress-induced 
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signals by activation of their main effector protein Rho-kinase. The activated Rho-
kinase initiates the alterations in the phosphorylation status and reorganisation of key 
cytoskeletal components i.e. myosin and actin, thereby enhancing stress fibre 
formation and cytoskeletal remodelling.  
     Since the RhoA/Rho-kinase pathway has been associated with many vascular 
abnormalities including oxidative stress (Shiotani et al., 2004), our next study under 
OGD±R pathology investigated the role of Rho-kinase in activation of oxidant-
dependent mechanisms responsible for the BBB disruption. Previous in vitro studies 
with bovine pulmonary microvessel endothelial cells have shown that reoxygenation 
of endothelial cells disrupts the endothelial-barrier integrity and increases the 
paracellular permeability (Lum et al., 1992). Moreover, recent in vivo studies on rats 
have shown increased paracellular permeability in brain microvessels followed by 
brain oedema formation under conditions of hypoxia and subsequent reoxygenation 
(Mark and Davis, 2002, Witt et al., 2008). Hence, the results obtained from our 
OGD±R studies have shown that the enhanced expression and activity of pro-oxidant 
NADPH oxidase enzyme complex potentiated the ROS production and accumulation, 
which may have resulted in the oxidative stress-mediated cerebral-barrier disruption. 
Moreover, it appeared that the OGD±R-induced oxidative stress was being regulated 
by RhoA/Rho-kinase as interference with this pathway by specific inhibitors 
attenuated the NADPH activation and checked the enhanced ROS production and 
accumulation, which proved to be cerebrovascular protective by improving the 
endothelial-barrier integrity.  
     In addition, the OGD±R-mediated modulation of tight junction and adherens 
junction protein levels were also studied in HBMEC and data presented in the thesis 
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have highlighted the role of RhoA/Rho-kinase pathway in modulating tight junction 
and adherens junction proteins. Recent in vitro and in vivo studies are in coherence 
with our data and have shown that activations of RhoA and/or Rho-kinase 
phosphorylates the occludin and claudin-5 tight junction proteins thereby triggering 
their relocalisation, inducing gap formations, and potentiating the loss in the 
endothelial-barrier integrity (Yamamoto et al., 2008). In contrast, the specific 
inhibition of Rho-kinase reverted these effects and improved the barrier integrity, 
which is in conjunction with our data and also corelates the improved occludin levels 
after Rho-kinase inhibition to the enhanced endothelial-barrier integrity. The studies 
with mice brian sections to investigate the effects of fasudil on aforementioned 
proteins after ischaemic injury appeared to have no significant results. This may be 
due to the complexity of the brain tissue which is composed of different kinds of cells 
which may not respond to the IR stress in the similar manner.     
     Brain oedema emerging from disruption of the BBB constitutes one of the leading 
causes of mortality after a stroke and appears to be more prevalent in stroke patients 
with diabetes than those without thereby implying a prominent role for 
hyperglycaemia in the BBB breakdown. Although hyperglycaemia represents a 
common pathology in ischaemic stroke patients, about two-thirds of whom are 
diagnosed as hyperglycaemic at some stage within the first 48 hours of the event due 
to acute stress response or previously diagnosed diabetes, the mechanisms by which it 
may compromise the cerebral barrier integrity and/or exacerbate vascular damage 
remain largely unknown. Identification of these mechanisms is of particular 
importance given the limitations of tPA (tissue plasminogen activator), the currently 
approved sole therapeutic agent, which has a short treatment window for 
recanalisation (within 4.5 h of stroke onset) and is inherently associated with elevated 
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risk of haemorrhagic transformation, especially in hyperglycaemic patients. Bearing 
these in mind, the current studies focused on the relevance of two apparently distinct 
pathways, namely PKC and RhoA/Rho-kinase/MLC2 to hyperglycaemia-mediated 
barrier damage using an in vitro model of human BBB composed of HBMEC and 
HA. It is thought that elucidating the nature of correlation between these pathways 
that collectively regulate vasomotor function, cell proliferation, survival, migration, 
oxidative stress, immune responses and modulate the productions of extracellular 
matrix and cytokines may prove extremely beneficial in identifying novel targets for 
future therapeutic approaches (Ishii et al., 1998, Nonaka et al., 2000, Kowluru, 2001, 
Kelly et al., 2003). The results outlined in this thesis have confirmed that exposures to 
longer periods of hyperglycaemic insult disrupts the BBB integrity by activating 
RhoA/Rho-kinase, promoting the cytoskeletal remodelling and perturbing the tight 
junction protein expression and localisations.  
     The hyperglycaemic pathology was further scrutinised to delineate the signalling 
molecules dictating the RhoA and Rho-kinase activities. The PKC isoform-specific 
activation of RhoA and Rho-kinase has been shown to be the driving force behind the 
RhoA/Rho-kinase-mediated aforementioned alterations disrupting the BBB and 
introducing hyperpermeability. The specific PKC-α and PKC-β pharmacological 
inhibitions and their gene knockdown studies illustrated the hyperglycaemia-mediated 
PKC-α and PKC-β overactivities governs the RhoA/Rho-kinase pathway and 
modulate the tight junction protein expression and localisation. Recent in vitro and in 
vivo studies support our data and show the PKC-β-mediated phosphorylation and 
ubiquitination of occludin along with trafficking of tight junction proteins in bovine 
retinal vascular endothelial cells to be responsible for the enhanced vascular 
permeability (Murakami et al., 2012).   
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     Although OGD±R and hyperglycaemia are two distinct pathological conditions, 
the deleterious effects of these pathologies seem to originate from the induction of 
oxidative stress, activation of inflammatory responses and activation of proteases 
through common signalling pathway like RhoA/Rho-kinase (Shiotani et al., 2004, 
Ando et al., 2011, Zhang et al., 2011). The activations of RhoA and Rho-kinase have 
been shown to enhance the cytoskeletal remodelling and modulate the tight junction 
protein expression and/or localisation. Interestingly, the pharmacological inhibition of 
RhoA/Rho-kinase normalised the endothelial morphology, increased the endothelial-
barrier tightness and improved the cerebral-barrier properties under the 
aforementioned pathological conditions. Figure 8 illustrates the similarities between 
the effects of OGD±R and hyperglycaemia on HBMEC studied in this thesis. 
Moreover, recent in vitro and in vivo studies have addressed the interdependent link 
between the pro-oxidant enzyme-mediated oxidative stress and the PKC-β-mediated 
RhoA activation under hyperglycaemia by demonstrating a positive feedback loop 
which also involves Rho-kinase, caveolae (Zhang et al., 2011, Soliman et al., 2012). 
Hence, the aforementioned studies in this thesis have demonstrated that specific 
pharmacological inhibition of PKC-β overactivity has been cerebrovascular protective 
and may be used as an effective novel agent to; (a) improve post-stroke survival rate, 
(b) reduce the occurrence of the secondary strokes, and (c)  abate the occurrence of 
other similar vascular abnormalities including myocardial infarction. 
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Figure 8. Diagrammatic representation of the similarities between the effects OGD±R 
and hyperglycaemia using HBMEC and the in vitro model of BBB.  
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1. Limitations to the current studies 
     The data presented in this thesis are derived from in vitro experiments using 
mainly HBMEC and an in vitro model of human BBB comprising of HBMEC and 
HA. The outlined findings exhibit the molecular mechanisms behind the 
hyperglycaemia and OGD±R-mediated modulation of the endothelial-barrier 
integrity. It remains critical to confirm the role of PKC/RhoA/Rho-kinase signalling 
pathway potentiated under aforementioned pathologies, and to dissect the cooperative 
or additive roles of diabetes to ischaemic stroke-mediated cerebral-barrier 
complications in in vivo settings by using rodent models of diabetes, ischaemic stroke, 
and a combination of two.  
     The in vitro model of human BBB was established by coculturing the HBMEC and 
HA. However, it is essential to further improve the human BBB model by including 
pericytes and microglia in the BBB architecture because of their significant role 
during ischaemic stress by enhancing the ROS, cytokine, and chemokine productions 
which exacerbate the ischaemic injury. Moreover, it is also essential to study the 
significance of diabetes and ischaemia-mediated BBB dysfunction on the neuronal 
viability by measuring the rate of neuronal apoptosis during and after the pathological 
conditions because area of cerebral infarction largely constitutes the dead neurons in 
ischaemic stroke.           
     Some of the immunocytochemistry experiments which include the tight junction 
protein stainings were carried out in HBMEC under hyperglycaemic pathology as 
illustrated in the thesis. However, these experiments failed during the longer OGD 
exposures to the HBMEC because majority of HBMEC cultured on coverslips came 
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off the surface during OGD exposures. Hence, short OGD exposures and time-
dependent observations are suggested to address this issue. 
2. Future directions 
      Since stability of tight junction proteins and adherens junction proteins is critical 
in maintaining the BBB integrity, the OGD or hyperglycaemia-mediated alterations in 
the expression and relocalisation of these proteins warrants further investigation. By 
using cell fractionation techniques, different components of HBMEC or HA i.e. 
membrane fraction, cytoplasmic fraction, nuclear fraction, and actomyosin fraction; 
can be used to detect the rate of destabilisation and cytoplasmic trafficking for these 
proteins. Since adherens junction proteins like β-catenin act as transcription factors 
and modulate the protein expression of claudin-5, the cell fractionation data will 
confirm the hypothesis and will be useful in addressing the phosphorylation and 
subsequent relocalisation of tight junction proteins from cell periphery. Moreover it 
will be interesting to study the role of transcription factors like NF-κB and AP-1 in 
the destabilisation of these proteins under aforementioned pathologies by 
investigating the activation and translocation of these transcription factors from 
cytoplasm to nucleus and their transcription regulation at binding sites at promoter 
region on the genes by using techniques like chromatin immunoprecipitaions (ChIP).        
     As mentioned earlier, PKC overactivity regulates the RhoA/Rho-kinase signalling. 
However, little is known about the molecular mechanisms behind this regulation. 
Hence, it will be interesting to delineate the role of PKC isoforms in regulating the 
expression/activity of the activator of RhoA-GTPase i.e. GEFs, GAPs and GDI in 
HBMEC. 
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     Our recent publication showed the OGD-mediated RhoA/Rho-kinase overactivity 
in astrocytes (Allen et al., 2010). Since RhoA/Rho-kinase overactivities are linked 
with ROS generation, it will be interesting to study the pro-oxidant and antioxidant 
parameters and ROS metabolism in HBMEC and HA cocultures to compare any 
differences from single cell set ups. 
     Recent studies on cardiomyocytes have shown that RhoA/Rho-kinase pathway 
plays an important role in the cell survival as increased RhoA/Rho-kinase activity can 
upregulate the proapoptotic marker gene Bax and induce apoptosis (Del Re et al., 
2007). Indeed, in vitro studies with rat PC12 cell line have shown that H2O2 exposure 
increases the Bax mRNA and protein levels and induce apoptosis. Inhibition of Rho-
kinase by fasudil mesylate reversed the H2O2-mediated effects and improved cell 
survival rates (Li et al., 2011a). Since the oxidative stress in endothelial cells during 
IR injury might induce apoptosis, it will be interesting to study the effects of Rho-
kinase inhibitors on the apoptotic genes like Bax and Bcl-2 in HBMEC and HA to 
further substantiate the cerebrovascular protective effects of these inhibitors.  
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1. Appendix I 
Recipe for Western blotting buffers and gels 
The following buffers were used detected the protein bands by Western blotting 
technique in HBMEC lysates. 
1. 10X Running buffer (1 Litre) 
24.2 g   Tris-base 
144.0 g  Glycine 
10.0 g   SDS 
1000 mL distilled water 
2. 1X Running buffer (1 Litre) 
  100 mL  10X Running buffer 
  900 mL distilled water 
3. 10X Transfer buffer (1 Litre) 
  24.2 g  Tris-base 
144.0 g  Glycine 
1000 mL distilled water 
4. 1X Transfer buffer (2 Litres) 
  200 mL  10X Transfer buffer 
  400 mL  methanol (100%) 
  1400 mL  distilled water 
5. 10X TBST (1 Litre) 
  24.2 g  Tris-base 
  87.6 g  Sodium Chloride 
  1000 mL distilled water 
    pH 7.4-7.6 
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  10 mL  Tween-20 
6. 1X TBST (1 Litre) 
  100 mL  10X TBST 
  900 mL distilled water 
7. Blotto blocking buffer (5%) 
  2.5 g   Blotto milk 
  50 mL  1X TBST 
8. Ammonium persulphate (APS; 10%) 
  0.5 g  Ammonium persulphate 
  5 mL  distilled water 
9. L-Tris buffer (1.87 M, 0.5 Litres) 
  113.6 g Tris-base 
  500 mL distilled water 
    pH 8.8 adjusted with Conc. Hydrochloric acid 
10. U-Tris buffer (1.25 M, 0.5 Litres) 
  75.7 g   Tris-base 
  500 mL  distilled water  
    pH 6.8 adjusted with Conc. Hydrochloric acid 
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Polyacrylamide gel electrophoresis (PAGE) recipe 
 
Gel components Resolving (7.5%)  (10%) (15%) Stacking (4%) 
 (mL) (mL) (mL) (mL) 
Ultra-pure water 7.600 6.201 3.405 3.680 
40% w/v Acrylamide 2.740 3.653 5.475 0.490 
2% Bis-acrylamide 1.460 1.946 2.920 0.260 
L-Tris (1.87 M) 3.000 3.000 3.000 - 
U-Tris (1.25 M) - - - 0.500 
10% SDS 0.150 0.150 0.150 0.050 
10% APS 0.100 0.100 0.100 0.040 
TEMED 0.015 0.015 0.015 0.010 
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2. Appendix II 
Antibodies detecting proteins of human and mouse origin by Western blotting 
The following human proteins were detected in HBMEC lysates. 
 Proteins Size (kDa) Gel (%) Antibody Conc. Quantity (g) 
1. CuZn-SOD 16 15 (1:5000) 2.5 
2. Catalase 65 10 (1:2000) 15 
3. gp91-phox 91 10 (1:300) 50 
4. RhoA 24 15 (1:300) 25 
5. Rho-kinase-2 160 7.5 (1:1000) 25 
6. MLC2 20 15 (1:300) 25 
7. p-MLC2-Ser19 18 15 (1:300) 25 
8. p-MLC2Thr18/Ser19 18 15 (1:300) 25 
9. Occludin 78 10 (1:700) 25 
10. ZO-1 240 7.5 (1 g/mL) 25 
11. Claudin-5 23 15 (1:500) 50 
12. β-catenin 96 10 (1:5000) 10 
13. Vinculin 116 10 (1:1000) 25 
14. PKC-α 80 10 (1:300) 25 
15. PKC-β 80 10 (1:75) 25 
16. β-actin 44 10 (1:30,000) 2.5 
 
 
 
 
 
208 
 
3. Appendix III 
siRNA oligonucleotide sequences targeting human PKC isoforms 
The following siRNA oligonucleotides were used for gene silencing in HBMEC.   
 
1. ON-TARGET plus SMART pool, human PKC-βI, 5 nmol 
 1. GGUCAUGCUUUCAGAACGA 
 2. CCUGUCAGAUCCCUACGUA 
3. GAUUUGGGAUUGGGAUUUG 
4. UCAUUGUCCUCGUAAGAGA 
 
2. ON-TARGET plus SMART pool, human PKC-α, 5 nmol  
 1. UCACUGCUCUAUGGACUUA 
 2. GAAGGGUUCUCGUAUGUCA 
 3. UUAUAGGGAUCUGAAGUUA 
 4. UAAGGAACCACAAGCAGUA   
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4. Appendix IV 
Recipe for the buffers used in total PKC activity 
The following buffers were used for measuring the total PKC activity in the HBMEC 
lysates. 
 1. PKC extraction buffer 
25 mM  Tris-HCl (pH 7.4) 
0.5 mM  EDTA 
0.5 mM  EGTA 
0.05%   Triton X-100 
10 mM  β-mercaptoethanol 
1 g/mL  Leupeptin 
1 g/mL  Aprotinin 
2. PepTag C1 peptide 
L-R-R-A-S-L-G 
0.4 g/L in water 
3. PepTag PKC reaction 5X buffer 
  100 mM  HEPES (pH 7.4) 
  6.5 mM  CaCl2 
  5 mM   DTT 
  50 mM  MgCl2 
  5 mM   ATP 
 
 
 
 
